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Abstract 
The aim of this thesis was to identify novel techniques in the assessment of 
nutritional intervention effects upon cognition.  The impact of combining different cognitive 
and physiological assessments of nutritional interventions was explored in order to 
establish whether it could provide a more detailed picture of any effects, as well as the 
mechanisms by which they may occur.  
This thesis initially used two different technologies, electroencephalography (EEG) 
and near infrared spectroscopy (NIRS) to assess the cerebro-electrical and 
haemodynamic impact of cognitive task performance following Ginkgo biloba and a 
Ginkgo biloba/Panax ginseng combination, in healthy young adults.  Following on from 
this, the effects of two different doses of Ginkgo biloba were investigated on cerebral 
blood flow and oxygenation parameters during the repeated administration of cognitively 
demanding tasks.  The synergistic effect of two interventions believed to possess 
disparate effects on cerebral blood flow; caffeine and L-theanine, were then assessed 
during the performance of a range of cognitive tasks.  To evaluate the peripheral as well 
as the central impact of task performance, a further assessment of (two doses) caffeine 
was conducted whilst cerebral blood flow and oxygenation parameters were monitored 
alongside an assessment of metabolism via indirect calorimetry (ICa).  In an extension of 
the methodology, an exercise element was incorporated into the protocol and beetroot 
juice was administered whilst cerebral blood flow and haemodynamics were monitored 
during task performance, before, during and after cycling at different exercise intensities. 
The results of this thesis have identified that the methodologies adopted are 
capable of detecting changes in cerebral oxygenation as a result of, nutritional challenge; 
differing doses of the same intervention; the synergistic effect of two different interventions, 
and during incremental exercise whilst performing cognitive tasks.  The concomitant 
measurement of NIRS and ICa were also shown to be effective in simultaneously 
determining the somatic and cognitive demands of a task.  These findings demonstrate 
the positive contribution to research of combining technologies and methodologies in the 
assessment of nutritional interventions and provide valuable information in respect of their 
use in cognitive research. 
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Chapter 1. Introduction 
1.1 General Introduction 
The influence of diet upon physical and mental health has been of interest for a 
number of years.  However, with an ageing population, there is increased interest in the 
use of nutraceuticals, functional foods and nutritional interventions that can modulate 
cognition or physiological parameters in a positive or indeed, negative way.  There are 
many methodologies that can be adopted and technologies that can be employed in order 
to measure behavioural and or physiological outcomes.  Yet, either because of practical or 
technological limitations, their implementation in combination with nutritional interventions 
of interest to cognition has, in some cases, been overlooked.  The benefit of combining 
different methods of cognitive and physiological assessment is that a more thorough and 
detailed picture of the effects and the mechanisms by which the effects occur can be 
obtained.  A workshop by the Nutrition and Mental Performance Task Force of the 
European branch of the International Life Sciences Institute took place in 2009 with the 
aim of pinpointing gaps in our knowledge in relation to cognitive performance assessment 
and identifying nutritional and methodological opportunities for improving brain function 
and cognitive performance.  A number of recommendations focussed on improving 
current approaches were made, including, the use of biomarkers and risk factor measures 
for cognitive impairment to supplement clinical or cognitive measures; a greater focus on 
the prevention as opposed to the treatment of cognitive decline (i.e. targeting younger 
people); focussing on particular cognitive tests that are relevant to the areas of brain 
function at which the intervention is aimed; more widespread use of computerised 
cognitive tests in order to standardise administration and provide parallel versions of tasks; 
the delivery of tasks in multiple languages and the inclusion of brain imaging techniques 
as biomarkers in order to supplement cognitive methods.   
Proposals such as this highlight the importance of reviewing our methodological 
approach to nutrition and cognition research.  In cognitive assessments of nutritional 
interventions, creating opportunities to integrate methodologies and technologies enables 
an assessment of the ‘bigger picture’.  By consequence, we are then able to determine at 
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more than one level, the intervention in questions’ ability (or indeed absence of ability) to 
convey cognitive and or physiological benefits, both in the short and the long-term. 
 
1.2 Methods of assessing nutritional interventions of interest to cognition in 
healthy young populations 
1.2.1 Cognitive Tasks 
With a vast number of nutritional interventions having the ability to modulate 
cognition, the approach used to elicit and measure these effects is wide ranging.  They 
may include simple assessments looking at the effects upon an individual outcome or the 
use of complex paradigms incorporating different technologies where any number of 
behavioural and/or physiological outcomes are assessed.  From the simplest study to the 
most complex however, when there is an outcome determining behavioural performance, 
this is typically measured by the use of cognitive task(s), with or without an assessment of 
subjective mood. 
1.2.1.1 Considerations in the use of cognitive tasks when assessing the effects of 
nutritional interventions 
 Frequently, within nutritional intervention studies where the main focus is the 
cognition enhancing properties of the intervention, the primary outcome measures centre 
around behavioural performance on one or more cognitive tasks.  The decision to include 
a task is usually taken based upon the tasks ability to assess a specific area of cognition 
(for example, attention or memory).  It also commonly reflects prior knowledge of the 
interventions ability to modulate this area.  When selecting appropriate tasks for use within 
a nutritional intervention study, the tasks should have previously demonstrated their 
sensitivity to the nutritional intervention in question, in addition to their validity and 
reliability.  Task sensitivity is an important consideration when assessing the effects of any 
nutritional intervention since the observed effects may be very subtle.   Good practice 
therefore dictates that only those tasks that have reliably, and (preferably) more than once 
demonstrated their ability to detect a change in cognitive function, should be included 
(Wesnes, 2010).  Due to a strong association with sensitivity, measures also need to 
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demonstrate their reliability for retesting.  They should therefore exhibit little variation after 
repeated assessment, since greater variability in performance can adversely affect the 
detection of a significant effect as a result of nutritional challenge (Schmitt, Benton, & 
Kallus, 2005).  The validity of a task - that a task is measuring what it purports to measure 
(i.e. that a task of attention is indeed measuring attention) is also a minimum requirement 
when planning what measures should be included within any interventional study.  
Another important consideration is mode of presentation, since in some instances, paper 
and pencil as well as automated versions may be available.  The advantages of 
computerised versions are that the presentation of the tasks can be standardised and 
responses can be captured in a detailed and accurate manner (Schmitt et al., 2005), 
allowing less room for human error during scoring.  Within nutritional cognitive research, 
the speed at which participants respond to a stimulus can be equally as interesting as 
their level of accuracy.  Computerised testing facilitates this by providing the capability to 
record reaction times alongside other measures and identify reaction times more precisely.  
It also enables the inclusion of tasks such as choice or simple reaction time (Wesnes, 
2010).  Computerised systems with the capability of delivering a battery of tasks also 
minimise researcher input/interruption thereby preventing or at least limiting any 
researcher bias.  Overall, this leads to a smoother delivery and efficient transition between 
tasks.  All of these considerations are important when planning a nutritional intervention 
study with a cognitive element, as they ensure good practice and increase the likelihood 
of observing an effect of treatment.  
 
1.2.2 Manipulating cognitive demand/fatigue 
Age-related cognitive decline is a feature of ageing that is well documented (Craik 
& Salthouse, 2008; Salthouse, 1991; Salthouse & Babcock, 1991), with some aspects of 
decline appearing as early as between 20 and 30 years of age (Salthouse, 2009).   By 
contrast, healthy young adults who are at the peak of their cognitive abilities and have not 
yet entered a phase of cognitive decline are more susceptible to ceiling effects during 
assessments of behavioural performance.  This can be problematic when attempting to 
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assess the cognition-modulating properties of an intervention as any effects could be 
masked.  One approach when testing healthy young participants, who by their nature 
should be at the peak of their abilities, is to introduce a level of cognitive demand or 
fatigue to the protocol.  Assessing the effects on performance of an intervention in this 
way can highlight its capacity to recover function, in addition to its ability to prevent 
continued decline in performance.  Introducing a degree of cognitive demand through the 
use of complex tasks, tasks of increasing difficulty or the repeated performance of tasks is 
one means of manipulating demand with a view to increasing fatigue.  It has previously 
been identified that there exists a relationship between the delivery and use of glucose 
and oxygen, in that both can facilitate cognitive performance (Kennedy & Scholey, 2000; 
Moss & Scholey, 1996; Moss, Scholey, & Wesnes, 1998; Scholey, Harper, & Kennedy, 
2001; Scholey, Moss, Neave, & Wesnes, 1999).  This effect is found to be more apparent 
when the level of cognitive demand is high (Kennedy & Scholey, 2000; Scholey et al., 
2001).  With the aim of manipulating the level of effort required during behavioural 
performance, the same research group as referred to above, introduced a group of tasks 
called the ‘Cognitive Demand Battery’ (CDB).  This battery consisted of 2 minutes each of 
the performance of serial 3s and serial 7s subtractions, followed by 5 minutes of the rapid 
visual information processing (RVIP) task followed by a subjective mental fatigue scale.  
This set of tasks was then repeated six times over the period of an hour.  The purpose of 
this battery was to increase mental fatigue, producing a state in which cognitive 
performance in healthy young participants was likely to decline.  Using this method, 
significant improvements in cognitive performance have been demonstrated in healthy 
young adults following the administration of glucose, Panax ginseng and cocoa flavanols 
(Kennedy & Scholey, 2004; Reay, Kennedy, & Scholey, 2005, 2006; Scholey et al., 2009).   
1.2.2.1 Exercise, cognition and fatigue  
A further approach is to manipulate demands on the body through the use of 
physical exercise.  Including an exercise element in the protocol during the performance 
of cognitive tasks introduces an additional level of fatigue.  Studies that have adopted this 
methodology have aimed to determine the acute and longitudinal effects of physical 
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exercise on cognitive performance.  The importance of this approach has been validated 
by coaches and athletes alike, since attentional and strategic choices that have to be 
made in a short space of time can be key to successful performances in sport (Brisswalter, 
Collardeau, & Rene, 2002).  Research within this field has incorporated an assessment of 
cognition either prior to the onset of exercise, whilst participants are actively exercising, 
during the post-exercise recovery period, or via a combination of these three paradigms.  
Due to potential practical limitations such as instrument/equipment set-up, it could be 
suggested that the more challenging approach is measuring cognitive function whilst 
participants are actively exercising.  However, cognitive task performance has been 
successfully measured during a range of exercise methods: simple reaction time during 
cycling at 20-80 % of maximal aerobic power (Brisswalter, Arcelin, Audiffren, & 
Delignieres, 1997) and whilst running on a treadmill (Bender & McGlynn, 1976; Collardeau 
& Brisswalter, 2001);  performing a choice reaction time task during moderate sub-
maximal cycling (Arcelin, Delignieres, & Brisswalter, 1998; Davranche & Audiffren, 2004; 
Davranche, Audiffren, & Denjean, 2006) and during prolonged cycling (Chmura, 
Krysztofiak, Ziemba, Nazar, & Kaciuba-Uscilko, 1997); and completing a speed of visual 
search task whilst cycling at 70 % and 100 % maximal power (McMorris & Graydon, 1997).   
The influence of nutrition and nutritional supplementation upon exercise is an area 
of research that has received attention for many years, with interventions such as caffeine 
and carbohydrates known to positively facilitate aspects of exercise performance (Glaister 
et al., 2008; Karelis, Smith, Passe, & Peronnet, 2010).  However, comparatively few 
studies have monitored cognition whilst participants are actively exercising, in the 
presence of a nutritional intervention known to improve either cognitive or exercise 
performance.  Those that have, have used attentional and reaction time tasks during 
prolonged exercise, such as cycling, running or aerobic activity, in the presence of 
caffeine or carbohydrates (Collardeau, Brisswalter, Vercruyssen, Audiffren, & Goubault, 
2001; Hogervorst et al., 2008; Lieberman, Falco, & Slade, 2002) and have demonstrated 
positive results on cognition in some cases (Hogervorst et al., 2008; Lieberman et al., 
2002). 
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1.2.2.1.1 Indirect calorimetry (ICa) 
 Indirect calorimetry (ICa) is a non-invasive and portable method of determining 
estimates of energy expenditure during exercise and resting states from inspired and 
expired air.  The method is termed indirect since energy expenditure readings are 
obtained as a result of formulas derived from measures of oxygen consumption and 
carbon dioxide production as opposed to a direct measure of heat loss (Reaburn, Reed, 
Dascombe, Jones, & Weyers, 2011).  The use of this method is popular within exercise 
and nutrition research protocols (Acheson, Zahorskamarkiewicz, Pittet, Anantharaman, & 
Jequier, 1980; Astrup et al., 1990; Hodgson, Randell, & Jeukendrup, 2013; Hollands, Arch, 
& Cawthorne, 1981; Saffle et al., 1985) as well as within clinical settings (Garcia-Peris et 
al., 2005; Miller, Daniels, Bannerman, & Crotty, 2005; Reeves, Battistutta, Capra, Bauer, 
& Davies, 2006), where it remains the gold standard for measuring energy expenditure 
(Haugen, Chan, & Li, 2007). 
 
1.3 Technologies for assessing interventions of interest to cognition 
 During cognitive testing, there are a range of neurophysiological methods and 
techniques that may also be adopted.  These techniques can be used either alone or in 
conjunction with one another, in order to provide a fuller picture of a supplements’ ability 
to modulate cognition. 
1.3.1 Measuring cerebral activation and blood flow 
 Cerebral blood flow (CBF) controls the delivery of metabolic substrates (glucose 
and oxygen) to the brain (Scholey, 2001).  At the simplest level, increases in CBF, oxygen 
delivery and consumption occur when the metabolic demand of neurons change as 
electrical signals are passed between cells due to neuronal activation (Lloyd-Fox, Blasi, & 
Elwell, 2009).  Fox et al, (1988) were the first to identify that the resulting increase in blood 
flow exceeds the rate at which oxygen is utilised and as a result leads to an increase in 
oxygenated haemoglobin (oxy-Hb) in activated areas.   In terms of the haemodynamic 
response during functional activation, this is generally demonstrated by an increase in 
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oxygenated haemoglobin and a corresponding decrease in deoxygenated haemoglobin 
(deoxy-Hb) in the area of activation (Obrig et al., 2000). 
1.3.1.1 Ageing and cerebral blood flow 
 Cerebral blood flow is a measurement that is susceptible to change dependent 
upon the population being assessed.  Age differences have been implicated as having an 
influence on CBF.  Cerebral blood flow is thought to reduce with age, and a number of 
studies, using different methodologies, including positron emission tomography (PET)  
(Leenders et al., 1990; Marchal et al., 1992; Martin, Friston, Colebatch, & Frackowiak, 
1991), single photon emission tomography (SPET) (Larsson et al., 2001) and 133Xenon 
inhalation method (Melamed, Lavy, Bentin, Cooper, & Rinot, 1980) have demonstrated 
this.  However, there is also research to suggest that CBF remains stable, even with 
advancing age (Itoh et al., 1990; Yamaguchi et al., 1986).  As a consequence, within the 
present thesis in order to remove age as a confounding factor, only young, healthy 
populations were assessed. 
1.3.2 Functional magnetic resonance imaging (fMRI) 
Functional Magnetic Resonance Imaging (fMRI) uses magnetic resonance imaging 
technology to examine changes in blood flow in a specific brain region as a direct result of 
stimulation, for example during performance of a cognitive task.  The technique of fMRI 
relies on the assumption that changes in neural activity are closely related to changes in 
blood flow.  Therefore, as neural activity increases there is a corresponding increase in 
blood flow in that area of the brain.  Blood Oxygen-Level Dependent (BOLD) contrast 
fMRI was developed by Ogawa et al., (1993) and uses the magnetic property differences 
of deoxy-Hb and oxy-Hb to identify changing signal variations as a result of activation.  It 
is currently considered the gold standard for measuring functional brain activation, due 
predominately to the high level of spatial resolution fMRI provides (Bunce, Izzetoglu, 
Izzetoglu, Onaral, & Pourrezaei, 2006).  However, there are limitations to this method 
including low temporal resolution, as data collected is limited to the order of seconds as 
opposed to milliseconds.  It is also very restrictive and participants are required to lie very 
still to minimise movement and prevent contamination of the data.  As a consequence, the 
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tasks and protocols that can be utilised in conjunction with fMRI are limited.  fMRI has 
been used frequently in cognition research in order to identify the neural correlates of 
performing a task (Buckner et al., 1996; Dove, Pollmann, Schubert, Wiggins, & Yves von 
Cramon, 2000; Milham et al., 2002; Rissman, Gazzaley, & D'Esposito, 2004) and in the 
absence as well as in the presence of nutritional interventions (Chen & Parrish, 2009b; 
Francis, Head, Morris, & Macdonald, 2006; Laurienti et al., 2002). 
 
1.3.3 Electroencephalography (EEG) 
Electroencephalography (EEG) is a non-invasive measurement of electrical activity 
in the scalp as a result of the activation of neurons.  This activation is captured as electric 
potential differences between numerous pairs of electrodes placed at specific points on 
the head that correspond to different regions of the brain.  The electrical activity shows a 
pattern of oscillations, displayed as waves of electrical potential at a variety of frequencies 
and amplitudes.  These characteristics are well established and can change depending on 
the situation and the brain location in which the recordings take place, for example, frontal 
or occipital, awake versus sleeping, eyes open versus eyes closed etc. (Lieberman, 
Kanarek, & Prasad, 2005).  The technique of EEG can also record electrical activity that is 
associated with a specific external stimulus (sensory, cognitive, motor–related etc.) and 
this type of response is known as an event-related potential (ERP).  It is recorded in the 
same way as spontaneous activity (via use of electrodes placed on the scalp); however, it 
is measured at the precise time the external stimulus takes place and it displays a 
characteristic waveform (Luck, 2014).  Benefits of this technique include a high temporal 
resolution including the monitoring of changes in electrical activity within milliseconds.  It is 
silent and is not as susceptible to contamination from artefacts as a result of movements.  
In comparison to some imaging techniques such as fMRI, it is also low cost.  However, it 
does have disadvantages, including low spatial resolution - making it difficult to clearly 
identify specific areas of the brain that are activated.  The set-up of EEG can also be time-
consuming, depending upon the number of electrodes used in a study, as they may have 
to be connected individually.  EEG is most commonly used in the diagnosis of medical 
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conditions such as epilepsy and coma (Salinsky, Kanter, & Dasheiff, 1987; Smith, 2005; 
Young, 2000).  However, EEG is also used in cognition research as well as in the 
presence of nutritional interventions (Brown & Riby, 2013; Kennedy et al., 2003; Riby et 
al., 2008; Smith, Riby, Sunram-Lea, Van Eekelen, & Foster, 2009). 
 
1.3.4 Near infrared spectroscopy (NIRS) 
Although, as previously discussed, fMRI is considered the current gold standard 
for measuring brain activation, in certain situations, or indeed, within some populations, 
the requirements of fMRI monitoring cannot be met.  In this instance, NIRS is emerging as 
an alternative imaging technique, due to its practical application and high temporal 
resolution.  An alternative to brain imaging techniques such as fMRI and positron emission 
tomography (PET); methods which have been described as expensive, physically 
constraining, and in the case of PET, may expose participants to potentially harmful 
materials (Izzetoglu, Yurtsever, Bozkurt, & Bunce, 2003).  NIRS is a safe, portable, non-
invasive, negligibly intrusive, and (comparatively) inexpensive method of imaging that 
does not require participants to be confined to restricted positions.  It also provides a more 
thorough assessment of the haemodynamic response as (unlike fMRI) it gives 
measurements of both oxy-Hb and deoxy-Hb (Lloyd-Fox et al., 2009).  The use of NIRS 
for a variety of applications has become increasingly popular since its inception over 20 
years ago, and consequently the number of NIRS publications has doubled every 3.5 
years since (Boas, Elwell, Ferrari, & Taga, 2014).  This is perhaps due in part, to its 
applicability within certain situations or populations where other imaging techniques (such 
as fMRI, PET etc) would not be suitable, for example in young populations such as 
neonates, babies and toddlers (Gervain et al., 2011).  NIRS has also been successfully 
adopted as a monitoring tool during (non-cardiac) surgery to monitor cerebral saturation 
(Moerman & De Hert, 2015) and during exercise, at a range of intensities (Ide, Horn, & 
Secher, 1999; Miyai et al., 2001; Subudhi, Dimmen, & Roach, 2007; Suzuki et al., 2004) 
including maximal (Subudhi et al., 2007; Subudhi, Miramon, Granger, & Roach, 2009; 
Thomas & Stephane, 2008).  In the context of the current thesis, NIRS is also suitable for 
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use during cognitively demanding situations that require complete concentration.  Since, 
in contrast to fMRI, NIRS is silent, thereby limiting the distraction to participants during 
cognitive tasks and enabling the presentation of stimuli both visual and auditory.  In 
addition, NIRS can be used repeatedly with the same participants, making it useful for 
repeated measures designs and suitable for the study of cognition related haemodynamic 
changes (Izzetoglu et al., 2003).  It also allows the assessment of interpersonal activation 
patterns through the monitoring of simultaneous haemodynamic responses as a result of 
two-person experimental paradigms.  For example, when two participants perform a dual 
task, that may have an advantage over the single performance of that task (Dommer, 
Jaeger, Scholkmann, Wolf, & Holper, 2012; Holper, Scholkmann, & Wolf, 2012). 
1.3.4.1 Principles of NIRS 
Near infrared spectroscopy measures functional activation through monitoring 
changes in the haemodynamic properties of the brain (Huppert, Hoge, Diamond, 
Franceschini, & Boas, 2006).  Three distinct types of near infrared implementation have 
been developed: time-resolved systems, frequency domain systems and continuous wave 
spectroscopy systems, each of which has its own strengths and limitations (Bunce et al., 
2006).  A review of the different methods is beyond the scope of this thesis; however, see 
Delpy & Cope (1997) for further information.  The method that will be discussed in the 
following chapter and throughout this thesis is continuous wave spectroscopy.  This 
method of spectroscopy works via the application of continuous or slow pulsed light to 
tissue (Bunce et al., 2006) and enables the observation of changes in regional cerebral 
blood flow as it happens through the measurement of concentration changes in oxy-Hb, 
deoxy-Hb and total-Hb (calculated from the values of oxy-Hb and deoxy-Hb) (Hoshi, 2007).  
In the near-infrared range of 700-1000 nm, biological tissue is largely transparent to light.  
This non-invasive imaging technique uses two wavelengths of light that are differentially 
absorbed by oxy-Hb and deoxy-Hb haemoglobin (wavelengths of ~830 and 750 nm and 
are generally adopted in NIRS research (Boas, Dale, & Franceschini, 2004)).  They are 
introduced through the skull via a laser emitter and measured following transit through the 
upper surface of the cortex by an optode (termed the receiver) placed at a pre-set 
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distance from the light source (Bunce et al., 2006).  As light travels through the tissue, 
some is absorbed and some is scattered, the light that remains is collected by the receiver 
(which is normally placed 2-7 cm away from the emitter), once it has passed through the 
tissue beneath the optodes (Villringer & Chance, 1997).  See figure 1.1 for an example of 
the 2-channel NIRS set-up over the pre-frontal cortex, used in the current thesis.  The 
number of channels used within a study varies depending upon the brain area under 
investigation and paradigm being assessed, with systems having been developed that can 
measure up to 128 channels (Lloyd-Fox et al., 2009). The concentration changes of oxy-
Hb and deoxy-Hb can be calculated from the amount of light absorption at their specific 
wavelengths via the modified Beer-Lambert law (Fallgatter & Strik, 1998).  The Beer-
Lambert law is an empirical description of optical attenuation in a highly scattering 
medium (Bunce et al., 2006).  At a distance of 4 cm between emitter and receiver optodes, 
the NIRS signal becomes sensitive to haemodynamic changes within the top 2-3 mm of 
the cortex extending laterally 1 cm to either side (Chance et al., 1998). 
                             
Figure 1.1 Example of 2-channel NIRS device and configuration of optodes over pre-
frontal cortex as used in the current thesis. 
1.3.4.2 Limitations of NIRS 
NIRS, however, does have its limitations.  One of the main criticisms of NIRS and 
a significant challenge facing functional near infrared spectroscopy (fNIRS) research is its 
low spatial resolution.  As a result, defining the precise area of brain under investigation is 
difficult and fNIRS studies have had to rely on the international 10-20 system to roughly 
deduce the area being measured (Hoshi, 2007).  The 10-20 system uses anatomical 
markers such as nasion, inion and preauricular points in the placement of electrodes.  It is 
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based on the association between the position of an electrode and the underlying area of 
the cerebral cortex.  The ‘10’ ‘20’ in the title relates to the fact that the electrodes are 
spaced to the adjacent electrode at distances of either 10 or 20 % of the total front-back, 
right-left distance of the skull (Klem, Lüders, Jasper, & Elger, 1999).  NIRS also has low 
depth penetration thereby limiting assessment of cerebral activation to the cortical grey 
matter (Villringer & Chance, 1997).  This factor has bearing upon the distance between 
transmitter and receiver optodes, since to reach the cortex the distance between the 
source and the detector optodes must be (at a minimum), double that of the distance 
between the skin surface and the surface of the cortex (Lloyd-Fox et al., 2009).  As a 
consequence, distances between transmitter and receiver optodes are usually fixed at a 
set distance within individual fNIRS studies.  However, there is large inter-subject 
variability in the dimensions of subjects’ foreheads.  This, combined with differences in 
brain size mean that identifying the exact area under investigation where haemodynamic 
changes are taking place can be difficult (Izzetoglu, Bunce, Onaral, Pourrezaei, & Chance, 
2004).  Motion artefacts and the method by which they are handled (if indeed at all), is 
another of the challenges faced in fNIRS research.  Motion artefacts are defined as 
“abrupt changes in signals occurring in several channels simultaneously which are 
distinctive from the slow and smooth haemodynamic response that is usually seen” 
(Lloyd-Fox et al., 2009).  Such artefacts are caused by displacement (however slight) of 
the optodes, usually as a result of head movements, body movements, involuntary actions 
(yawning, sneezing etc.) or touching of the optodes when the device is in use.  As a result, 
external light may be detected by the receiver, or light may pass from the transmitter to 
the detector without passing through the tissue (Izzetoglu et al., 2004).  Head movements 
can also result in changes in CBF and alterations in oxygen levels that can mimic 
haemodynamic changes as a result of brain activation and these can be almost 
indistinguishable from the normal response (Izzetoglu, Devaraj, Bunce, & Onaral, 2005).  
Unfortunately there is currently no universal approach for dealing with motion artefacts in 
fNIRS research, as with other imaging techniques (Robertson, Douglas, & Meintjes, 2010).  
There are, however, a number of methods proposed to minimise the impact of such 
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artefacts.  One of the simplest is to visually identify where the artefact occurs (via a time 
stamp, block of data or participant) and remove this data from the analysis (Nakano, 
Watanabe, Homae, & Taga, 2009).  Alternative techniques include wavelet-based filtering 
(Molavi & Dumont, 2012; Robertson et al., 2010) or the use of algorithms (Izzetoglu et al., 
2005).  Other approaches have focussed on procedures that can be adopted in order to 
reduce the occurrence of artefacts.  Methods include the use of a light absorbing band 
(Fallgatter & Strik, 1998) and adhesive fixation discs that secure the headband to the skin.  
However, criticisms remain that even though improved development of the 
headband/connection of the optodes to the skin will reduce the occurrence of artefacts, it 
is unlikely to fully solve the issue (Lloyd-Fox et al., 2009).   
1.3.4.3 Functional near infrared spectroscopy (fNIRS) 
Functional optical imaging is the assessment of physiological changes associated 
with brain activity by optical methods (Villringer & Chance, 1997).  The ability of NIRS to 
measure a hemodynamic change during motor, visual and auditory stimulation (Cutini, 
Scatturin, Basso Moro, & Zorzi, 2014; Herrmann, Ehlis, Wagener, Jacob, & Fallgatter, 
2005; Kotilahti et al., 2005; Obrig et al., 1996; Sakatani, Chen, Lichty, Zuo, & Wang, 1999; 
Taga, Asakawa, Hirasawa, & Konishi, 2003), in addition to more subtle processes such as 
deception (Izzetoglu et al., 2002; Tian, Sharma, Kozel, & Liu, 2009) has been validated.  
Of specific relevance here, however, is the capacity of NIRS to identify cerebral activation 
as a result of cognitively demanding tasks.  Izzetoglu et al. (2003) used NIRS across the 
forehead in a 4 x 10, 16 channel design  to monitor cerebral haemodynamics in the frontal 
region of the brain during tasks which assessed attention and working memory (target 
categorisation and N-back) (see figure 1.2 for example of a multi-channel NIRS 
configuration).  Cognitively intact males aged 18-35 years completed either a target 
categorisation task (n=7) or the n-back task (n=4).  Oxy-Hb was seen to increase with 
increasing task difficulty during the n-back task (0 back – 2 back) with a reduction in oxy-
Hb during 3-back.  It was concluded that, in the case of the most difficult version of the 
task, the demands required exceeded the subject’s ability to keep up leading to a 
decrease in oxygenation.  There was no report of measurements of deoxy-Hb or total-Hb.  
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A later study by the same research group, using the same NIRS spatial configuration 
demonstrated similar findings in a marginally older cohort.  Here, the impact of a task 
used to approximate naval warfare (requiring spatial and verbal working memory and 
decision-making processes), in the dorsolateral prefrontal cortex was assessed.  Eight 
healthy subjects aged 18-50 years took part in the study.  They observed (as anticipated 
based on the findings of their previous study) that as task difficulty increased so too did 
cerebral oxygenation, until the most difficult task where there was no further increase in 
oxy-Hb.   Again it was concluded that the demands of a task can signal a change in 
oxygenation (Izzetoglu et al., 2004).  Once again, no measurements of either deoxy-Hb or 
total-Hb were reported.   Within the same study, it was also concluded that the rate of 
oxygenation change provides an index of sustained attention (in a complex working 
memory and decision-making task).  This was demonstrated by a strong positive 
correlation between blood oxygenation and performance of the most difficult condition.   
This pattern whereby there is an increase in oxygenation as a result of increasing task 
difficulty was also observed by Shibuya-Tayoshi et al. (2007).  In this study, 41 healthy 
participants aged 22–49 years (mean age 27.6 years) completed the trail-making task - a 
task of executive function, whilst prefrontal cortex activation was measured using NIRS, 
positioned across the forehead in a 22-channel configuration.  This task is made up of two 
parts (A and B) with part A being easier than the more difficult part B. The main finding 
was that of a significantly larger increase in oxy-Hb during the more difficult part B than 
during part A of the task.  No correlation was observed however between oxy-Hb and task 
performance and once again, no effects on deoxy-Hb or total-Hb were reported.   
Studies where the effects on deoxy-Hb and total-Hb are reported (in addition to 
those on oxy-Hb), perhaps give a fuller picture of the effects of task performance and 
difficulty on cerebral oxygenation.   Schroeter et al., (2002) measured haemodynamics 
using NIRS in the frontal cortex during neutral, congruent and incongruent trials of the 
Stroop task in 14 healthy young male participants aged 19-29 years (mean age 23.9 
years).  The results demonstrated that concentrations of oxy-Hb and total-Hb increased 
and deoxy-Hb decreased.  Furthermore, the incongruent trials led to a stronger vascular 
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response than neutral trials, a finding which confirmed an increase in neuronal activity as 
a result of the interference caused by the (more difficult) incongruent version of the task.  
In an assessment of the haemodynamic impact of the Wisconsin Card Sorting task 
(WCST), Fallgatter and Strik, (1998) measured oxy-Hb and deoxy-Hb in the frontal cortex 
of 10 healthy young subjects aged 27-33 years (mean age 30 years).  Their findings 
demonstrated a significant increase in oxy-Hb during performance on the WCST as 
compared to a resting baseline.  A corresponding decrease in deoxy-Hb was also 
reported; however, this effect failed to reach significance.  Medvedev et al., (2011) 
assessed haemodynamic change in the pre-frontal cortex using a 3 x 8 configuration 
across the inferior frontal gyrus.  Eleven healthy participants aged 18-30 (mean age 23 
years) were required to perform the object recognition task (Go-NoGo task).  They 
observed an increase in oxy-Hb, with a corresponding decrease in deoxy-Hb that was 
found to be greater in the left versus the right hemisphere.   
The evidence from functional NIRS studies during the performance of cognitive 
tasks would appear to suggest that cerebral activation as identified by fNIRS is expressed 
as an increase in oxy-Hb (and or total-Hb) and (in some instances) a corresponding 
decrease in deoxy-Hb.  However, as will be discussed in the next section, this pattern of 
effects is subject to change with the introduction of nutritional or pharmacological 
interventions. 
 
Figure 1.2 Example of arrangement of NIRS device optodes, showing a multi-channel, 5 x 
4 (emitter by detector) 12-channel configuration across each hemisphere, taken from Sato 
et al (2011).  Included for reference purposes to demonstrate a multi-channel system.  For 
example of configuration used in present thesis, please see figure 1.1. 
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1.3.4.4 fNIRS and fMRI 
Since fMRI is considered the current gold standard for functional neuroimaging, a 
number of studies have sought to evaluate the concurrent use of NIRS and fMRI methods 
in an attempt to validate the NIRS technique as well as attempting to overcome each 
modality’s inherent limitations.  With a view to confirm the response pattern as a result of 
functional activation, Kleinschmidt et al., (1996) mapped the effects of a finger tapping 
task during the simultaneous acquisition of MRI and NIRS measurements.  Through exact 
spatial matching of the NIRS optodes to the task-activated motor cortex area (identified by 
MRI), they confirmed that both methods observed a decrease in deoxy-Hb, NIRS also 
documented an increase in oxy-Hb; however, this was reasoned to be smaller and less 
specific than that of deoxy-Hb.  Cui et al., (2011) monitored simultaneous NIRS and fMRI 
measurements during the completion of a battery of cognitive tasks.  Here it was observed 
that whilst both oxy-Hb and deoxy-Hb correlated with the fMRI BOLD signal, oxy-Hb 
demonstrated a statistically significant advantage over deoxy-Hb (albeit a small one).  In 
other studies of NIRS and fMRI data acquisition, the simultaneous use of these systems 
has established that although NIRS has lower signal-to-noise ratio, NIRS measures of 
both deoxy-Hb (Huppert et al., 2006; Sato et al., 2013; Schroeter, Kupka, Mildner, Uludag, 
& Von Cramon, 2006; Toronov, Webb, & Choi, 2001) and oxy-Hb (Strangman, Culver, 
Thompson, & Boas, 2002) correlate well with the fMRI BOLD signal.  Furthermore, Obrig 
et al. (2000) identified a decrease in deoxy-Hb during fNIRS studies as a robust indicator 
of haemodynamic change as a result cerebral activation. 
1.3.4.5 fNIRS and EEG 
 There are an increasing number of studies that are using EEG in combination with 
NIRS in order to provide a concomitant assessment of cerebral activation.  The benefit of 
this approach is that simultaneous measures of local haemodynamic and neuronal 
electrical activity can be obtained at a high temporal resolution.  These measures can be 
achieved over lengthy periods of time, in a quiet setting, under conditions that more 
closely reflect everyday life, where participants are not immobilised (Wallois, 
Mahmoudzadeh, Patil, & Grebe, 2012).  The integration of NIRS and EEG technologies 
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has been successfully adopted in children in the assessment of the new-born auditory 
cortex and its sensitivity to the temporal structure of sounds (Telkemeyer et al., 2009).  It 
has also been applied to determine the relationship between spontaneous neuronal 
activity and cerebral haemodynamic processes in sleeping premature neonates (Roche-
Labarbe, Wallois, Ponchel, Kongolo, & Grebe, 2007).  In adults, co-registration of these 
two methods has been demonstrated during functional activation whilst responding to a 
simple checkerboard stimulus (Obrig et al., 2002), performing the odd-ball task (Tong et 
al., 2005) and processing emotional stimuli (Herrmann et al., 2008).  It has also been used 
in the assessment of brain computer interface research (Fazli et al., 2012), and during 
language processing (Ehlis et al., 2009; Wallois et al., 2012). 
1.3.4.6 fNIRS and interventions of interest to cognition 
Nutritional interventions, which have demonstrated positive effects on behaviour, 
may, in some cases, also be capable of augmenting cerebral haemodynamics and blood 
flow.  It is this relationship between the observed behavioural and physiological cognitive 
response, which is of great interest, and one which requires additional research within the 
nutritional interventions field.  Assessment of cerebral activation (using NIRS) as a result 
of cognitive performance following the administration of interventions of nutritional interest 
is an area that is receiving more attention in the literature.  A number of studies have been 
conducted that have demonstrated changes in cerebral oxygenation using NIRS during 
task performance in the presence of a range of acute and chronic nutritional challenges.   
Unless otherwise stated all of the following studies are double-blind, placebo-
controlled, crossover studies. 
1.3.4.6.1 fNIRS and caffeine 
In one of the very first fNIRS interventional studies, Niioka and Sasaki, (2003) 
measured cerebral blood flow in the left prefrontal cortex using a 1 x 1 (1-channel) 
configuration.   Following administration of placebo or 200 mg caffeine (a member of the 
methylxanthine family known for its vasoconstrictive effects), participants completed the 
Stroop task.  Ten, healthy participants (no ages reported) took part and the findings 
demonstrated that caffeine significantly reduced oxy-Hb and total-Hb as compared to 
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placebo during performance of the Stroop task.  No effects of caffeine on performance of 
the task were found, however.  Similarly, Higashi et al., (2004) utilised NIRS to measure 
regional cerebral blood volume (rCBV) in the frontal cortex during a mentally demanding 
task following acute caffeine consumption.  Here, 14 participants (21-50 years) completed 
the Uchida-Kraepelin psychodiagnostic (UKP) test (a serial addition test) at baseline and 
following 180 mg caffeine.  Caffeine intake led to a significant reduction in rCBV as 
compared to placebo.  A significant improvement in the number of correct answers was 
also observed following caffeine consumption, although this was not found to be coupled 
with the corresponding change in rCBV.  There are, however, a number of limitations to 
both of these studies; firstly, the caffeine conditions were compared against ‘caffeine-free’ 
or decaffeinated coffee.  Decaffeinated coffee cannot be regarded as a true caffeine free 
alternative as decaffeinated coffee still contains caffeine at levels shown to have 
psychoactive effects (Haskell, Kennedy, Milne, Wesnes, & Scholey, 2008a).  In addition, 
coffee is a beverage that contains other psychoactive compounds (including polyphenols, 
which have been shown to increase CBF) therefore any effects observed may not be 
wholly attributable to the effects of caffeine alone.  Furthermore, within both studies, the 
authors did not account for caffeine consumption status.  This is an important factor when 
assessing the effects of caffeine, as although effects have been demonstrated in both 
consumers and non-consumers, differences exist between their response, both 
behaviourally (Haskell, Kennedy, Wesnes, & Scholey, 2005; Smit & Rogers, 2000) and 
physiologically in terms of blood flow (Addicott et al., 2009; Field, Laurienti, Yen, Burdette, 
& Moody, 2003; Kennedy & Haskell, 2011).  Finally, in the latter study, the age range used 
(21-50 years) is very wide-ranging, particularly considering that CBF is thought to reduce 
with increasing age (Leenders et al., 1990; Martin et al., 1991; Pantano et al., 1984), a 
factor that may have impacted upon the results.  In a more recent study, Heilbronner et al., 
(2015) assessed the CBF effects of caffeine during a working memory (2-back) task in 10 
moderate caffeine consumers (19-34 years, mean age 29.1 years).  Using a 3 x 11 (52 
channel) NIRS configuration, they found that 200 mg caffeine led to a significant reduction 
in oxy-Hb in both the left and right hemisphere of the inferior frontal cortex, with a 
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corresponding increase in deoxy-Hb in the left hemisphere, alone.   There were no effects 
of caffeine on behavioural performance.  Although this study took caffeine consumption 
status into consideration, there were a number of other issues with the study that the 
authors themselves acknowledged.  The study was not placebo controlled, nor was it 
double blind and the order in which participants completed the control and treatment 
sessions were not counterbalanced.  Furthermore, participants were only restricted from 
specifically coffee intake on the morning of the study visit, not caffeine, and as it is well 
known, caffeine can be found in many sources other than coffee.   In a more thorough 
investigation of the acute effects of caffeine, Kennedy and Haskell, (2011) used a 2 x 1 (2-
channel) configuration on the frontal cortex, to examine the effects of 75 mg caffeine, in 
habitual and non-habitual caffeine consumers.   Twenty, healthy young adults (mean age 
21.4 years; 10 habitual consumers and 10 non-habitual consumers) completed the CDB.  
As previously discussed, the CDB is a series of cognitively demanding tasks that have 
been shown to be sensitive to nutritional interventions.  It was demonstrated that 75 mg 
caffeine led to a significant reduction in total-Hb during cognitive task performance as 
compared to placebo; however, this effect was only observed in non-habitual consumers.  
Despite this isolated effect of blood flow, behavioural effects were demonstrated across 
groups, where caffeine led to a significant reduction in the number of serial 7s 
subtractions errors as compared to placebo, irrespective of consumer status.  A consistent 
pattern within the aforementioned fNIRS studies where caffeine is administered, is that the 
reductions in oxy-Hb and or total-Hb (CBF), or changes in deoxy-Hb, do not negatively 
impact upon behavioural performance.  The relevance and mechanism of this effect will 
be discussed later.  However, observations such as this - where there is a change in 
cerebral oxygenation during task performance that does not translate to positive or 
negative behavioural effects has also been observed following other interventions. 
1.3.4.6.2 fNIRS and polyphenols 
Using the same 2-channel NIRS configuration to interrogate the pre-frontal cortex 
as described by Kennedy and Haskell (2011), Wightman et al., (2012) assessed the 
effects of 2 acute doses (135 mg and 270 mg) of epigallocatechin gallate (EGCG).  A 
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polyphenol found in the tea plant, EGCG is thought to confer a number of health benefits, 
including modulation of blood flow and brain function.  Twenty-seven healthy young adults 
(mean age 22 years), performed a range of cognitive tasks whilst haemodynamics were 
monitored via NIRS.  The results demonstrated that EGCG led to a significant decrease in 
total-Hb and oxy-Hb during the task period following the lower (135 mg) dose as 
compared to placebo, in the absence of any change in behavioural performance.  In an 
attempt to delineate the cerebrovascular effects of the polyphenol and vasodilator 
resveratrol, Kennedy et al., (2010) employed NIRS to detect oxygenation changes in the 
frontal cortex using the same configuration and during completion of the same tasks as 
described by Kennedy and Haskell (2011).  Following administration of doses of 250 mg 
and 500 mg, they observed that the 500 mg dose of resveratrol led to significant increases 
in total-Hb and deoxy-Hb as compared to placebo in healthy young adults (mean age 20.2 
years).  They identified this finding as indicative of increased blood flow and oxygen 
extraction, in the absence of any effects on behavioural performance.  In a further study of 
23 healthy young adults, aged 19-34 (mean 21 years) using the same design (with 
additional tasks), 250 mg resveratrol was administered alone and in combination with 20 
mg piperine.  It was anticipated that this alkaloid would enhance the bioavailability and 
bioefficacy of resveratrol.  Following co-administration with piperine, resveratrol led to a 
significant increase in oxy-Hb, deoxy-Hb and total-Hb as compared to placebo and 
resveratrol alone, during the performance of cognitive tasks.  However, once again, no 
concomitant effects of treatment on cognitive performance were observed (Wightman et 
al., 2014).  A chronic investigation of resveratrol was conducted by the same group, using 
the same NIRS configuration and similar tasks.  Here a 500 mg dose administered to 60 
healthy adults aged 18-30 years (parallel groups design), failed to modulate cerebral 
haemodynamics following 28 days’ supplementation.   However, the initial, acute dose, 
led to an increase in oxy-Hb and total-Hb and, in contrast to previous studies, a reduction 
in deoxy-Hb.  In this study there were also findings in relation to behaviour; however, they 
were not consistent in terms of their direction and the authors concluded they should be 
treated with caution (Wightman, Haskell-Ramsay, Reay, et al., 2015).  Again, it is of 
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interest here that despite the augmentation of oxy-Hb as well as total-Hb (and in some 
cases deoxy-Hb), there were few or no concomitant improvements in behavioural 
performance across these studies. 
1.3.4.6.3 fNIRS and fish oil 
Jackson et al., (2012a) assessed the impact of chronic supplementation of omega-
3 polyunsaturated fatty acid (PUFA) on cerebral oxygenation, using the same 2-channel 
configuration as Kennedy and Haskell (2011).  In an independent measures study, 22 
healthy young adults (mean age 21.9 years) received 12 weeks’ daily supplementation of 
1 g docosahexaenoic acid (DHA)-rich fish oil, 1 g eicosapentaenoic (EPA)-rich fish oil or 
placebo (olive oil).  Chronic supplementation with 1 g DHA-rich fish oil led to a significant 
increase in oxy-Hb during the Stroop task, and a significant increase in total-Hb during the 
Stroop, peg and ball and 3-back tasks as compared to placebo.  There were, however, no 
associated effects upon cognition.  In a further study,  Jackson, Reay, Scholey, and 
Kennedy (2012b) administered 1 g or 2 g of DHA-rich fish oil or placebo for 12 weeks to 
65 healthy adults (mean age 20.6 years) whilst cerebral oxygenation was measured in the 
pre-frontal cortex (PFC) (as above), during cognitive tasks.  They observed that both 
doses led to a significant increase in oxy-Hb during the entire testing battery (which 
included a range of memory, attention and executive function tasks).  For total-Hb the 
same consistent pattern of significant effects was observed across tasks for the 2 g dose; 
however, following the 1 g dose, it was only observed during two of the cognitive tasks, 
suggesting a dose-response effect for total-Hb.  There were no effects of either dose on 
deoxy-Hb.  There was some evidence of modulation of behavioural performance on 
reaction time and a task of attention; however, the authors note they should be treated 
with caution, since, if corrections for multiple testing had been conducted, these significant 
effects would have been lost.  NIRS has also been used to measure changes in 
oxygenation status following chronic administration of PUFAs in healthy elderly adults.  
Using an independent measures design, Konagai et al., (2013) administered either 2 g 
krill oil (an omega-3 PUFA-rich plankton oil), sardine oil (also high in omega-3 PUFAs) or 
a placebo (containing medium-chain triglycerides) to 42 healthy older males aged 61-72 
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(mean age 67.1 years) every day for 12 weeks.  Performance on a version of the 2-back 
working memory task was assessed via simultaneous fNIRS and EEG and performance 
of the UKP task was assessed via fNIRS following 6 and 12 weeks’ supplementation.  A 
24-channel array measured NIRS readings from the dorsolateral pre-frontal cortex.  It was 
found that 12 weeks’ supplementation of both krill and sardine oil led to significantly 
elevated levels of oxy-Hb as compared to placebo during the 2-back task.  Krill oil alone 
significantly increased oxy-Hb as compared to placebo during the UKP test.  Krill oil also 
resulted in a significant reduction in P300 latency at Cz and Pz sites as compared to 
placebo, following 12 weeks’ supplementation.  Unfortunately, no details were provided 
regarding performance on either of the cognitive tasks so it is not possible to draw any 
conclusions on whether the observed increases in oxy-Hb or the reduction in P300 latency 
translated into positive or negative behavioural effects, or if there was an absence of an 
effect altogether. 
1.3.4.6.4 fNIRS and other nutritional interventions 
In a further chronic study, Konagai et al., (2013) assessed cerebral oxygenation 
following 7 days supplementation with essence of chicken extract.  Essence of chicken 
(EOC) is a traditional protein, peptide and amino acid containing drink, consumed 
regularly in Southeast Asia as a nutritional supplement and as a treatment for a number of 
ailments, including anxiety.  Twelve healthy older participants, aged 60-68 (mean age 
62.3 years) were assessed during the performance of tasks assessing working memory, 
spatial memory and reaction time.    fNIRS readings were recorded from the pre-frontal 
cortex using a 25-channel configuration.  It was demonstrated that compared to baseline 
performance of the 2-back task, oxy-Hb was significantly elevated following 7 days’ 
supplementation with EOC.  In contrast, there were no effects following placebo and there 
were no concomitant effects on behavioural performance.  Unfortunately, no comparison 
of active treatment to placebo was made within this study.  In an evaluation of the chronic 
effects of creatine, Wantanabe et al, (2002) assessed cerebral oxygenation following 
administration of 8 mg/day for 5 days during performance of the UKP task and the level of 
fatigue elicited as a result.  As compared to pre-treatment task performance, creatine led 
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to a significant reduction in oxy-Hb and a significant increase in deoxy-Hb, in addition to a 
reduction in mental fatigue.  However, again, despite a placebo condition being tested, no 
comparisons of active treatment were made against placebo within this study.  Bonoczk et 
al., (2002) used NIRS in conjunction with transcranial Doppler (TCD) to investigate 
cerebral blood flow and oxygenation changes in stroke patients following the intravenous 
administration of vinpocetine.  Vinpocetine is a vinca alkaloid, derived from the periwinkle 
plant, which is capable of increasing microcirculation and cerebral oxygen uptake.  In an 
independent measures study, ischemic stroke patients (mean age 65 years) were 
administered either 20 mg vinpocetine or placebo. NIRS readings were taken at rest, 
fronto-laterally on the lesional side, with TCD readings taken from the middle cerebral 
artery (MCA) on the lesional side.  The results demonstrated that vinpocetine infusion led 
to a significant increase in deoxy-Hb and a significant increase in Doppler spectral 
intensity (DSI) as compared to placebo, with the authors concluding that these findings 
are indicative of increased regional cerebral blood flow and oxygen extraction. 
Based on the fNIRS studies presented here it would be fair to surmise that 
modulation of cerebral oxygenation as a result of nutritional challenge, does not 
necessarily predict the presence or absence of a behavioural effect.  The interaction of 
these factors is clearly complex and requires further research. 
 
1.4 Nutritional interventions of cognitive interest 
There is a wealth of research that has been conducted assessing the cognitive 
benefits that nutritional interventions can convey.  Intervention-related cognitive research 
tends to focus on the behavioural effects of interventions, through the use of testing 
batteries or via tasks specific to relevant cognitive domains (memory, attention etc.); 
however, some also take into account measures of physiological effects.  Examples of 
interventions that have received a lot of interest in terms of their effects on cognition are 
detailed in the following section, with a spotlight on those that have an impact on cognition 
in young, healthy adults and the ability to modulate neurophysiological parameters. 
38 
 
1.4.1 Interventions of interest to cognition 
1.4.1.1 Herbal extracts 
 The use of herbal extracts for the improvement of health and wellbeing has gained 
increased interest in more recent times, with people looking for seemingly more ‘natural’ 
methods where they can self-medicate in order to benefit health.  Of the extracts that have 
received attention, two examples have received a degree of interest in terms of research 
for their purported cognitive enhancing effects; Panax ginseng and Ginkgo biloba. 
1.4.1.1.1 Ginkgo biloba 
Ginkgo biloba is an extract taken from the leaves of the Ginkgo biloba (or maiden 
hair) tree, used for centuries within Chinese medicine for a range of ailments.  Ginkgo 
biloba belongs to the Ginkgoceae botanical family and the ginkgo tree from which the 
extract is obtained is one of the oldest living species on the planet (Mahadevan & Park, 
2008).  It has received attention more recently, as a therapy capable of modulating 
‘cerebral insufficiency’ or memory impairment in older populations (Kleijnen & Knipschild, 
1992), as a potential treatment for dementia (LeBars et al., 1997) and for augmenting 
cerebral blood flow (Mashayekh et al., 2011).  Although at present, the specific 
mechanisms by which ginkgo augments peripheral and cognitive parameters are not fully 
understood, biflavone glycosides and terpene lactones are the active constituents within 
ginkgo that are thought to underlie its effects (Park, Rhee, & Lee, 2005).  In-vivo and in-
vitro assessments of these fractions have demonstrated that their administration leads to 
a number of effects that may explain some of ginkgo’s therapeutic actions, for example 
platelet activating factor antagonism (Koch, 2005; Stromgaard et al., 2002), implicated as 
a mechanism by which ginkgo may exert its neuroprotective action (Smith, Maclennan, & 
Darlington, 1996).  These fractions have also led to modulation of neurotransmitters, for 
example through the increased uptake of serotonin (Ramassamy, Christen, Clostre, & 
Costentin, 1992).  Increases in dopamine and noradrenaline release have also been 
observed, which may relate to improvements in cognitive function (Kehr et al., 2012).  
Increased nitric oxide production via endothelial nitric oxide synthase which may lead to 
vasodilation (Ahlemeyer & Krieglstein, 2003).  It also possesses antioxidant properties 
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(Bridi, Crossetti, Steffen, & Henriques, 2001; Maitra, Marcocci, Droylefaix, & Packer, 
1995). 
The methodological approach adopted by studies assessing the cognition-related 
efficacy of ginkgo in older populations, has focussed on the cognitive task related effects 
of ginkgo as a primary outcome measure, specifically tasks that assess learning and 
memory (Gold, Cahill, & Wenk, 2002).  Recent reviews of ginkgo’s efficacy within clinical 
populations have determined that in the treatment of Alzheimer’s disease (AD) ginkgo 
performs better than placebo and is able to help with the cognitive symptoms of sufferers 
of established AD (Weinmann, Roll, Schwarzbach, Vauth, & Willich, 2010; Yang et al., 
2014); although it does not prevent the disease’s neurodegenerative progression (Yang et 
al., 2014).  Other approaches in the evaluation of ginkgo’s cognitive effects in older 
populations have included EEG assessments of cerebro-electrical activity.  Here ginkgo 
has been shown to reduce P300 latency in patients with age associated memory 
impairments (AAMI) (Semlitsch, Anderer, Saletu, Binder, & Decker, 1995).  It has also led 
to modulation of theta and alpha activity in dementia sufferers (Hofferberth, 1994; Itil, 
Eralp, Ahmed, Kunitz, & Itil, 1998) as well as in healthy older participants (Gessner, Voelp, 
& Klasser, 1985; Itil, Itil, Eralp, & Le Bars, 1996).  Research of the extracts’ vascular 
effects, particularly in terms of CBF, includes only a limited number of studies.  
Assessments using dynamic susceptibility contrast-enhanced magnetic resonance 
imaging and Single Photon Emission Computer Tomography have demonstrated that in 
healthy older participants, chronic ginkgo administration leads to increased CBF 
(Mashayekh et al., 2011; Santos et al., 2003).  One study to date has assessed the 
chronic effects of ginkgo on blood oxygenation using NIRS.  The study found that reaction 
time on a working memory task was improved in middle aged women (44-55) and that the 
pattern of PFC activation was changed to right-dominant, following 6 weeks of 120 
mg/day gingko supplementation (Sakatani, Tanida, Hirao, & Takemura, 2014) 
Within healthy young populations, ginkgo research has also tended to focus on the 
cognitive-task related effects of the extract, with few studies employing additional methods 
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of evaluation such as neuroimaging, to investigate neurophysiological correlates.  
Assessments of cognitive ability have, in the majority of studies, been focussed on tasks 
of attention and memory, with largely positive outcomes being observed as a result of 
ginkgo administration (Elsabagh, Hartley, Ali, Williamson, & File, 2005; Kennedy, Jackson, 
Haskell, & Scholey, 2007; Kennedy, Scholey, & Wesnes, 2000, 2002; Stough, Clarke, 
Lloyd, & Nathan, 2001).  The limited number of studies that have adopted other methods 
of assessment have utilised EEG to monitor cerebro-electrical activity within this 
population.  However, although modulation of activity has been observed following ginkgo 
administration across all EEG studies, the findings are relatively inconsistent overall (Itil et 
al., 1996; Kennedy et al., 2003; Kunkel, 1993). 
1.4.1.1.2 Panax ginseng 
The ginseng plant belongs to the Araliaceae family; Panax ginseng is one of 13 
species of ginseng and is grown in the USA, Russia and most notably the Far East where 
it has been used for thousands of years as a medicinal herb (Yun, 2001).  Panax ginseng 
is an extract sourced from the root of the ginseng plant and is a herbal remedy which has 
had a long history of medicinal use in a number of countries for its ability as a tonic.  In 
this respect it has been used to strengthen and invigorate a weakened body and to 
alleviate symptoms including headache, fatigue, dizziness, nausea, haemorrhage and 
impotence (Park et al., 2005).  The active constituents within ginseng are saponins or 
ginsenosides, with the most prevalent in Panax ginseng being Rg1 and Rb1 (Sengupta et 
al., 2004).  The main focus of ginseng research in humans has been upon its potential to 
modulate cognition.  Within clinical populations, ginseng has been shown to enhance 
cognitive performance in both AD patients (Lee, Chu, Sim, Heo, & Kim, 2008) and those 
with age, associated memory impairments (AAMI) (Neri, Andermarcher, Pradelli, & 
Salvioli, 1995).  However, reviews of the extracts’ efficacy on neurodegenerative diseases 
have reported that evidence for its use as an AD treatment is scarce and inconclusive 
(Lee et al., 2008) and there is a lack of high quality evidence of its effects in dementia 
(Geng et al., 2010).  Within younger populations, a more exploratory approach has been 
adopted to identify behavioural effects of the extract.  Studies have employed a range of 
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tasks assessing attention, reaction time, executive function, memory and mood and these 
studies have obtained mixed results in terms of ginsengs’ efficacy following acute and 
chronic supplementation (Dangelo et al., 1986; Kennedy, Haskell, Wesnes, & Scholey, 
2004; Kennedy, Scholey, & Wesnes, 2001b; Kennedy et al., 2002; Reay et al., 2005, 2006; 
Sunram-Lea, Birchall, Wesnes, & Petrini, 2005).  Despite the interest in ginsengs’ effects 
on cognitive performance, human studies assessing the associated neurophysiological 
effects of the extract are few, with only one study to date evaluating its cerebro-electrical 
effects using EEG (Kennedy et al., 2003).   
1.4.1.2 Caffeine 
 A member of the methylxanthine family and a substance that is found to occur 
naturally in plants, caffeine is another example of a nutritional intervention that is able to 
convey cognitive benefits.  The mechanism by which caffeine exerts its effects is now 
largely accepted to be through antagonism of adenosine A1 and A2A receptors (Fredholm, 
Battig, Holmen, Nehlig, & Zvartau, 1999a), with antagonism of A1 effects being more 
closely related to neural activation and A2A antagonism resulting in vascular effects 
(Laurienti et al., 2003).  There is an abundance of research assessing caffeine’s 
behavioural effects on cognition, and its ability to improve subjective alertness and 
performance on tasks of attention are well documented (Childs & de Wit, 2006; Haskell, 
Kennedy, Milne, Wesnes, & Scholey, 2008b; Quinlan et al., 2000; Rogers, 2007; Smit & 
Rogers, 2000).  Findings such as these have perhaps contributed to its reputation for 
being the most widely consumed psychoactive substance in the world (Fredholm et al., 
1999a).  Caffeine is also known for its vascular effects and studies have documented both 
elevations in blood pressure (Noordzij et al., 2005; Nurminen, Niittynen, Korpela, & 
Vapaatalo, 1999; Rogers, Smith, Heatherley, & Pleydell-Pearce, 2008) as well as 
constricting effects on the cerebral vasculature.  Magnetic resonance imaging (Addicott et 
al., 2009; Chen & Parrish, 2009a; Field et al., 2003; Haller et al., 2013; Laurienti et al., 
2003; Mathew & Wilson, 1991; Rack-Gomer, Liau, & Liu, 2009) as well as NIRS studies 
(Kennedy & Haskell, 2011) have demonstrated that caffeine significantly reduces cerebral 
blood flow.  Reductions in cerebral blood velocity have also been observed, as assessed 
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by transcranial Doppler (Hasse et al 2005).  Interventional studies that have had a 
cognitive focus have therefore adopted measurements of peripheral and or central 
physiological parameters during caffeine’s assessment (Haller et al., 2013; Kennedy & 
Haskell, 2011; Rogers et al., 2008).  One way in which caffeine could be termed unique in 
comparison to many other nutritional interventions, is in its capacity to uncouple blood 
flow.  Calibrated to hypercapnia BOLD fMRI studies have demonstrated that following a 
~200 mg dose of caffeine, CBF is reduced; however, the cerebral metabolic rate of 
oxygen (CMRO2) remains unchanged (Perthen, Lansing, Liau, Liu, & Buxton, 2008), or 
increases in response to task stimulation (Chen & Parrish, 2009a).  For this reason its 
proposed use as a BOLD contrast booster in MRI studies (Mulderink, Gitelman, Mesulam, 
& Parrish, 2002) is controversial (Laurienti et al., 2003).  Owing to the way in which BOLD 
is measured (being sensitive to changes in the level of oxygenation as opposed to 
changes in blood flow directly), fMRI is not without its limitations in terms of the 
assessment of caffeine’s cerebro-vascular and neural effects, despite being the gold 
standard for neuro-imaging. 
1.4.1.3 L-theanine 
A naturally occurring amino-acid, L-theanine is found almost uniquely in tea 
(Camellia sinensis), where it coexists with caffeine.  L-theanine has a chemical structure 
similar to that of the neurotransmitter glutamic acid (Nathan, Lu, Gray, & Oliver, 2006) and 
is able to cross the blood-brain barrier.  It also has the ability to alter neurotransmitter 
concentrations; increases in dopamine concentrations have been observed in the rat brain 
in a dose dependent manner (Yokogoshi, Kobayashi, Mochizuki, & Terashima, 1998), 
intraperitoneal administration to mice led to an increase in GABA (Kimura & Murata, 1971) 
and modulation of serotonin levels in rats have also been observed (Yokogoshi et al., 
1995; Yokogoshi et al., 1998).  L-theanine has also been shown to protect against human 
neuronal cell death in vitro (Cho et al., 2008).  Interventional studies that have 
investigated its capacity as an anxiolytic have demonstrated positive effects (Kimura, 
Ozeki, Juneja, & Ohira, 2007; Rogers et al., 2008).  However, it has received most 
attention within human research for its cognitive effects, both alone and in combination 
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with caffeine (Gomez-Ramirez et al., 2007; Gomez-Ramirez, Kelly, Montesi, & Foxe, 2009; 
Haskell et al., 2008a; Kelly, Gomez-Ramirez, Montesi, & Foxe, 2008; Owen, Parnell, De 
Bruin, & Rycroft, 2008).  In terms of its neurophysiological effects, although there have 
been assessments of cerebro-electrical parameters as measured by EEG (Gomez-
Ramirez et al., 2007; Gomez-Ramirez et al., 2009; Juneja, Chu, Okubo, Nagato, & 
Yokogoshi, 1999; Nobre, Rao, & Owen, 2008), no studies to date have used alternative 
neuro-imaging techniques to measure the effects of L-theanine administration.  In addition, 
where cerebro-electrical activity and behaviour have been co-monitored, all studies have 
focussed on the effects during performance of predominantly attentional tasks (Gomez-
Ramirez et al., 2007; Gomez-Ramirez et al., 2009; Kelly et al., 2008). 
1.4.1.4 Beetroot 
 Beetroot is a member of the chenopodiaceae family and a vegetable receiving an 
increased level of interest within exercise and cognition-related studies, due to the 
comparatively high levels of nitrate it contains (Santamaria, Elia, Serio, & Todaro, 1999).  
The significance of this being that supplementary dietary nitrate has been associated with 
increased nitric oxide (NO) production (Webb et al., 2008).  Nitric oxide is a signalling 
molecule which, amongst other actions, is known to modulate cerebral and peripheral 
vasodilation (Moncada & Higgs, 1993; Toda, Ayajiki, & Okamura, 2009).  The majority of 
studies to date that have evaluated the effects of beetroot juice, have had a 
methodological focus that is primarily exercise-related (Bailey et al., 2010; Bailey et al., 
2009; Bond et al., 2013; Kelly et al., 2013; Kenjale et al., 2011; Lansley, Winyard, Bailey, 
et al., 2011; Lansley, Winyard, Fulford, et al., 2011; Vanhatalo et al., 2010).  Those that 
have included cognitive tasks, have either done so in the absence of exercise (Wightman, 
Haskell-Ramsay, Thompson, et al., 2015), or have conducted them post-exercise, (Kelly 
et al., 2013), with only two during exercise performance (Rattray et al., 2015; Thompson 
et al., 2015).  Of these two studies, only one simultaneously measured cerebral perfusion 
during performance of the tasks (Rattray et al., 2015).  Where neurophysiological 
assessments are concerned therefore, there are few studies that have explored the 
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effects of beetroot in healthy, young humans during cognitive and simultaneous exercise 
performance. 
 
1.5 General conclusions 
 The identification of nutritional interventions with the capability to improve cognitive 
performance or protect against cognitive decline is of increasing importance, particularly in 
light of an ageing population.  This, coupled with a heightened awareness of the potential 
for nutritional supplementation to improve our cognitive as well as our physiological health 
has meant that now, more than ever, public interest in this area is high.  This is 
demonstrated by a rise in the availability and sale of off-the-shelf remedies with a 
concomitant increase in self-medication.  Indeed in the UK in 2009, the dietary 
supplements and vitamins market was worth at least 670 million, representing a growth of 
over 16 % between 2006 and 2011 (NHS, 2011).  Patterns of behaviour such as this 
highlight the need for ongoing research into the effects of nutritional interventions and the 
benefits they may convey. 
The methods and technologies available to monitor the cognitive effects of 
nutritional interventions are wide-ranging; however, not all lend themselves to being 
suitable for integration with other technologies and methodologies.  The benefit of 
adopting such an approach is that it is possible to obtain information not only in relation to 
the cognitive effects the supplement can convey but also perhaps the physiological means 
by which these effects occur.  NIRS has established itself as a valid method for the 
measurement of cerebral oxygenation at rest and during the performance of cognitive 
tasks as well during active states and whilst exercising and also one that can be 
incorporated with other imaging modalities (for example fMRI and EEG).   
 
1.6 Summary and objectives of the thesis 
An increase in the availability of new technologies has meant that novel 
approaches for testing cognitive ability can be broached.  In conjunction, a growing 
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flexibility in the ability of imaging techniques such as NIRS to assess neurophysiological 
parameters under a variety of conditions means that there is now scope for assessing the 
impact of nutritional interventions within a range of paradigms.  There are a number of 
nutritional interventions known to modulate cerebral blood flow, examples of which include 
caffeine, L-theanine, ginkgo, ginseng and beetroot juice (nitrates).  This ability, coupled 
with the fact that each is also known to possess cognition enhancing properties means 
they are ideally suited for use within studies assessing not only behavioural but also 
neuro-physiological performance. 
The main aims of the thesis are: 
• The identification of technologies that can be used either together (or alone) in the 
novel assessment of nutritional interventions and their effects upon cognition. 
• To identify methodologies that can be implemented concomitantly during the 
assessment of interventions of interest to cognition. 
• To expand the current knowledge base on the ability of specific nutritional 
supplements to benefit cognitive and physiological performance. 
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Chapter 2. The effects of Ginkgo biloba and a Ginkgo biloba/Panax 
ginseng combination on cerebro-electrical activity and blood flow in 
healthy adults. 
 
2.1 Introduction 
Ginkgo biloba is currently marketed as a herbal remedy capable of enhancing 
cerebral blood flow and improving memory (Smith et al., 1996).  It is beyond the scope of 
this thesis to review all studies relating to ginkgo and its effects, therefore only the most 
pertinent in terms of those that have assessed behavioural or neurophysiological effects 
or a combination of these factors are discussed below.  In terms of behaviour, there have 
been a number of studies that have assessed the effects of an acute, single dose of 
ginkgo, (standardised to approximately 24% flavone glycosides, 6% terpene lactones) the 
majority of which have been conducted within healthy young populations.  Elsabagh et al. 
(2005) observed that an acute dose of 120 mg ginkgo led to an improvement in sustained 
attention.  Although this same dose has since been found to reduce the speed of 
performing attentional tasks (Kennedy, Jackson, et al., 2007), higher doses of 240 mg and 
360 mg have been found to significantly increase in the speed of performing attentional 
tasks, 2.5, 4 and 6 hours post treatment (Kennedy et al., 2000).  Enhanced performance 
on tasks of mental arithmetic has also been observed following a 360 mg dose, as 
demonstrated by a reduction in the number of errors made on a serial 3s subtraction task 
and an increase in total serial 7s subtractions responses (Kennedy et al., 2002).  Acute 
administration has also led to improvements in memory as assessed by a ‘quality of 
memory’ factor following doses of 120 mg and 360 mg (Kennedy, Jackson, et al., 2007; 
Kennedy et al., 2002).   Turning to chronic effects, again, there have been a number of 
studies assessing the behavioural impact of ginkgo supplementation; however here, a 
greater proportion of research has been conducted in older participants, in addition to 
healthy young populations.  Stough et al. (2001) observed that 30 days supplementation 
with 120 mg of ginkgo to healthy, young participants resulted in significant improvements 
in speed of working memory (Digit Span backwards) and memory consolidation (Auditory 
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Verbal Learning Test).  However, Elsabagh et al. (2005) found that the same dose, 
administered for 6 weeks (42 days) did not lead to any improvements in tasks measuring 
sustained attention, memory or mood.  Other studies assessing the behavioural effects of 
chronic ginkgo supplementation in healthy, older cohorts have shown that administration 
of 80 mg/day for 14 days resulted in a significant increase in accuracy on an object 
working memory task (Silberstein et al., 2011).  Mix & Crews, (2000) observed that 6 
weeks administration of 180 mg/day led to a significant improvement in performance on 
the Stroop task.  A further study by the same group identified that and identical dose of 
ginkgo over the same duration led to an increase in the recall and recognition of auditory-
verbal material on the Selective Reminding Test (SRT) (Mix & Crews, 2002).  A longer, 8 
month intervention with 80 mg/day ginkgo resulted in improvements on a number of tasks 
assessing attention, information processing speed and visuospatial ability (Santos et al., 
2003).  In summary, the evidence presented here, appears to suggest that overall acute 
supplementation with ginkgo in healthy young adults may lead to improvements in mental 
arithmetic, memory and attention, with improvements in speed of performing attentional 
tasks being observed following higher doses.  The evidence in relation to chronic 
supplementation also appears to reflect an encouraging pattern of effects in older 
populations; leading to improvements in memory, attention and executive function.  
However, in young adults, the findings are less consistent and although improvements 
have been observed in memory, an absence of effects in memory as well as other areas 
such as attention and mood have also been reported. 
In relation to the neurophysiological effects of ginkgo, there is a relative absence of 
human research into the impact on cerebral blood flow (CBF) following acute 
administration, despite evidence that its antioxidant effects and those on nitric oxide (NO) 
synthesis may underlie the increases in CBF seen in animal studies (Ahlemeyer & 
Krieglstein, 2003).  Where chronic administration has been assessed, most studies have 
focussed on healthy, older adults.  Ginkgo administered to a cognitively intact cohort, 
aged 60-70 years at 80 mg/day for 8 months led to an increase in cerebral perfusion in 
frontal, parietal and occipital areas of the brain as assessed by Single Photon Emission 
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Computer Tomography (SPECT) (Santos et al., 2003).  However, in a study of a similar 
cohort (cognitively intact, aged 51-71), the effects on CBF (as assessed by dynamic 
susceptibility contrast-enhanced magnetic resonance imaging) of 120 mg/day ginkgo over 
4 weeks, were less convincing.  Here a significant increase in the left parieto-occipital 
region was demonstrated; however, the increase was small and observed only when an 
uncorrected p-value (p<0.001) was applied (Mashayekh et al., 2011).  It is also of note 
here that sample size was small (n=9) and the duration of supplementation was much 
shorter than that of Santos et al. (2003).  In a study of pre-frontal cortex (PFC) activation, 
(using a larger sample, n=19), Sakatani et al. (2014) assessed the effects of 6 weeks 
supplementation with 120 mg ginkgo, in a healthy middle aged cohort (44-50 years) using 
NIRS.  They demonstrated that during performance of the Sternberg working memory test, 
ginkgo led to a shift from bilateral activation (observed during performance of the task in 
the absence of treatment) to right-dominant PFC activation.  Assessments of cerebro-
electrical effects of the extract have used EEG to monitor brain activity, with the majority 
of studies focussing on healthy older populations or those with age-associated cognitive 
impairment.  Acute administration in healthy populations (aged 18-65 years) has led to 
increases in alpha activity following 40 mg, 120 mg and 240 mg with effects being 
demonstrated 1 hour post-dose and continuing until 7 hours post-dose (Itil et al., 1996).  A 
chronic dose (57 days) of 120 mg also led to shortened P300 latency in participants with 
age-associated memory impairment (Semlitsch et al., 1995), and a single 240 mg dose 
resulted in increases in resting alpha and a reduction in slow waves in dementia patients 
(Itil et al., 1998).  Where cerebro-electrical activity has been assessed following chronic 
supplementation in healthy older adults (50-61 year olds), 80 mg/day for 14 days, led to 
an increase in amplitude and latency of steady state visually evoked potentials (SSVEP) 
during an object working memory task.   Taken in conjunction with improved behavioural 
performance, this finding was identified as being representative of more efficient 
processing (Silberstein et al., 2011).  In healthy older adults (aged 57-77 years) who 
reported some symptoms of cerebral deterioration and who had the weakest level of 
vigilance at baseline, 120 mg/day (administered for 4, 8 and 12 weeks) led to an increase 
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in resting alpha activity and an improvement in simple reaction times (Gessner et al., 
1985).  Where pathological cohorts have been used, administration of 120 mg for 57 days 
led to shortened P300 latency in participants with age-associated memory impairment 
(Semlitsch et al., 1995).  In Alzheimer’s dementia patients, 240 mg/day for 3 months led to 
a reduction in theta wave activity (Hofferberth, 1994).  Taken together the research to date 
suggests that ginkgo is capable of positively modulating CBF and cerebro-electrical 
activity; however, this is dependent upon dose and duration of supplementation. 
Panax Ginseng (G115 extract, standardised to contain 4% ginsenosides) has been 
evaluated in a number of exploratory behavioural studies within young healthy populations.  
The findings have demonstrated largely positive effects during assessments of memory, 
attention and mood (Kennedy et al., 2004; Kennedy et al., 2001b, 2002; Reay et al., 2005; 
Reay, Scholey, & Kennedy, 2010; Sunram-Lea et al., 2005).  Two hundred milligrams 
ginseng led to improved performance on a mentally demanding task (serial 7s 
subtractions) and reduced subjective feelings of mental fatigue (Reay et al., 2005) and 
both a 200 mg and 400 mg dose increased subjective feelings of calmness in healthy 
young adults (Reay et al., 2010).  It has also been shown to improve secondary as well as 
working memory performance following acute supplementation of 200 mg (Kennedy et al., 
2004) and 400 mg (Kennedy et al., 2001b, 2002; Reay et al., 2010) doses.  However, the 
200 mg dose has been shown to slow reaction time on a working memory task (Reay et 
al., 2010) and been associated with decrements in performance on a speed of attention 
factor (Kennedy et al., 2001b).  However, this effect on speed of attention was not 
replicated in a further study with a similar methodology by the same research group 
(Kennedy et al., 2002) and was contrary to the findings of a later study, which 
demonstrated that 200 mg ginseng led to a significant improvement in speed of attention 
at both 4 and 6 hours post-dose (Kennedy et al., 2004).  Similarly, a 400 mg dose of 
ginseng has also led to improvements in a speed of attention factor (Sunram-Lea et al., 
2005).  However, despite the positive effects on cognition, both a 200 mg and 400 mg 
dose have resulted in significant reductions in subjective alertness, six hours following 
treatment administration (Kennedy et al., 2001b).  Despite the attention ginseng has 
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received in terms of its cognitive effects, there is an absence of human research into its 
effects on cerebral blood flow, with the only animal study to date demonstrating an 
increase in resting cerebral blood flow as assessed by laser-doppler flowmetry, 30 
minutes after administration of 100 mg/kg of the crude saponin fraction of ginseng, to rats 
(Kim et al., 2002). 
Turning to the combined effects of these extracts, the majority of human research 
conducted has also focused upon the effects on cognition.  A study assessed three 
different acute doses of ginkgo/ginseng in combination (extracts standardised as 
previously reported) (320 mg combination = 120 mg ginkgo and 200 mg ginseng; 640 mg 
combination = 240 mg ginkgo and 400 mg ginseng; 960 mg combination = 360 mg ginkgo 
and 600 mg ginseng), in healthy young adults.  They found that 960 mg led to a significant 
improvement in memory, with the lower two doses leading to a significant reduction in 
speed of attention (Kennedy, Scholey, & Wesnes, 2001a).   A follow-up acute study in 
healthy young adults by the same research group assessing the highest 960 mg dose 
confirmed the effects on memory and also demonstrated a significant increase in the 
number of serial 3s and 7s subtraction responses made and a reduction in the number of 
serial 7s errors.  Participants also rated themselves as being more content.  However, a 
reduction in speed of attention was also reported at this dose (Kennedy et al., 2002).  
Findings across both of these studies were demonstrated between 1 and 6 hours post-
dose.  There are comparatively few studies assessing the behavioural effects of this 
combination, and with some inconsistencies in effects of those that have, there is 
evidently more scope for research in terms of the cognitive effects of this combination. 
Despite the majority of research focussing on the effects on cognitive performance, 
one study has assessed the effects of this combination on cerebro-electrical activity via 
EEG.  Dimpfel et al. (2006) administered a soft drink containing fruit juices and a 
combination of 114 mg ginseng and 980 mg ginkgo for 3 days to healthy participants aged 
33-55 years (as compared to a matched placebo).  They observed that the combination 
led to a significant increase in eyes-open delta power at rest and whilst reading a text in 
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central, parietal and occipital regions 2 hours after treatment, with a significant increase in 
theta power also observed whilst reading a text, 1 hour after treatment.  In an attempt to 
delineate the acute cerebro-electrical effects of these individual herbal extracts, Kennedy 
et al. (2003) administered separate doses of 360 mg ginkgo and 200 mg ginseng to 
healthy young volunteers and measured EEG activity during resting eyes open/closed and 
whilst completing an auditory version of the oddball task.  It was demonstrated that both 
ginkgo and ginseng led to a decrease in resting eyes closed theta and beta activity in the 
frontal region of the brain.  Ginseng also led to a decrease in alpha activity and a 
reduction in P300 latency 4 hours post-treatment in left temporal and occipital brain 
regions.  Overall, it was tentatively concluded that the EEG effects of ginseng were 
stronger than those of ginkgo, at the doses tested.  The ability of ginkgo, ginseng, and 
their combination to modulate cerebro-electrical activity has been demonstrated; however, 
once again, the findings are not wholly consistent and therefore require further 
investigation.  
With this in mind, the present study looked to extend this research and further 
explore the cerebro-electrical (EEG) activity of standardised (see treatment section of 
methodology) ginkgo and ginseng extracts, at rest and during task performance.  
Administration of a 207 mg dose of ginkgo, alone and in combination with a 207 mg dose 
of ginseng will be assessed following acute and chronic supplementation.  The 
haemodynamic response to task performance will also be monitored (using NIRS) in order 
to explore the impact of these extracts during behavioural performance.   
An extension of this research to include an exploration of the combination of these 
extracts was deemed necessary as previous research is limited to primarily behavioural 
outcomes.  The only study looking at the effects of this combination on brain activity (via 
EEG), assessed the sub-acute (3 days) effects and used what appear to be 
unstandardised extracts and doses of ginkgo considerably larger than those used 
historically (Dimpfel et al., 2006).  No studies to date have used EEG to assess the 
chronic effects of a ginkgo/ginseng combination on brain activity.  In terms of cerebral 
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oxygenation, there is a complete absence of research into the effects of this combination, 
following acute or chronic administration across both young and older populations.  The 
inclusion of NIRS will provide a direct measure of task-related cerebral haemodynamics 
and elucidate the effects of such a combination during behavioural performance.  Despite 
ginkgo’s historical reputation as an extract capable of improving CBF, human research in 
this area (either alone or in combination with other active substances) is limited.  The 
present study will address this.  It is anticipated that the use of NIRS to assess 
haemodynamics during cognitive performance, in conjunction with EEG will provide a 
more thorough insight into the effects of these extracts, particularly in light of the disparity 
in findings to date in relation to cerebro-electrical activity. 
The tasks chosen in the current study are those that have previously been shown 
to be sensitive to one or both of the extracts, for example, serial 3s subtractions, serial 7s 
subtractions and RVIP (Kennedy et al., 2004; Kennedy et al., 2002; Reay et al., 2005, 
2006).  Tasks were also selected based on their ability to activate the pre-frontal cortex 
and in this regard, the 3-back task and Stroop task were also included in addition to serial 
7s subtractions and RVIP (Cohen et al., 1997; Drummond et al., 1999; Lawrence, Ross, & 
Stein, 2002; Schroeter et al., 2002).   
The majority of ginseng studies have looked at doses of either 200 mg and 400 mg 
with positive effects demonstrated at both doses (Dangelo et al., 1986; Kennedy, Reay, & 
Scholey, 2007; Kennedy et al., 2004; Kennedy et al., 2001b, 2002; Reay et al., 2005; 
Reay et al., 2010; Sorensen & Sonne, 1996; Sunram-Lea et al., 2005), whereas ginkgo 
studies have focussed on doses of 120 mg, 180 mg, 240 mg and 360 mg, with an 
absence of research into the effects of a ~200 mg dose.  An increment of this proportion 
may appear small; however, when the differences in behavioural and physiological effects 
at the aforementioned doses are considered, it could be that even a slight variation in 
ginkgo dose may be of significance.  Therefore, with previous EEG research 
demonstrating significant effects of ginseng following a 200 mg dose and with limited 
research into the effects of this dose overall for ginkgo, it seemed appropriate to 
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investigate the effects of these extracts at ~200 mg.  Incorporating both a chronic and an 
acute assessment extends the research in healthy, young populations, delineating 
whether the effects are cumulative or have more impact following a single dose.  The time 
course of acute assessment (beginning at 2 hours post-dose and continuing for 
approximately 1 hour) was chosen based on previous acute behavioural research.  In 
young healthy adults, an effect of these extracts either alone and/or in combination has 
been identified within this time-frame (Kennedy et al., 2004; Kennedy et al., 2000, 2001a, 
2002). 
The aim of the present study was to assess the effects of two herbal extracts 
known to have psychoactive properties, in order to explore their effects on cerebro-
electrical activity and the haemodynamic response to behavioural task performance.  This 
randomised double-blind, placebo-controlled, balanced, crossover study therefore 
examined the acute and chronic effects of Ginkgo biloba and a Ginkgo biloba/Panax 
ginseng combination, on brain activity as assessed by EEG and NIRS, during the 
completion of a range of cognitive tasks administered by the Computerised Mental 
Performance Assessment System (COMPASS). 
 
2.2 Method 
2.2.1 Participants 
Eighteen healthy young volunteers (6 males, 12 females) between the ages of 19 
and 38 (mean age 22.9, SD 5.04; BMI 23.8, SD 2.7) were recruited.  The study was 
approved by Northumbria University’s School of Psychology and Sports Sciences ethics 
committee and was conducted in accordance with the Declaration of Helsinki.  Prior to 
participation in the study, participants were required to provide informed consent.  All 
participants reported that they were in good health and were taking no illicit drugs.  
Additionally, they were free from any ‘over the counter’, herbal or prescribed medications, 
with the exception of the contraceptive pill for some female participants.  They had not 
taken any dietary supplements in the past 3 months and were not pregnant or seeking to 
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become pregnant.  Habitual smokers consuming more than 3 cigarettes per day were 
excluded from the study as were those who consumed more than 6 cups of coffee per 
day (or the equivalent in caffeine from other sources). 
 
2.2.2 Design and treatment 
           A randomised, double-blind, counter-balanced, within subjects, placebo-controlled 
design was utilised.  Participants attended six study visits and at visits 1, 3, and 5 were 
randomised to receive 1 of the following treatments; 207 mg Ginkgo biloba; 207 mg 
Ginkgo biloba and 207 mg Panax ginseng in combination, or placebo.  Each treatment 
was administered in the form of 6 tablets containing either standardised dried extract of 
Ginkgo Biloba leaves (DER (drug to extract ratio) 50:1) or a combination of dried extract of 
Ginkgo Biloba leaves (DER  50:1) and standardised dried extract of Panax Ginseng root 
(DER 3, 6:1), or placebo (all treatments were supplied by Phytolab GmbH & Co., 
Frankfurt).  The participant remained blind to the treatment they had received.  
Participants were randomly allocated to a treatment regime using a Latin square design 
that counterbalanced the order of treatments across the cohort and treatment periods.  
Each treatment was ingested for a total of 15 days, with a 13-day no-treatment wash-out 
between each.  All participants met the 80 % treatment compliance level across the study 
period.   
2.2.3 Physiological, cognitive and mood measures 
2.2.3.1 Near-infrared spectroscopy measurements 
Relative changes in the absorption of near infrared light were measured at a time 
resolution of 10 Hz using a 12 channel Oxymon system (Artinis Medical Systems B.V.).  
The system emitted 2 nominal wavelengths of light (~765 and 855 nm) with an 
emitter/optode separation distance of 4 cm.  The differential pathlength factor was 
adjusted according to the age of the participant.  Relative concentration changes in oxy-
Hb, deoxy-Hb and total-Hb were calculated by means of a modified Beer–Lambert law 
using the proprietorial software.  In this study, a simple two emitter/receiver optode pair 
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configuration was utilised (i.e. 2 channels) (see figure 1.1).  The emitter/receiver optode 
pairs were positioned over the left and right pre-frontal cortex using a standard optode 
holder headband (each emitter optode was at a 16.5 mm distance from the midline and 4 
cm laterally from the corresponding receiver optode).  This separated the emitter/receiver 
pairs from each other by 33 mm. 
2.2.3.2 Cognitive and mood measures 
Cognitive measures were delivered using the Computerised Mental Performance 
Assessment System (COMPASS), University of Northumbria at Newcastle, a purpose 
designed software application for the flexible delivery of randomly generated parallel 
versions of standard and novel cognitive assessment tasks that has previously been 
shown to be sensitive to nutritional interventions e.g. (Haskell et al., 2010; Kennedy, 
Veasey, et al., 2010).  The tasks were chosen based on their ability to activate the pre-
frontal cortex (Cohen et al., 1997; Drummond et al., 1999; Lawrence et al., 2002; 
Schroeter et al., 2002) and/or their known sensitivity to one or both of the nutritional 
interventions under investigation (Kennedy et al., 2004; Kennedy et al., 2002; Reay et al., 
2005).  The tasks were delivered in the following order; serial 3s subtraction task (2 
minutes), serial 7s subtraction task (2 minutes), a rapid visual information processing task 
(RVIP – 5 mins), mental fatigue visual analogue scale, Stroop task (4 minutes) and the N-
back (3-back task) (2 minutes). 
2.2.3.2.1 Serial 3s: 
The serial subtractions task is a measure of concentration and working memory, 
which can be manipulated in terms of its cognitive load, by augmenting the number to be 
subtracted.  Since it was first described, as a tool for the measurement of mental 
impairment (Hayman, 1942), it has been used in a number of studies assessing cognitive 
ability in the presence of a range of nutritional interventions e.g. (Kennedy, Wightman, et 
al., 2010; Reay et al., 2006; Scholey et al., 2001).  In this task, a starting number between 
800 and 999 appears on the screen and participants are instructed to count backwards as 
quickly and as accurately as possible from this number in 3s, using the keyboards linear 
number keys to make their response.  Each digit is represented on screen by an asterisk 
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and responses are cleared when the ‘enter’ key is pressed.  Participants are only shown 
one number on screen and the rest of the numbers are generated by subtracting from the 
previous number in their head.  In the case of incorrect responses, subsequent responses 
are scored as positive if they are correct in relation to the new number.  This task was 
scored for number of correct responses and number of errors. 
2.2.3.2.2 Serial 7s: 
The serial 7s task was identical to the serial 3s task, except that it involved serial 
subtraction of 7s. 
2.2.3.2.3 Rapid visual information processing task (RVIP): 
The RVIP task is a measure of sustained attention and working memory that is 
known to give rise to fronto-parietal activation (Coull, Frith, Frackowiak, & Grasby, 1996).  
During this task, the participant monitors a continuous series of digits for targets of 3 
consecutive odd or 3 consecutive even digits.  The digits are presented on the computer 
screen at the rate of 100 per minute in pseudo-random order and the participant responds 
to the detection of a target string by pressing the space bar as quickly as possible.  The 
task is continuous and lasts for 5 minutes, with 8 correct target strings being presented in 
each minute.  This task was scored for percentage of target strings correctly detected, 
average reaction time for correct detections, and number of false alarms. 
2.2.3.2.4 Stroop: 
The Stroop task is a response inhibition task and a measure of executive 
functioning and is known to activate the pre-frontal cortex (Cabeza & Nyberg, 2000).  In 
this task, a series of colour names appear on the screen one at a time in different 
coloured fonts.  Participants are required to use a colour coded response pad to select the 
colour that matches the colour font that the word is written in.  The words that are 
presented are either ‘congruent’ (name of colour and colour of ink the same) or 
‘incongruent’ (name of colour and colour of ink different) and are presented randomly.  
Participants are asked to respond as quickly and as accurately as possible.  The task 
lasts for 4 minutes and the number of stimuli presented are determined by the speed at 
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which the participant responds.  This task was scored for percentage accuracy and 
reaction time. 
2.2.3.2.5 3-Back: 
N-back is a task that assesses working memory that is known to activate the pre-
frontal cortex (Owen, McMillan, Laird, & Bullmore, 2005).  In the present study, a 3-back 
version of the task was utilised.  A series of letters appear on the screen one at a time and 
participants have to identify whether that letter was presented 3 letters previously in the 
series of letters or not by pressing corresponding ‘yes’ and ‘no’ buttons using keys on the 
keyboard.  Participants were required to respond to 45 letter presentations, with 15 target 
letters.  This task was scored for percentage of correct responses and reaction time. 
2.2.3.2.6 Subjective mental fatigue visual analogue scale: 
Participants were asked to rate how mentally fatigued they felt by placing an ‘x’ on 
a 100 mm line with the end points labelled ‘not at all’ (left hand end) and ‘extremely’ (right 
hand end). 
2.2.3.3 Electroencephalography measurements 
EEG was recorded from 32+2 channels using an electrode cap (sintered silver-
silver chloride electrodes; BioSemi B.V. The Netherlands) according to the international 
10-20 system.  EEG was obtained using BioSemi ActiveTwo amplifier (BioSemi, B.V.) and 
Acquire 4.3 software (Neuroscan).  Amp settings during the recording periods were as 
follows: low pass 30 Hz, high pass 0.46 Hz.  The montage included four midline sites (FZ; 
CZ; PZ; OZ), 14 sites over the left hemisphere (FP1; AF3; F3; F7; FC1; FC5; C3; T7; CP1; 
CP5; P3; P7; PO3; O1) and 14 sites over the right hemisphere (FP2; AF4; F4; F8; FC2; 
FC6; C4; T8; CP2; CP6; P4; P8; PO4; O2), all referred to linked mastoids (see figure 2.1).  
Inter-electrode impedance levels were kept below 5 kΩ.  Participants were asked to 
visually fixate on a small cross, initially displayed on the monitor, to minimise eye 
movements during all eyes open EEG recordings.  Any sections of the EEG recording still 
contaminated with eye movements, muscular activity, or other artefacts were excluded 
from the analysis using automatic eye-blink correction, artefact rejection carried out using 
Edit 4.3 (Neuroscan).    Event-related potentials and waveband analyses were conducted 
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using Edit 4.3 (Neuroscan).  Time windows of 300-500 milliseconds (ms), 280-700 ms 
and 180-280 ms were used to respectively capture P3a, P3b and P2 ERP components.   
 
Figure 2.1 Example of EEG electrode set-up as used in current chapter.  Taken from 
BioSemi website; http://www.biosemi.com/index.htm (BioSemi, 2016). 
 
2.2.3.3.1 Three-stimulus odd ball task: 
The task was administered in three, 4-minute blocks.  Participants were instructed 
to press the spacebar, every time they identified a target stimulus (small green square) 
and to ignore all other stimuli (frequent stimuli: small red circle and novel stimuli: large 
blue square).  The experimental tasks presented 450 stimuli in total, which comprised the 
following; 60 target stimuli, 330 frequent stimuli and 60 novel stimuli.  The stimuli 
remained on the screen for 100 ms.  Immediately pre and post task, 40 seconds of 
continuous resting eyes open and eyes closed activity was recorded.  The order of which 
was randomly generated by the computer.  Prior to the experimental blocks at each 
session, a practice block was administered without the novel stimuli.  
2.2.4 Procedure 
Participants attended the Brain, Performance and Nutrition Research Centre 
(BPNRC) at Northumbria University on 7 separate occasions (introductory (screening) 
visit and Study Visits 1, 2, 3, 4, 5, 6) with each of the 6 study visits separated by 2 weeks.  
Testing took place in a suite of testing facilities and participants were assessed 
individually.  The screening visit comprised: informing volunteers about the nature of the 
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study, its requirements and restrictions and obtaining informed consent.  Demographic 
data was then collected and familiarisation with the testing battery was completed.  Once 
participants’ eligibility to participate was confirmed, they were randomly allocated, utilising 
a computer generated random number list, to a position on a Latin Square, which 
counterbalanced the order of treatments across the cohort and study days.  The 
remaining 6 study visits were identical apart from the treatment administered.  Each visit 
involved attending the laboratory between 8:30 am and 9.30 am on 6 separate occasions, 
2 weeks apart (visits 1, 2, 3, 4, 5, 6).  Participants were required to fast since waking and 
abstain from alcohol from 8.30 pm the previous evening.  On each of the 6 visits, 
participants were assessed with regards compliance to the study requirements and 
restrictions and were then asked to take the appropriate day’s investigational product.  
They were then provided with a standardised light breakfast of 2 slices of buttered toast 
with jam and a 200 ml glass of orange juice.  Two hours after treatment consumption, they 
underwent assessment of cerebro-electrical activity at rest (40 seconds eyes open and 40 
seconds eyes closed) and during the 3-stimulus odd ball task utilising EEG.  Immediately 
following this, they underwent a NIRS assessment of cerebral oxygenation parameters at 
rest (a 4-minute period where participants were required to clear their mind and 
concentrate on their breathing) and during tasks delivered by the COMPASS testing 
battery relevant to frontal areas of the brain.  After testing for the day had ceased, 
participants were given 13 days’ supply of the treatment to take home with them, to take 
between visits 1-2, 3-4 and 5-6.  During visits 2-3 and 4-5 a no-treatment ‘wash out’ period 
was observed.  Upon return to the lab at visits 2, 4 and 6, participants were administered 
day 15 of the relevant treatment in the lab.  Consequently, at visits 1, 3 and 5 participants 
consumed day 1 of their treatment and completed their ‘acute’ assessment.  At visits 2, 4 
and 6 participants consumed day 15 of their treatment and completed their ‘chronic’ 
assessment in the presence of an acute dose.  The study outline is shown in fig. 2.2 and 
the testing schedule for each visit is shown in fig.2.3 
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Fig. 2.2. Treatment and study outline across the 10 weeks of the study. Individual 
participants took each of the 3 treatments (ginkgo, ginkgo/ginseng, placebo) during one of 
the three 15-day active treatment periods in a counterbalanced order (to eliminate order 
effects). Cognitive function/electrical activity and haemodynamic response to task 
performance was tested on the first and last day of this period. A 13 day no treatment 
wash-out was interposed between active treatment periods. 
 
 
 
Fig. 2.3. Testing schedule for Visits 1, 2, 3, 4, 5 and 6 
 
2.2.5 Statistics 
Prior to the primary NIRS analysis a within subjects ANOVA was carried out with 
left/right optode included as a factor to examine any treatment related hemispheric 
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differences in response. As there were no interpretable interactions involving this factor 
the data from the 2 channels were averaged for the analysis. 
For the primary NIRS analysis, the question under investigation was whether 
Ginkgo biloba, or Ginkgo biloba and Panax ginseng in combination, would modulate the 
haemodynamic response to overall task performance in comparison to placebo and if 
acute/chronic dosing was a factor in this response.  Data for oxy-Hb, deoxy-Hb and total-
Hb was averaged across the duration of each individual task (2, 4 or 5 minutes) baseline 
adjusted to the 4 minute, post-dose, pre-task resting baseline measurement.  It was then 
analysed by 3-way repeated measures ANOVA (treatment (207 mg Ginkgo biloba, 207 
mg Ginkgo biloba and 207 mg Panax ginseng in combination, or placebo) X task (serial 3s, 
serial 7s, RVIP, Stroop, 3-back) X day (acute and chronic)).  Significant treatment related 
interactions were then described with reference to a priori planned comparisons, in which 
averaged data from each task epoch for each active treatment was compared to placebo 
utilising t-tests calculated with the Mean Squares Error from the ANOVA (Keppel, 1991).  
In order to reduce the potential for Type I errors only those planned comparisons 
associated with a statistically significant difference on the initial ANOVA are reported.  In 
addition, only those instances where a consistent pattern of significant differences are 
maintained across epochs are identified as reportable significant effects.   
In order to identify if there was a pattern of effects within each task over time and if 
the haemodynamic response was modulated differently throughout the course of task 
performance, data from each task was broken down into smaller, 10 second epochs and 
analysed together as a series of epochs over time. Secondary analysis of the NIRS data 
therefore involved averaging each task across 10 second epochs and baseline adjusting 
to the 4-minute pre-task resting baseline measurement.  It was then analysed by 3-way 
repeated measures ANOVA (treatment (as per primary analysis) X 10 second epoch (90) 
X day (as per primary analysis).  Planned comparisons were conducted as per primary 
analysis, documented above. 
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Following transformation of the EEG data, the effects of the treatment on the 
latency and amplitude of evoked potentials were assessed by 3-way ANOVA (treatment 
(as above) X scalp site (P3a, P3b, P2) X day (as above)).  Electrode scalp sites were as 
follows; sites FZ and CZ (P3a), PZ and CZ (P3b) and FZ and CZ (P2).  Delta, theta, alpha 
and beta waveband activity is represented as statistical maps.   
Cognitive performance and subjective mood were analysed by 2-way repeated 
measures ANOVA (treatment (as above) X day (as above).  Significant treatment related 
effects were described with reference to a priori planned comparisons (as above) where 
each active treatment was compared to placebo. 
Performance on the oddball task was analysed by repeated measures, two-way 
ANOVA (treatment (as above) X day (as above). 
 
2.3 Results 
2.3.1 Near infrared spectroscopy 
2.3.1.1 Primary analysis 
Effects of treatment on cerebral haemodynamics over time during task 
performance. 
2.3.1.1.1 Oxygenated haemoglobin 
There were no treatment-related differences on oxy-Hb, see fig. 2.4a. 
2.3.1.1.2 Deoxygenated haemoglobin 
A significant interaction effect (treatment X task) was observed for deoxy-Hb [F(8, 
136)=2.50, p=0.014].  Planned comparisons revealed that irrespective of acute or chronic 
dosing, deoxy-Hb was significantly increased during the Stroop [t(136)=3.44, p<0.0008, 
d=-0.53] and 3-back tasks [t(136)=3.28, p=0.0013, d=-0.49] following ginkgo as compared 
to placebo, see fig. 2.4b. 
2.3.1.1.3 Total haemoglobin 
There were no treatment-related differences on total-Hb, see fig. 2.4c. 
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 Fig. 2.4.  Concentration changes of oxy-Hb (a), deoxy-Hb (b) and total-Hb (c) during 
cognitive tasks following placebo, 207 mg G. biloba, or 207 mg G. biloba and P. ginseng.  
Means and SEM are presented.  Treatment X task interaction effects are shown for (b) 
deoxy-Hb.  Significance is compared to placebo (t-tests calculated with the Mean Squares 
Error from the ANOVA) (*** p<0.005, **** p<0.001). 
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2.3.1.2 Secondary analysis 
Effects of treatment on cerebral haemodynamics during task performance 
using smaller duration (10 second) epochs. 
2.3.1.2.1 Oxygenated haemoglobin 
There were no treatment-related differences on oxy-Hb, see fig. 2.5a. 
2.3.1.2.2 Deoxygenated haemoglobin 
A significant interaction effect (treatment X epoch) was observed for deoxy-Hb 
[F(178, 3026)=1.90, p<0.001].  Planned comparisons revealed that irrespective of acute or 
chronic dosing, deoxy-Hb was significantly increased consistently throughout the Stroop 
task and 3-back tasks following ginkgo as compared to placebo and at individual epochs 
during RVIP, see fig. 2.5b for details of significant effects at each epoch. 
2.3.1.2.3 Total haemoglobin 
There were no treatment-related differences on total-Hb, see fig. 2.6. 
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 Fig. 2.5.  Concentration changes of oxy-Hb (a) and deoxy-Hb (b) during cognitive tasks 
following placebo, 207 mg G. biloba, or 207 mg G. biloba and P. ginseng.  Means and 
SEM are presented.  Treatment X task interaction effects are shown for (b) deoxy-Hb.  
Significance is compared to placebo (t-tests calculated with the Mean Squares Error from 
the ANOVA) (* p<0.05, ** p<0.01, *** p<0.005, **** p<0.001). 
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 Fig. 2.6.  Concentration changes of total-Hb during cognitive tasks following placebo, 207 
mg G. biloba, or 207 mg G. biloba and P. ginseng.  Means and SEM are presented. 
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2.3.2 Cognitive performance and mood 
2.3.2.1 Serial 7s 
There was a significant main effect of treatment on serial 7s subtractions errors 
[F(2, 32)=4.05, p=0.027].  However, planned comparisons revealed that there were no 
significant differences on this measure between active treatments and placebo. 
2.3.2.2 RVIP 
There was a significant treatment x day interaction for number of RVIP false 
alarms [F(2, 34)=4.22, p=0.023].  Planned comparisons revealed that following the acute 
dose of ginkgo/ginseng combination, there was a significant increase in the number of 
false alarms as compared to placebo [t (34)=2.22, p=0.033, d=-0.62], see fig. 2.7. 
 
Fig. 2.7.  Number of false alarms on RVIP task following ginkgo, ginkgo/ginseng 
combination and placebo following acute and chronic treatment (* p<0.05). 
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2.3.3 Electroencephalography measurements  
2.3.3.1 Waveband activity 
The mean power (post-task eyes closed) for the frequency bands (delta, theta, 
alpha and beta) in the individual brain regions following ingestion of either 207 mg G. 
biloba, or 207 mg G. biloba and 207mg P. ginseng as compared to placebo are presented 
in table 2.2. 
Table 2.1. Raw scores for serial subtractions, RVIP, mental fatigue, Stroop and 3-back 
tasks for each treatment.  Means ±SEM values are presented with F and p values from the 
primary ANOVA of treatment effects and treatment x acute/chronic dose interactions.  
Significant measures are shown in bold. 
Measure n Treatment 120 minutes post-dose Treat 
effect 
Treat x day 
interaction Acute Chronic 
Serial 3s 
subs correct 
(number) 
 
18 
Placebo 40.83±3.25 42.94±3.11  
F<1 
F=1.13 
p>0.1 Ginkgo 41.56±3.02 41.22±2.70 
Ginkgo/Ginseng 40.89±3.04 39.94±2.80 
Serial 3s 
subs errors 
(number) 
 
18 
Placebo 1.94±0.48 1.78±0.44  
F<1 
F=1.07 
p>0.1 Ginkgo 2.00±0.30 2.44±0.54 
Ginkgo/Ginseng 1.67±0.38 2.94±0.56 
Serial 7s 
subs correct 
(number) 
 
17 
Placebo 26.24±2.09 25.47±2.23  
F<1 
F=1.01 
p>0.1 Ginkgo 24.71±2.62 26.12±2.23 
Ginkgo/Ginseng 25.59±2.53 25.76±2.35 
Serial 7s 
subs errors 
(number) 
 
17 
Placebo 1.82±0.44 2.18±0.37 F=4.05 
p=0.03 
 
F<1 Ginkgo 3.24±0.74 2.94±0.75 
Ginkgo/Ginseng 2.29±0.64 2.53±0.42 
RVIP correct  
(%) 
 
18 
Placebo 74.17±4.10 68.75±3.75  
F<1 
F=2.57 
p=0.09 Ginkgo 72.22±4.51 69.58±4.31 
Ginkgo/Ginseng 70.69±3.56 73.75±3.61 
RVIP RT 
(ms) 
 
18 
Placebo 464.74±14.63 472.48±15.70 F=1.13 
p>0.1 
 
F=1.67 
p>0.1 Ginkgo 463.11±18.68 445.55±16.91 
Ginkgo/Ginseng 463.75±14.14 457.61±12.67 
RVIP  
false alarms  
(number) 
 
18 
Placebo 1.56±0.44 2.67±0.66  
F<1 
F=4.22 
p=0.02 Ginkgo 2.17±0.47 2.28±0.55 
Ginkgo/Ginseng 2.67±0.40 1.72±0.36 
Mental  
fatigue 
(mm) 
 
18 
Placebo 53.67±4.39 57.61±4.40  
F<1 
 
F<1 Ginkgo 55.17±5.34 56.33±4.76 
Ginkgo/Ginseng 53.67±4.27 52.94±4.56 
Stroop  
overall 
correct (%) 
 
18 
Placebo 98.21±0.46 98.18±0.38  
F<1 
 
F<1 Ginkgo 98.15±0.44 98.11±0.35 
Ginkgo/Ginseng 98.40±0.34 98.39±0.35 
Stroop  
overall RT 
(ms) 
 
18 
Placebo 656.28±28.43 648.11±23.51  
F<1 
 
F<1 Ginkgo 655±21.49 654.89±22.94 
Ginkgo/Ginseng 647.28±21.48 649.78±21.64 
3-back  
correct  
(%) 
 
18 
Placebo 92.59±1.51 91.11±1.69  
F<1 
 
F<1 Ginkgo 91.85±1.76 87.65±3.60 
Ginkgo/Ginseng 89.01±3.65 90±3.61 
3-back RT 
(ms) 
 
18 
Placebo 1283±161 1326±171  
F<1 
 
F<1 
 
Ginkgo 1313±183 1229±173 
Ginkgo/Ginseng 1246±151 1262±167 
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 Table 2.2.  Mean ‘eyes closed’ power in the delta, theta, alpha and beta wavebands for 
ginkgo, ginkgo/ginseng combination, and placebo.  
 
2.3.3.1.1 Acute effects (post-task eyes closed) 
Demonstration of the effects of acute ingestion of ginkgo and ginkgo/ginseng 
combination as compared to placebo are presented as descriptive probability maps.  
Associated significant areas are highlighted.  See figures 2.8 and 2.9. 
2.3.3.1.1.1 Delta (0.50-4.00 Hz) 
Both ginkgo and ginkgo/ginseng combination led to an increase in frontal delta 
activity, with the combination treatment also leading to an increase in left and right parietal 
activity, as compared to placebo. 
Delta Frontal 27.95 50.39 34.53 30.01 38.72 42.86 
(0.50-4.00 Hz) Left frontal 21.50 22.91 23.99 25.10 23.48 23.77 
Right frontal 20.64 51.56 26.71 28.73 29.11 24.60 
Left parietal 8.50 10.04 10.31 9.24 9.49 10.67 
Right parietal 9.83 10.17 10.55 9.65 10.64 11.70 
Occipital 13.99 14.08 15.01 13.27 12.57 15.27 
Theta Frontal 1.90 2.52 2.86 2.34 2.30 2.25 
(4.00-8.00Hz) Left frontal 1.83 2.35 2.59 2.11 2.02 2.14 
Right frontal 1.73 2.39 2.23 1.98 2.04 2.13 
Left parietal 1.90 2.40 2.51 2.04 2.16 2.11 
Right parietal 2.05 2.71 2.69 2.27 2.11 2.02 
Occipital 3.55 4.35 4.11 3.60 3.80 3.51 
Alpha Frontal 5.91 6.55 5.81 4.43 5.77 5.01 
Left frontal 4.69 5.08 4.69 3.96 4.53 4.24 
Right frontal 4.84 5.58 4.61 3.89 4.93 4.37 
Left parietal 7.91 10.29 8.48 7.39 8.85 7.59 
Right parietal 8.06 9.19 7.93 7.24 8.71 7.13 
Occipital 23.49 25.83 21.50 18.88 23.71 22.22 
Beta Frontal 0.47 0.44 0.43 0.40 0.45 0.47 
Left frontal 0.37 0.43 0.38 0.34 0.37 0.37 
Right frontal 0.38 0.42 0.38 0.33 0.37 0.38 
Left parietal 0.42 0.53 0.48 0.42 0.46 0.45 
Right parietal 0.44 0.54 0.48 0.42 0.46 0.48 
Occipital 0.94 1.20 1.02 0.87 1.03 0.99 
Acute (Day 1) Chronic (Day 15) 
Mean power (µV2/Hz) 'eyes closed' 
Ginkgo/Ginseng  
combination 
Ginkgo/Ginseng  
combination Placebo  Ginkgo Placebo  Ginkgo 
(14.00-25.00Hz,  
25.00-35.00Hz) 
Mean power (µV2/Hz) 'eyes closed' 
(8.00-11.00Hz,  
11.00-14.0Hz) 
Waveband  Scalp region 
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2.3.3.1.1.2 Theta (4.00-8.00 Hz) 
The ginkgo/ginseng combination led to an increase in theta activity in the frontal 
and right parietal regions as compared to placebo.   
2.3.3.1.1.3 Alpha (8.00-11.00 Hz, 11.00-14.00 Hz) 
Neither ginkgo or the ginkgo/ginseng combination led to a change in alpha activity 
as compared to placebo. 
2.3.3.1.1.4 Beta (14.00-25.00 Hz, 25.00-35.00 Hz) 
Both ginkgo and ginkgo/ginseng combination led to a reduction in frontal beta 
activity and ginkgo led to an increase in right parietal beta activity as compared to placebo.   
2.3.3.1.2 Chronic effects (Post-Task Eyes Closed) 
Demonstration of the effects of chronic ingestion of ginkgo and ginkgo/ginseng 
combination as compared to placebo are presented as descriptive probability maps.  
Associated significant areas are highlighted.  See figures 2.10 and 2.11. 
2.3.3.1.2.1 Delta (0.50-4.00 Hz) 
Ginkgo led to an increase in frontal and left occipital delta activity and the 
ginkgo/ginseng combination led to an increase in frontal delta activity as compared to 
placebo.  The increase in frontal activity was more marked for the combination treatment, 
than for ginkgo alone. 
2.3.3.1.2.2 Theta (4.00-8.00 Hz) 
Neither ginkgo or ginkgo/ginseng combination led to a change in theta activity as 
compared to placebo. 
2.3.3.1.2.3 Alpha (8.00-11.00 Hz, 11.00-14.00 Hz) 
Neither ginkgo or ginkgo/ginseng combination led to a change in alpha activity as 
compared placebo. 
2.3.3.1.2.4 Beta (14.00-25.00 Hz, 25.00-35.00 Hz) 
The ginkgo/ginseng combination led to an increase in right parietal beta activity in 
the 25.00-35.00Hz range only, as compared to placebo. 
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 Fig. 2.8. Descriptive probability maps showing increases in EEG power in frontal delta 
and right parietal beta and a reduction in frontal beta wavebands in comparison to 
placebo following acute dose of ginkgo. 
 
 
Fig. 2.9.  Descriptive probability maps showing increases in EEG power in frontal and 
parietal delta and theta wavebands and a reduction in frontal beta wavebands in 
comparison to placebo following acute dose of ginkgo/ginseng combination. 
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 Fig. 2.10.  Descriptive probability maps showing increases in EEG power in frontal and 
left occipital delta wavebands in comparison to placebo following chronic dose of ginkgo. 
 
 
Fig. 2.11.  Descriptive probability maps showing increases in EEG power in frontal delta 
and right parietal beta wavebands in comparison to placebo following chronic dose of 
ginkgo/ginseng combination. 
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2.3.3.2 P300 Latency and amplitude 
2.3.3.2.1 Amplitude  
There were no significant differences between placebo and each of the active 
treatments following either acute or chronic doses in amplitude of P3a, P3b or P2 ERP 
components. 
2.3.3.2.2 Latency 
There were no significant differences between placebo and each of the active 
treatments following either acute or chronic doses in latency of P3a, P3b or P2 ERP 
components. 
2.3.3.3 EEG task performance 
2.3.3.3.1 Odd ball task accuracy 
There were no significant differences between placebo and each of the active 
treatments following either the acute or chronic doses. 
2.3.3.3.2 Odd ball task reaction time 
There were no significant differences between placebo and each of the active 
treatments following either the acute or chronic doses. 
 
2.4 Discussion 
The findings of the present study demonstrate that irrespective of acute or chronic 
dosing, ginkgo administered alone leads to an increase in deoxy-Hb as compared to 
placebo in the pre-frontal cortex, during performance of the Stroop and 3-back tasks.  
Further analysis of each task over time revealed that this effect was maintained 
continuously for the duration of both the Stroop task and the 3-back task, and also 
occurred at individual epochs during the RVIP task.   
In terms of the effects on cerebro-electrical activity, an acute dose of ginkgo in 
isolation led to an increase in frontal delta and right parietal beta activity and a reduction 
in frontal beta activity as compared to placebo.  However, the chronic dose led to an 
increase in frontal and left occipital delta activity only.  The acute dose of ginkgo/ginseng 
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combination treatment resulted in an increase in frontal and parietal delta activity, an 
increase in frontal and right parietal theta activity and a decrease in frontal beta activity as 
compared to placebo.  The chronic dose of the ginkgo/ginseng combination led to an 
increase in frontal delta, and right fronto-parietal beta activity as compared to placebo. 
In relation to the effects on cognition, the only finding was that of a significant 
increase in the number of RVIP false alarms following the acute dose of the 
ginkgo/ginseng combination treatment. 
Overall and irrespective of treatment, the pattern of haemodynamic change (a task-related 
increase in oxy-Hb and decrease in deoxy-Hb as compared to resting baseline) is in line 
with previous NIRS research involving both the Stroop and N-back tasks (Hoshi, 2003; 
Schroeter et al., 2002).  As previously discussed, an expected pattern of haemodynamic 
effects during cognitive task performance includes a 2-3 fold increase in oxy-Hb with a 
reduction in deoxy-Hb in areas of cortical activation, as blood flow exceeds the rate at 
which oxygen is utilised.   However, the main treatment-related finding with regards the 
haemodynamic response in the present study, was the significant increase in deoxy-Hb 
following ginkgo as compared to placebo during cognitive task performance.  This effect 
was initially observed at individual epochs within the last 3 minutes of the RVIP task and 
was then sustained across epochs for the duration of the Stroop and 3-back tasks.  It is 
plausible that this reflects not simply an effect of task, but as an effect of time, since the 
task order was not randomised and participants completed the tasks at the same time, in 
the same order.  The onset of the significant effect would represent a time-point of 
approximately 2.5 hours post-dose, behavioural research has documented improved 
speed of attention at this time-point and at 4 and 6 hours post-dose (Elsabagh et al., 2005; 
Kennedy et al., 2000).  Indeed, here the significant effect was maintained until the end of 
testing at approximately 2hours 50 minutes post-dose.  In the presence of an increase in 
total-Hb, an increase in deoxy-Hb has in previous interventional NIRS research, been 
taken to be indicative of increased oxygen extraction following resveratrol (Kennedy, 
Wightman, et al., 2010), and vinpocetine administration (Bonoczk et al., 2002).  However, 
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in the present study, the task-related increase in deoxy-Hb occurred in the absence of any 
task-related changes to oxy-Hb or total-Hb.  With these previous findings in mind it is 
therefore less clear if the increase in deoxy-Hb seen here reflects a similar, task-related 
increase in oxygen extraction.  Having said this, the absence of a concomitant treatment 
related increase in oxy-Hb/total-Hb during task performance may simply reflect a state 
whereby improved extraction of oxygen means there is less of a requirement to increase 
blood flow.   
Perhaps a more likely explanation, however, for the absence of a treatment related 
effect during task performance is that an increase in oxy-Hb or total-Hb had already 
occurred.  Continuous wave NIRS (CW-NIRS) (as used in the current thesis) only 
measures acute changes in cerebral haemodynamics during a single, continuous 
recording session.  This is because the concentration change data it generates is 
baseline-adjusted to the concentration reading taken immediately before the first data 
point in the recording session.  It therefore cannot be used to quantify gross changes in 
CBF parameters that take place between two separate recording sessions.  In the present 
study NIRS recordings began approximately 2.5 hours post-dose (and there was no 
baseline measure in the absence of treatment).  It is possible therefore, that an effect of 
treatment had already occurred in oxy-Hb/total-Hb before baseline measures were taken 
and there was no additional increase in these parameters in response to tasks.  Instead, 
as perhaps reflected by the observed increase in deoxy-Hb, there was an increase in 
metabolism. 
In terms of cerebro-electrical effects, the most consistent findings were those of 
increased frontal delta activity following acute and chronic administration of ginkgo alone 
and the ginkgo ginseng combination.  There was also a corresponding reduction in frontal 
beta activity following both treatments after the acute dose only.  Interestingly the 200 mg 
dose of ginkgo administered here did not lead to a significant modulation of alpha activity.  
Previous studies have observed changes in alpha waves (whether an increase or a 
decrease) following acute and chronic ginkgo supplementation, in healthy populations (Itil 
et al., 1996), those displaying age-associated cognitive impairments (Gessner et al., 1985) 
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and dementia patients (Itil et al., 1998).  Kunkel (1993), however, found that in a group of 
healthy young males, aged 24-29 years (mean age, 27 years - a cohort that more closely 
reflects the one used in the present study) alpha frequency and power was the least 
affected after 3 days supplementation with either 40, 60 or 160 mg ginkgo.  Furthermore, 
in a group of healthy volunteers aged 19-39 years (mean age 26 years) the observed 
modulation of alpha following 360 mg ginkgo, failed to reach significance (Kennedy et al., 
2003).  This may suggest that a younger, healthy cohort may not be as susceptible to 
modulation in alpha activity as a result of ginkgo supplementation.    An increase in delta 
(slow waves) in conjunction with a reduction in alpha activity (fast waves) has previously 
been associated with a decrease in vigilance (Itil et al., 1996).  Although no change in 
alpha activity was observed here, alongside the observed increase in frontal delta, there 
was a corresponding decrease in beta activity (fast waves), following both treatments.  
Reduced frontal beta activity following the acute dose of both treatment conditions, is 
consistent with that of Kennedy et al. (2003) who demonstrated a significant reduction in 
eyes closed beta activity following separate doses of 360 mg ginkgo and 200 mg ginseng.  
Following chronic administration, however, the pattern of reduced beta activity was lost for 
both treatments, to be replaced following ginkgo/ginseng combination with an increase in 
beta activity.  In terms of the effects on delta activity, although a previous, acute 
assessment of this combination in healthy middle aged cohorts observed a significant 
increase in delta activity in central, parietal and occipital positions, no significant changes 
in frontal delta activity were observed (Dimpfel et al., 2006).  Similarly Kennedy et al. 
(2003) observed increases in theta activity but did not observe any changes in delta 
activity in healthy young adults following acute supplementation of both extracts in 
isolation.   
In relation to performance on the RVIP task, the finding of an increased number of 
false alarms following an acute dose of the combination treatment is consistent with the 
decrement in speed of attention observed previously following a combination of these 2 
treatments (Kennedy et al., 2001a).  Furthermore, it is one that is not observed following 
each treatment in isolation (Kennedy et al., 2004; Kennedy et al., 2000).  When 
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considered in conjunction with neurophysiological effects, the negative impact upon 
behavioural performance following the combination treatment occurred in the absence of 
any change in deoxy-Hb.  Interestingly, following ginkgo supplementation where a 
significant increase in deoxy-Hb was observed at individual epochs during the RVIP, there 
was no decrement in behavioural performance on this task.  There is a possibility that the 
increase in deoxy-Hb seen following ginkgo, protected against the decrement in 
performance observed following the combination treatment.  However, this explanation 
does not translate into significant positive behavioural effects during the Stroop and 3-
back tasks where the increase in deoxy-Hb was maintained for the duration of each task, 
despite the suggestion that this may reflect an increase in metabolism, or evidence of 
increased oxygen extraction. 
Interestingly there were no additional effects of taking ginkgo or the 
ginkgo/ginseng combination treatment for an extended 14-day period as compared to 
those of an acute dose.  An intervention period of 2 weeks was selected since (apart from 
acute administration), 14 days’ supplementation has been the minimum duration for 
eliciting either a behavioural or neurophysiological effect following chronic or sub-chronic 
dosing.  In terms of haemodynamic effects during task performance, there were no 
changes observed as a result of the administration of either treatment following the 
chronic dose.  There was also an absence of behavioural effects following chronic 
supplementation of both treatments.  In terms of EEG, it could also be suggested 
(although only tentatively as no direct comparisons were made) that the chronic profile 
following each treatment was similar, if not marginally less marked, to that of the acute.  
Although studies assessing the chronic effects of these two treatments in combination are 
few in number, assessments of chronic ginkgo or ginseng supplementation in isolation 
have generally reported both behavioural (Dangelo et al., 1986; Mix & Crews, 2000, 2002; 
Silberstein et al., 2011; Sorensen & Sonne, 1996; Stough et al., 2001) and physiological 
effects (Santos et al., 2003; Silberstein et al., 2011) following a minimum of 14 days 
supplementation.  However, it is important to point out that in the present study, the 
chronic effects of treatment were measured in the presence of an acute dose.   
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Consequently, it is difficult to definitively state that any chronic effects observed are truly 
those of a chronic dose alone, as they may reflect those of an acute dose superimposed 
on those of a chronic.   
There were, however, limitations to the present study, in particular the absence of 
a pre-treatment resting baseline session to obtain NIRS measurements and cognitive task 
performance data in the absence of treatment.  This was because doing so would have 
required participants to remain seated and connected to the NIRS device throughout the 
absorption period, for up to 3 hours prior to the cognitive assessment, which was 
unfortunately not viable.  The significance of this is that gross changes in haemodynamic 
parameters as a result of treatment administration could not be measured, due to the 
absence of a pre-treatment, resting baseline.  It should also be noted that since 
integration of the methods of EEG and NIRS could not be achieved they had to be 
implemented separately.  Owing to the time-consuming nature of EEG set-up (‘capping-
up’), within the present study, EEG was implemented first so that set-up could occur 
during the absorption period.  This therefore makes it difficult to compare findings from 
each assessment, in order to make overall conclusions as the observed electrical activity 
was recorded up to 1 hour prior to the modulation of cerebral oxygenation.  This also 
leads to the possibility that some early effects of treatment on task-related 
haemodynamics could have been missed, since NIRS recordings did not occur until ~2.5 
hours post-dose. Future studies would benefit from better understanding of how NIRS and 
EEG technologies could be implemented in unison via their integration.  This would allow 
a true parallel assessment of cerebro-electrical and cerebral haemodynamic effects during 
task performance. 
In conclusion, the current study has demonstrated that an acute 207mg dose of 
ginkgo leads to significant increase in deoxy-Hb during performance of tasks that activate 
the pre-frontal cortex and that both ginkgo and a ginkgo/ginseng combination modulate 
cerebro-electrical activity following both acute and chronic supplementation. 
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Chapter 3: The acute effects of two doses of Ginkgo biloba on cerebral 
blood flow, cognitive performance and mood in healthy adults. 
 
3.1 Introduction 
Chapter 2 established that a ~200 mg dose of ginkgo is capable of augmenting the 
haemodynamic changes in cerebral oxygenation parameters, in this case deoxy-Hb, 
caused by the performance of cognitive tasks in healthy young adults.   However, it also 
highlighted that the absence of a pre-treatment NIRS baseline was a methodological 
limitation that needed to be addressed, since without it there could be no measure of 
gross changes in cerebral oxygenation/blood flow as a result of treatment. 
Previous research of ginkgo’s cerebro-vascular effects in healthy older adults, has 
demonstrated that chronic supplementation of 80 mg Ginkgo biloba results in an increase 
in cerebral perfusion (Santos et al., 2003).  A 120 mg dose has led to an increase in 
cerebral blood flow (Mashayekh et al., 2011), and a shift from bilateral activation to right 
dominant activation during a memory task (Sakatani et al., 2014).   As a consequence of 
the limited research into the cerebral blood flow effects of ginkgo supplementation in 
healthy young populations, and with the most interesting findings from chapter 2 being 
those on cerebral oxygenation following ginkgo alone (as opposed to being combined with 
ginseng), it was evident that these effects needed to be explored further and more 
thoroughly within this population.  This would be achieved by evaluating the cognitive and 
cerebral blood flow effects of Ginkgo biloba in isolation within a healthy young population, 
at different doses, following acute supplementation.  Since the findings of chapter 2 did 
not reveal any effects specific to the chronic dose, it was therefore decided to include an 
acute assessment of dose only. 
  As previously discussed, cognition research has documented that ginkgo, at a 
range of doses, is capable of modulating performance in healthy young volunteers.  For 
example, it has led to positive effects on a number of tasks, including memory, attention 
and speed of attention as well as improving subjective feelings of alertness and 
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contentment  (Elsabagh et al., 2005; Kennedy, Jackson, et al., 2007; Kennedy et al., 2000, 
2002).  The results from the previous chapter have demonstrated that a 207 mg dose of 
Ginkgo biloba is capable of increasing deoxy-Hb in response to task performance in a 
healthy young population.   The present study aimed to expand on this research by 
determining if this finding would extend to different doses, namely 180 mg and 360 mg.  It 
also aimed to address the methodological limitations of the previous chapter, by including 
a pre-treatment NIRS baseline measure, to determine if gross changes in cerebral 
oxygenation would be also be observed at these doses.  From a series of previous 
assessments of ginkgo supplementation, as described above, the 360 mg dose has been 
identified as the most beneficial in terms of its acute effects on cognition and mood in 
healthy young populations (Kennedy et al., 2002).  Neurophysiological research of this 
dose, however, is lacking.  In contrast, in healthy young populations, 180 mg is a dose 
that has rarely been assessed in acute ginkgo research for either its impact on cognition 
or neurophysiological effects.  This is despite a number of studies choosing to assess the 
physiological and cognitive effects of doses ranging around this level, including 120 mg, 
200 mg and 240 mg (Elsabagh et al., 2005; Itil et al., 1996; Jezova, Duncko, Lassanova, 
Kriska, & Moncek, 2002; Kennedy, Jackson, et al., 2007; Kennedy et al., 2003; Kennedy 
et al., 2000). 
It was anticipated in chapter 2 that, based on ginkgo’s previously documented 
ability to modulate blood flow, there would be some evidence of this effect following 
ginkgo alone or when administered in combination with ginseng (see chapter 2).  
Methodological issues of this initial study aside (for example, the absence of a pre-
treatment NIRS baseline), an alternative explanation for ginkgo’s lack of effects in chapter 
2, may be because the young healthy population used were, by their nature, already 
performing close to the peak of their abilities.  Therefore the demands of the tasks may 
not have been high enough to detect an effect of treatment.  Indeed, in populations where 
cognitive and physiological processes are undermined and there exists ‘room for 
improvement’ (such as in those with age-related cognitive decline or clinical conditions 
normally associated with ageing), ginkgo has received a degree of attention in terms of 
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cognitive and vascular research.  This is largely due to the predominantly positive effects 
it is capable of eliciting (Mashayekh et al., 2011; Santos et al., 2003; Winther, Randlov, 
Rein, & Mehlsen, 1998; Wu et al., 2008).  Perhaps therefore in young, healthy populations, 
a higher level of demand is required in order to more clearly observe any effects of 
treatment, this could be generated by manipulating the level of difficulty required of the 
tasks and increasing the level of mental fatigue experienced as a result.   It is anticipated 
that increasing the difficulty of the tasks would limit ceiling effects and create an 
environment where the identification of any effects as a result of treatment are more 
apparent.  Similarly, the increased demands of the tasks would elevate CBF (which 
ginkgo has been shown to facilitate), which in turn would mean that any shortfalls induced 
by limited substrates, would be reduced.  Cognition research in healthy young adults has 
demonstrated that increased availability of metabolic substrates can lead to measurable 
improvements in cognitive performance (Kennedy & Scholey, 2000; Moss et al., 1998; 
Scholey et al., 2001), in particular when task demand is high (Kennedy & Scholey, 2000; 
Scholey et al., 2001).  With this in mind, a manipulation of task demand through the 
repeated use of the most subjectively difficult tasks may lead to a sensitive backdrop from 
which to identify any beneficial effects of ginkgo in a healthy young population.  Chapter 2 
has verified that NIRS is able to detect specific, task-related changes in deoxy-Hb 
following ginkgo administration and previous research has established the ability of NIRS 
to identify changes in cerebral oxygenation as a result of increasing task demand 
(Izzetoglu et al., 2004; Izzetoglu et al., 2003; Shibuya-Tayoshi et al., 2007).   
There are a limited number of studies to date that have assessed the influence of 
Ginkgo biloba on cerebral blood flow during the performance of cognitive tasks, despite 
the herbal extracts separately documented, cognitive (Elsabagh et al., 2005; Kennedy, 
Jackson, et al., 2007; Kennedy et al., 2000, 2002) and vascular effects (Galduroz, 
Antunes, & Santos, 2007; Sakatani et al., 2014; Santos et al., 2003).  The most probable 
reason for this being that the majority of methods for assessing cerebral blood flow are 
restrictive and the range of tasks it is possible to administer whilst implementing these 
methods are limited.  The present study will therefore address this gap in literature by 
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administering a range cognitively demanding tasks whilst CBF is measured via NIRS 
following acute ginkgo administration of 2 different doses. 
The findings of chapter 2 demonstrated that there were limitations in terms of the 
methodology adopted.  The inclusion of a pre-treatment baseline measurement for 
cognitive performance as well as a resting pre-treatment baseline for NIRS assessment is 
also particularly important.  This will clearly define any on-treatment, task-related effects 
and delineate any changes in cerebral oxygenation/CBF as a result of treatment, over 
time.  A testing schedule that begins within and not from 2 hours of treatment 
administration is also necessary in order to ensure any early treatment effects are 
captured.  Ginkgo supplementation has demonstrated vascular, cerebro-electrical and 
cognitive effects from as early as 30/60 minutes post-dose (Itil et al., 1996; Jezova et al., 
2002; Kennedy, Jackson, et al., 2007; Kennedy et al., 2000, 2001b).  A shorter, 90-minute 
absorption period also provides the advantage of creating a less demanding schedule for 
the participant.   This is particularly relevant here since the inclusion of a pre-treatment 
NIRS baseline would mean participants would not be able leave their seat from arrival 
until the end of testing, a time which would total ~2.5-3 hours.  In line with this, the EEG 
assessment included in chapter 2 was removed in order to focus on the cerebro-vascular 
effects of the extract.  Although there are studies that have successfully combined these 
methods to provide simultaneous EEG and NIRS measurements (Fazli et al., 2012; 
Roche-Labarbe et al., 2008; Wallois et al., 2012), the time necessary and equipment 
required for their successful integration in the current project was not available.  Given 
that NIRS permits assessments in a wider range of scenarios than EEG, and due to the 
observed changes in cerebral oxygenation as a result of ginkgo supplementation in 
chapter 2, it was felt that this measure would provide the most informative results in the 
current study.  With regards to the tasks administered, a similar group was employed to 
those in chapter 2 (including serial 7s, 3-back and RVIP); however, with the inclusion of 
more mental arithmetic tasks (serial 13s, 17s).  This feature, in combination with the 
repetition of the tasks 6 times in succession, meant this battery was therefore deemed to 
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be harder.  The inclusion of blood pressure and heart rate measurements were intended 
to provide a measure of the peripheral effects of acute ginkgo supplementation. 
The aim of the present placebo-controlled, double blind, crossover study was 
therefore to determine the acute cerebro-vascular, cognitive and mood effects of two 
doses (180 mg and 360 mg) of ginkgo.  It would also assess if the repeated use of tasks 
that are more demanding and fatiguing will lead to a more pronounced physiological and 
behavioural cognitive effect in a young, healthy population. 
 
3.2 Method 
3.2.1 Participants 
Twenty-four healthy young participants (9 males, 15 females) between the ages of 
18 and 27 (mean age 21.9, SD 2.74; BMI 22.7, SD 2.7) were recruited.  The study was 
approved by the Northumbria University, Division of Psychology and Sport Sciences 
ethics committee and conducted in accordance with the Declaration of Helsinki.  Prior to 
participation, volunteers were required to sign an informed consent form, see appendix A 
for example of information sheet provided.  A general health screen (see appendix B) 
informed volunteers that they would not be eligible to take part if they had a history of 
neurological, vascular or psychiatric illness, a history or current diagnosis of drug or 
alcohol abuse, a current diagnosis of depression or anxiety, anaemia, high blood pressure, 
a heart or respiratory disorder, type 1 diabetes or phenylketonuria.  They would also not 
be eligible if they had a history of head trauma, migraines, learning difficulties, dyslexia or 
attention deficit hyperactivity disorder (ADHD).  All participants reported that they were in 
good health, had normal or corrected-to-normal vision and had no known allergies to the 
treatment ingredients.  Additionally, they were not currently taking any dietary 
supplements and were free from any ‘over the counter’, herbal or prescribed medications, 
with the exception, for some female participants, of the contraceptive pill.  Female 
volunteers also reported that they were not pregnant or seeking to become pregnant.  
Habitual smokers consuming more than three cigarettes per day were excluded from the 
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study.   Since testing was taking place in the afternoon, participants who reported 
drinking >6 cups of coffee per day (or the equivalent in caffeine from other sources) were 
excluded.  From the self-report caffeine consumption questionnaire (see appendix C), 
participants reported consuming caffeine on a daily basis, but <6 cups (range 64 mg-382 
mg per day). 
 
3.2.2 Design and treatment 
A randomised, double-blind, counter-balanced, within subjects, placebo-controlled 
design was utilised.  Participants attended 3 study visits and at each received 1 of the 
following treatments: 180 mg Ginkgo biloba LI 1370, a standardised extract containing 25 % 
total ginkgo flavonoids and 6 % percent total terpene lactones (Lichtwer Healthcare GmbH 
& Co, Germany); 360 mg Ginkgo biloba LI 1370, or placebo.  Each treatment was 
administered in the form of 4 capsules in order to mask any taste differences and ensure 
participants remained blind to the treatment they had received.  The order in which 
participants received each treatment was determined by Latin square. 
 
3.2.3 Physiological, cognitive and mood measures 
3.2.3.1 Near-infrared spectroscopy measurements 
Please see chapter 2 for a description of the NIRS method used, which is identical 
to that used in the present chapter. 
3.2.3.2 Cognitive and mood measures 
All cognitive and mood measures were delivered using COMPASS.  Please see 
chapter 2 for a description.  The tasks were chosen based on their ability to activate the 
pre-frontal cortex (Cohen et al., 1997; Drummond et al., 1999; Lawrence et al., 2002) or 
their sensitivity to Ginkgo biloba (Kennedy et al., 2002).  Tasks were also chosen based 
on their identification previously as being the most cognitively demanding tasks within 
COMPASS (Wightman, 2013).  All baseline and post-dose tasks lasted 2 minutes and 
were presented in the following order; serial 7s subtractions, serial 13s subtractions, serial 
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17s subtractions, RVIP and N-back (3-back).  Prior to the completion of baseline tasks 
and following the completion of post-dose tasks, participants were required to complete a 
subjective assessment of their mood via the Bond Lader visual analogue scales and a 
subjective mental fatigue rating scale.  Tasks completed at baseline and post-dose were 
identical and followed the same order.  At baseline each task was completed once and at 
post-dose each set of tasks was completed 6 times.   
3.2.3.2.1 Serial 7s: 
Please see chapter 2 for a description of this task.  This task was scored for 
number of correct responses and number of errors. 
3.2.3.2.2 Serial 13s: 
The serial 13s task was identical to the serial 3s task as described in chapter 2, 
except that it involved serial subtraction of 13s.  This task was scored for number of 
correct responses and number of errors. 
3.2.3.2.3 Serial 17s: 
The serial 17s task was identical to the serial 3s task as described in chapter 2, 
except that it involved serial subtraction of 17s.  This task was scored for number of 
correct responses and number of errors. 
3.2.3.2.4 RVIP: 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage of target strings correctly detected, average reaction time for correct 
detections, and number of false alarms. 
3.2.3.2.5 3-Back: 
 Please see chapter 2 for a description of this task.  This task was scored for 
percentage of correct responses and reaction time. 
3.2.3.2.6 Subjective mental fatigue visual analogue scale: 
 Please see chapter 2 for a description of this task. 
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3.2.3.2.7 Bond lader visual analogue scales: 
 The Bond Lader Visual Analogue Scales (Bond & Lader, 1974) consist of a series 
of 16 antonyms assessing aspects of mood (e.g. Calm-Excited, Alert-Drowsy, Interested-
Bored, etc.) which anchor a 100 mm scale.  In the current study the antonyms were 
presented to the participants on-screen and they were required to respond by using a 
mouse to click at a point on the line which best described how they felt in relation to the 
relevant antonym.  The participants’ answers were then combined to form three mood 
factors as recommended by the authors: alertness, calmness and contentment.  These 
analogue scales have previously been shown to be sensitive to Ginkgo biloba (Kennedy, 
Haskell, Mauri, & Scholey, 2007; Kennedy et al., 2002).  
 
3.2.3.3 Blood pressure and heart rate 
Blood pressure and heart rate were monitored using the Boso-Medicus Prestige 
(Bosch + Sohn, Germany), an automatic device that provides measures of heart rate (bpm) 
and systolic and diastolic blood pressure (mmHg).  Readings were taken from the upper 
left arm following 5 minutes seated rest at each visit upon arrival and following post-dose 
completion of the cognitive tasks. 
 
3.2.4 Procedure 
Participants were required to attend the laboratory on 4 separate occasions.  The 
first visit was a screening session and participants were informed about the nature of the 
study, its requirements and its restrictions.  Informed consent was obtained and their 
eligibility to participate was confirmed.  Habitual caffeine intake and source were assessed 
via questionnaire (see appendix II) and familiarisation with the tasks to be administered on 
the study days was conducted.  The remaining 3 study visits were identical, apart from the 
treatment subjects received.  On these days, participants attended the lab at 1.30 pm after 
abstaining from alcohol from 8 pm the previous evening and following a 2 hour fast where 
they were permitted to only drink water.  Prior to the 2 hour fast they were required to 
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consume the same light breakfast (toast or cereal was suggested) on each study day.  If 
they were caffeine consumers they were required to consume their usual caffeinated 
beverage with breakfast, at least 2 hours prior to their study session, to reduce the 
possibility of overnight caffeine withdrawal impacting upon cognitive or physiological 
parameters.  Upon arrival at the laboratory, heart rate and blood pressure readings were 
taken and baseline mood and mental fatigue scales were completed.  Participants were 
then provided with a light snack which they had 10 minutes to consume and consisted of a 
choice of either a plain cheese or plain ham sandwich and a glass of water.  The snack 
provided was the same at each visit.  The NIRS headband was then fitted, recording 
began and readings were allowed to stabilise before baseline performance for the day 
was determined on cognitive tasks.  Upon completion of the tasks participants were 
required to sit quietly for 10 minutes whilst the pre-treatment resting NIRS baseline 
readings were taken.  Participants were then required to take their treatment for the day.  
Ninety minutes post-dose (during which time participants kept the NIRS headband on and 
watched a non-stimulating home improvement DVD), participants completed a further 6 
sets of the cognitive tasks.  They then had their blood pressure and heart rate measured 
for a second time and a second set of mood and mental fatigue scales were completed 
(see Fig.3.1. for more details of procedure and task duration).  Participants returned for 
their next study visit following (at least) a 7-day washout period.   
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 Fig.3.1. Timeline representing flow of study day. 
 
3.2.5 Statistics 
Prior to the primary NIRS analysis a within subjects ANOVA was carried out with 
left/right optode included as a factor to examine any treatment related hemispheric 
differences in response. As there were no interpretable interactions involving this factor 
the data from the 2 channels were averaged for the analysis. 
For the primary NIRS analysis, the question under investigation was how Ginkgo 
biloba would modulate the haemodynamic response over time, during the course of the 
study visit (throughout the absorption period and during overall, individual task 
performance) in comparison to placebo.  Data for oxy-Hb, deoxy-Hb and total-Hb was 
averaged across 10 minute (absorption) and 2 minute (individual task) epochs and 
baseline adjusted to the post-task resting pre-treatment period.  It was then analysed by 
2-way repeated measures ANOVA (treatment (180 mg G. biloba, 360 mg G. biloba or 
placebo) X epoch (39).  Significant treatment related interactions were then described with 
reference to a priori planned comparisons, where each active treatment was compared to 
placebo at each epoch utilising t-tests calculated with the Mean Squares Error from the 
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ANOVA (Keppel, 1991).  In order to reduce the potential for Type I errors only those 
planned comparisons associated with a statistically significant difference on the initial 
ANOVA are reported.  In addition, only those instances where a consistent pattern of 
significant differences are maintained across epochs are identified as reportable 
significant effects. 
In order to explore the haemodynamic effects of individual task performance, 
without influence of the absorption period and to also to allow any effects of demand 
(experienced through continued repetition of the tasks) to be revealed, a further analysis 
was conducted on NIRS data during tasks with repetition included as a factor.  Analysis of 
the task period was conducted by 3-way repeated measures ANOVA (treatment (as 
above) X task (serial 7s, serial 13s, serial 17s, RVIP, 3-back) X repetition (6).  Planned 
comparisons were conducted as per primary analysis, documented above. 
Secondary analysis of the NIRS data was aimed at identifying the course of 
treatment-related haemodynamic effects within each task.  Therefore, NIRS data for each 
task was averaged across 10 second epochs and baseline adjusted to the post-task 
resting pre-treatment period.  It was then analysed by 3-way repeated measures ANOVA 
(treatment (as per primary analysis) X 10 second Epoch (60) X repetition (6).  Planned 
comparisons were conducted as per primary analysis, documented above.   
To assess the possibility of any on-day differences in cognitive performance, mood 
and autonomic measures at baseline, 1-way repeated measures ANOVAs were 
conducted on baseline data. 
Cognitive performance, subjective mood, heart rate and blood pressure data were 
analysed as ‘change from baseline’ by two-way repeated measures ANOVA (treatment X 
repetition) with planned comparisons conducted as above. 
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3.3 Results 
3.3.1 Near infrared spectroscopy 
3.3.1.1 Primary analysis 
Effects of treatment on cerebral blood flow over time. 
3.3.1.1.1 Oxygenated haemoglobin 
There were no treatment-related differences in oxy-Hb, see fig. 3.2a. 
3.3.1.1.2 Deoxygenated haemoglobin 
There were no treatment-related differences in deoxy-Hb, see fig.3.2b. 
3.3.1.1.3 Total haemoglobin 
There were no treatment-related differences in total-Hb, see fig 3.3. 
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 Fig. 3.2.  Concentration changes of oxy-Hb (a) and deoxy-Hb (b) represented in 10 minute 
epochs during absorption period and 2 minute epochs during cognitive tasks following 
placebo, 180 mg G. biloba, 360 mg G. biloba.  Means and SEM are presented as change 
from pre-treatment, resting baseline. 
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 Fig. 3.3.  Concentration change of total-Hb, represented in 10 minute epochs during 
absorption period and 2 minute epochs during cognitive tasks following placebo, 180 mg 
G. biloba, 360 mg G. biloba.  Means and SEM are presented as change from pre-
treatment, resting baseline. 
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3.3.1.1.4 Further primary analysis 
Effects of treatment on cerebral blood flow during performance of individual 
tasks. 
3.3.1.1.4.1 Oxygenated haemoglobin 
There were no treatment-related differences in oxy-Hb, see fig. 3.4. 
3.3.1.1.4.2 Deoxygenated haemoglobin 
A significant interaction effect (treatment X task) was observed for deoxy-Hb [F(8, 
920)=2.02, p=0.046].  Planned comparisons revealed that 180 mg ginkgo led to a 
significant increase in deoxy-Hb during the serial 7s [t(920)=2.83, p=0.0047, d=-0.24], and 
serial 13s subtractions tasks [t(920)=2.41, p=0.0162, d=-0.19], as compared to placebo.  
However, the 360 mg dose of ginkgo led to a significant reduction in deoxy-Hb during the 
serial 13s [t(920)=2.26, p=0.024, d=0.18], serial 17s [t(920)=2.08, p=0.038, d=0.16] and 
3-back [t(920)=2.03, p=0.043, d=0.17] tasks, as compared to placebo, see fig. 3.5. 
3.3.1.1.4.3 Total haemoglobin 
There were no treatment-related differences in total-Hb. 
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 Fig. 3.4. Concentration change of oxy-Hb during each individual task following placebo, 
180 mg G. biloba, 360 mg G. biloba.  Means and SEM are presented as change from pre-
treatment, resting baseline. 
 
 
Fig 3.5. Concentration change of deoxy-Hb during each individual task following placebo, 
180 mg G. biloba, 360 mg G. biloba.  Means and SEM are presented as change from pre-
treatment, resting baseline.  Treatment X task interaction effects are shown across all 
reps.  Significance is compared to placebo (t-tests calculated with the Mean Squares Error 
from the ANOVA) (* p<0.05, *** p<0.005). 
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3.3.1.2 Secondary analysis 
Effects of treatment on cerebral blood flow during task performance using 
smaller duration (10 second) epochs. 
3.3.1.2.1 Oxygenated haemoglobin 
There were no treatment-related differences in oxy-Hb. 
3.3.1.2.2 Deoxygenated haemoglobin 
There were no treatment-related differences in deoxy-Hb. 
3.3.1.2.3 Total haemoglobin 
There were no treatment-related differences in total-Hb. 
 
3.3.2 Cognitive performance and mood 
3.3.2.1 Serial 13s  
Due to incorrect task performance, only 23 participants are included in this 
analysis.  There was a significant main effect of treatment on serial 13s subtractions 
errors [F(2, 220)=3.62, p=0.035].  Planned comparisons revealed that significantly fewer 
errors were made overall, following 180 mg ginkgo as compared to placebo [t(220)=2.00, 
p=0.046, d=0.67], see fig. 3.6. 
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 Fig. 3.6.  Mean (and SEM) change from baseline scores on serial 13s subtractions errors, 
following 180 mg Ginkgo, 360 mg Ginkgo and placebo.  Significance is compared to 
placebo (t-tests calculated with the Mean Squares Error from the ANOVA) (* p<0.05). 
 
 
 
3.3.3 Blood pressure and heart rate 
3.3.3.1 Systolic blood pressure 
There were no significant differences in systolic blood pressure. 
3.3.3.2 Diastolic blood pressure 
There were no significant differences in diastolic blood pressure. 
3.3.3.3 Heart rate 
There were no significant differences in heart rate. 
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3.4 Discussion 
The current study has demonstrated that irrespective of task repetition, 180 mg 
ginkgo, as compared to placebo, leads to a significant increase in deoxy-Hb during serial 
7s and serial 13s subtraction tasks.  Whereas a 360 mg dose of ginkgo leads to a 
significant reduction in deoxy-Hb as compared to placebo during serial 13s, serial 17s and 
3-back tasks. 
In terms of cognitive effects, the only significant finding was that of a reduction in 
the number of serial 13s errors following the 180 mg dose of ginkgo as compared to 
placebo. 
In relation to the effects of ginkgo on cerebral oxygenation, in the previous chapter 
although ginkgo did not modulate oxy-Hb, a 207 mg dose led to a significant increase in 
deoxy-Hb as compared to placebo, for the duration of the Stroop and 3-back tasks as well 
as the RVIP task, but to a lesser extent.  It is interesting therefore that in the present study 
an increase in deoxy-Hb was only observed for the lower, 180 mg dose and only during 
the serial 7s and serial 13s tasks.   The 360 mg dose in contrast, evinced a significant 
reduction in deoxy-Hb as compared to placebo during the serial 13s task, which also 
extended to the serial 17s and 3-back tasks.  Why two doses of the same treatment 
should engender contrasting effects on the same cerebral oxygenation parameter is not 
readily apparent.  A decrease in deoxy-Hb with a corresponding increase in oxy-Hb, in the 
absence of any intervention, is generally accepted to be indicative of brain activation 
(Obrig & Villringer, 2003).  When considered in relation to the effects following 360 mg 
ginkgo (see fig. 3.5), although there was no significant effect on oxy-Hb here, the pattern 
of observed effects is suggestive of an increase as compared to placebo (see fig. 3.4).  
Turning to the contrasting effects following the lower 180 mg dose, an increase in deoxy-
Hb as a result of the administration of an intervention believed to increase cerebral blood 
flow (such as ginkgo) has been observed previously, as discussed in chapter 2.  At rest, 
Bönöczk et al. (2002) demonstrated similar findings in stroke patients following treatment 
with vinpocetine and in healthy young adults, Kennedy et al. (2010) observed the same 
pattern following the administration of resveratrol.  In the latter study the effects were 
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observed during completion of serial 7s subtractions and the RVIP task (both of which 
were used in the present study).  In both instances this modulation of deoxy-Hb was 
identified as indicative of increased oxygen utilisation and extraction (Bonoczk et al., 
2002).   Again, as discussed in chapter 2, the aforementioned studies also observed 
associated increases in oxy-Hb and total-Hb, which represent an increase in oxygen 
delivery and total blood flow, and are thought to occur in the presence of increased neural 
demand (Izzetoglu et al., 2004; Izzetoglu et al., 2003; Shibuya-Tayoshi et al., 2007).  This 
may therefore suggest that during certain tasks, following a ~200 mg dose of ginkgo, an 
increase in oxygen extraction and utilisation occurs in the absence of an increase in 
demand for neural substrates. 
The absence of an increase in cerebral blood flow in the present study could, 
perhaps, be explained by the dosing schedule in addition to the study population used.  
Santos et al. (2003) found that cerebral perfusion was significantly increased in frontal, 
parietal and occipital areas of the brain in healthy older adults (60-70 years) following 8 
months administration of an 80 mg/day dose of a standardised ginkgo extract.  Similarly 
Mashayekh et al. (2011) also documented an increase in cerebral blood flow in healthy 
older adults (51-71 years) following 4 weeks supplementation of 120 mg/day with a 
standardised dose of ginkgo.  However, the effects were milder than those of Santos et al. 
(2003) and only observed in the left parietal-occipital area of the brain.  It is possible that 
the shorter, 4 week dosing schedule administered by Mashayekh et al. (2011) was 
responsible, at least in part, for the difference in magnitude of the cerebral blood flow 
effects between the two studies.  Therefore, in terms of the present study, this may 
suggest that the acute dosing regimen used here was not sufficient to elicit an effect.  In 
terms of the study population used, both of the aforementioned studies were conducted in 
older cohorts and cerebral blood flow is known to reduce with age (Leenders et al., 1990; 
Martin et al., 1991; Pantano et al., 1984).  With this in mind, it could be that increases in 
cerebral blood flow as a result of ginkgo administration are not as readily identifiable in 
younger cohorts as they are in ageing populations where blood flow may be sub-optimal.  
Furthermore, the repeated use of difficult tasks employed in the present study to increase 
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cognitive demand, were perhaps not difficult or fatiguing enough to provide the room for 
improvement needed to observe an effect of treatment in a young population.  It is 
unfortunate therefore that no mental fatigue scales were included after the competition of 
each set of tasks, as this could have verified the level of mental fatigue the participants 
were experiencing.  It is also of interest to note that in the present study following both 
treatments as well as placebo, there was a reduction in oxy-Hb during the performance of 
cognitive tasks as compared to the resting baseline.  NIRS is capable of detecting 
cerebral activation during the completion of cognitively demanding tasks and as previously 
discussed, this is commonly expressed as an in increase in oxy-Hb with a corresponding 
decrease in deoxy-Hb.  However, in the current study, this pattern of effects was not 
observed for oxy-Hb, most pointedly where no intervention was used (i.e. following 
placebo).   One possibility is that this was due to falsely elevated oxy-Hb readings since 
measurement of the resting NIRS baseline occurred immediately after participants had 
completed their baseline cognitive assessment. 
The only finding in terms of behaviour was that of a reduction in serial 13s errors 
following the 180 mg dose, leading to the possibility that it was in fact, a type 1 error.  On 
the other hand, it could be said to be as expected, as ginkgo has elicited the same effects 
following a similar version of the same task (serial 3s), previously (Kennedy et al., 2002).  
However, it is interesting that it was the only cognitive/mood parameter to evince any 
benefit of ginkgo, when a 360 mg dose has previously led to an increase in serial 7s 
responses as well as an increase in alertness and contentedness using the same task 
and mood scales as in the present study (Kennedy et al., 2002).  However, a key 
difference between the present study and that of Kennedy et al. (2002) is that here 
participants were required to complete the tasks 6 times in succession, creating a more 
demanding environment where treatment related effects may have been lost.  The relative 
lack of cognitive effects is unfortunate but not entirely unexpected.  Although there have 
been a number of instances where similar doses to those used here have elucidated 
significant results, the effects from study to study have not always been consistent, 
despite the use of similar tasks and methodologies.  Although the treatment used was a 
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standardised extract, the means and method of processing such extracts can vary 
between manufacturers (Van Beek, 2002) a factor which may have had an influence upon 
the outcomes.  A further explanation for the lack of effects in the current study may have 
been the time at which testing took place.  Ginkgo has been reported as reaching its peak 
in the blood at 2.3 hours post-dose (Drago, Floriddia, Cro, & Giuffrida, 2002); however, in 
the present study testing began at 1.5 hours and only continued until 2.5 hours post-dose.  
This raises the possibility that any cognitive effects ginkgo may have engendered were 
missed by premature cessation of the post-dose testing period.  This proposal seems 
more likely considering that previously observed improvements in speed of attention 
(Kennedy et al., 2000, 2002) and mental arithmetic (Kennedy et al., 2002) were first 
observed at 2.5 and 4 hours respectively and then at 6 hours post-dose despite initial 
testing taking place 1 hour following treatment.   
Turning to autonomic measures, the absence of an effect on blood pressure and 
heart rate following acute administration of ginkgo has been documented previously (Jung, 
Mrowietz, Kiesewetter, & Wenzel, 1990; Keheyan, Dunn, & Hall, 2011).  However, a 
stress induced reduction in blood pressure has been reported following 120 mg ginkgo 
(Jezova et al., 2002).  Even though no specific stressor was applied in the present study, 
a testing battery such as the one administered here (difficult tasks re-administered 6 times 
over the period of an hour) could reasonably be regarded as a situation likely to induce a 
degree of stress.  Therefore, it is interesting that no effect of ginkgo was demonstrated 
here, particularly in view of ginkgo’s previously documented effects on blood flow and 
blood circulation. 
In terms of limitations, one of the most identifiable in the present study could be 
regarded as the duration of the post-dose testing window.  As previously discussed, 
ginkgo’s effects have been demonstrated as early as 1 hour and up until 6 hours post-
dose; however, the present study was only able to observe the effects within 1.5-2.5 hours 
of administration.  The main reason for this being, that once the NIRS equipment has 
been placed upon the participant’s head, it cannot be removed, due to the way in which 
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NIRS measures are taken (NIRS provides concentration change data from first reading 
prior to start of recording).  Therefore, expecting participants to sit for a period of up to 4 
or indeed 6 hours at a time without the chance of a break or rest would be unreasonable 
and likely lead to a high drop-out rate.  An alternative approach would be to use an 
intervention that had either a relatively quick absorption period and or a comparatively 
short psychoactive/biologically active phase, when using NIRS technology. 
In conclusion, the current research has demonstrated that Ginkgo biloba is 
capable of reducing the number of errors made on a demanding task of mental arithmetic 
as well as modulating deoxy-Hb, but that these effects are dependent upon the dose 
administered. In addition, this study has gone further to demonstrate that NIRS is 
sensitive enough to identify treatment-related changes in cerebral oxygenation 
parameters during the performance of demanding cognitive tasks. 
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Chapter 4: An evaluation of the effects of caffeine and L-theanine both 
alone and in combination on cerebral haemodynamics, cognitive 
performance and mood. 
 
4.1 Introduction 
The findings of chapters 2 and 3 demonstrated to an extent, that NIRS is able to 
detect changes in cerebral oxygenation parameters during the performance of cognitive 
tasks, in the presence of herbal extracts known for their vasodilatory properties.  However, 
in order to remove some of the uncertainty experienced in chapters 2 and 3 in terms of 
how the intervention would modulate behavioural and physiological parameters; it seemed 
prudent to administer an intervention with more robust behavioural and vascular effects, in 
this case, caffeine.  It was anticipated that this would provide the platform for a more 
thorough evaluation of the methodological approach adopted within this thesis.  
Additionally, since chapters 2 and 3 evaluated the effects of interventions with supposed 
vasodilating properties, the administration of caffeine - an intervention known for its 
opposing (vasoconstricting) effects on blood flow, also seemed appropriate.  The 
beneficial effects of caffeine on cognition and mood have been reported in a number of 
studies; however, relatively few studies have looked at the effects of caffeine in 
combination with other compounds (see Haskell et al. (2013) for review), despite the fact 
that caffeine is seldom consumed in isolation.  L-theanine is a naturally occurring amino-
acid that is found almost uniquely in tea (Camellia sinensis), where it coexists with 
caffeine and has been used for centuries in Asia in order to produce feelings of relaxation 
(Heese et al., 2009).  Although studies of the behavioural and peripheral effects of these 
two interventions combined have reported synergistic effects, the impact on cerebral 
blood flow of this combination remains unexplored. 
Caffeine is the most widely consumed psychoactive substance in the world, with 
coffee and tea representing our main dietary sources (Fredholm, Battig, Holmen, Nehlig, 
& Zvartau, 1999b).  Caffeine has been shown to reduce cerebral blood velocity as 
assessed by transcranial Doppler (Hasse, Becka, Kuhlmann, & Wensing, 2005) and 
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cerebral blood flow (CBF) as assessed by near infrared spectroscopy (NIRS) (Kennedy & 
Haskell, 2011) and magnetic resonance imaging (MRI) (Chen & Parrish, 2009a; Laurienti 
et al., 2003; Mathew & Wilson, 1991; Rack-Gomer et al., 2009). These effects on CBF 
have been shown to be dose-dependent following 1, 2.5 and 5 mg/kg caffeine (Chen & 
Parrish, 2009b).  Studies that have assessed the effects of caffeine administration on 
blood flow taking a participant’s caffeine consumption habits into consideration, have 
found (via quantitative perfusion MRI), that the effects are dependent upon the level of 
caffeine habitually consumed.  Following at least 30 hours abstention, habitual high 
consumers were shown to exhibit increased resting CBF as compared to low consumers 
and caffeine use was significantly positively correlated with CBF following both placebo 
and caffeine (Addicott et al., 2009; Field et al., 2003).  In addition, despite retaining a 
higher rate of CBF overall, high consumers also exhibited a greater acute reduction in 
CBF in response to a 250 mg dose of caffeine whilst in a state of withdrawal (Field et al., 
2003).  However, it should be noted that Addicott et al. (2009) found no difference 
between low, moderate and high consumers in response to caffeine which was 
administered whilst in a withdrawal state.   
In studies assessing cognitive performance and mood, caffeine has consistently 
been shown to improve reaction times (Childs & de Wit, 2006; Haskell et al., 2008b; Smit 
& Rogers, 2000) and alertness (Quinlan et al., 2000; Rogers et al., 2008), irrespective of 
consumption status (Haskell et al., 2005).   
Unlike caffeine, however, research into the effects of L-theanine in humans is 
limited.  In terms of anxiolytic effects, 200 mg L-theanine has been shown to reduce acute 
stress responses (subjective perception, heart rate and salivary immunoglobulin A) 
induced by a mental arithmetic task (Kimura et al., 2007).  A 250 mg dose of L-theanine 
was also found to slow reaction time on a visual probe task indicating reduced anxiety 
(Rogers et al., 2008).  EEG studies have also provided some support for these findings 
with increases in resting alpha activity observed following 50 mg (Nobre et al., 2008) and 
200 mg L-theanine (Juneja et al., 1999), which the authors interpret as being indicative of 
relaxation.  A dose of 250 mg of L-theanine has also been shown to differentially alter 
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alpha activity during task performance and at rest (Gomez-Ramirez et al., 2007; Gomez-
Ramirez et al., 2009).   
In terms of cognitive function, L-theanine in isolation has been shown to engender 
decrements in performance (Gomez-Ramirez et al., 2007; Haskell et al., 2008b) or, at 
best, an absence of effects (Gomez-Ramirez et al., 2009; Haskell et al., 2008b; Kelly et al., 
2008; Owen et al., 2008).    However, when administered together L-theanine modulates 
or potentiates the effects of caffeine.  For instance, Haskell et al. (2008b) reported that a 
number of effects were evident following a combination of 250 mg L-theanine and 150 mg 
caffeine that were not apparent when each treatment was administered alone.  
Improvements included increased speed on several tasks (simple reaction time, delayed 
word recognition, numeric working memory) and improved sentence verification accuracy.  
Participants also rated themselves as being more ‘alert’ and less ‘tired’.  In contrast, 
caffeine alone, but not the combination, only improved reaction times on a digit vigilance 
task.  Other studies have employed lower doses of L-theanine (~100 mg) and caffeine 
(~50 mg) to explore these effects (Einother, Martens, Rycroft, & De Bruin, 2010; Kelly et 
al., 2008; Owen et al., 2008).  These studies provide support for the findings from studies 
of higher doses, with the combination treatment leading to improved accuracy (Einother et 
al., 2010; Kelly et al., 2008; Owen et al., 2008) and speed (Einother et al., 2010; Owen et 
al., 2008) on tasks of attention, and improvements to measures of memory (Owen et al., 
2008).  L-theanine has also been shown to antagonise the physiological effects of caffeine.  
Rogers et al. (2008) demonstrated that although systolic and diastolic blood pressure 
were significantly higher following the administration of 250 mg caffeine when compared 
to placebo or 200 mg L-theanine alone, the combination of the two compounds led to an 
attenuation of this effect.  There was, however, no evidence of antagonism of mood 
effects.     
As discussed, previous research using a variety of methodologies has 
demonstrated that caffeine improves aspects of cognitive performance (Childs & de Wit, 
2006; Haskell et al., 2008b; Haskell et al., 2005; Quinlan et al., 2000; Rogers et al., 2008; 
Smit & Rogers, 2000) and consistently reduces cerebral blood-flow (Chen & Parrish, 
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2009a; Laurienti et al., 2003; Mathew & Wilson, 1991; Rack-Gomer et al., 2009).  
Specifically, a previous study using the dose of caffeine employed here (75 mg) showed 
that caffeine significantly reduced total-Hb as measured by NIRS (Kennedy & Haskell, 
2011).  Given that co-administration of L-theanine with caffeine has previously been 
demonstrated to attenuate its haemodynamic effects (Rogers et al., 2008), it remains a 
possibility that co-administration may also attenuate the cerebro-vascular effect of caffeine.  
The doses of L-theanine/caffeine and the ratios in which they have been administered in 
the majority of assessments of these two interventions to date have tended to contain 
higher levels of L-theanine than caffeine.  This is not representative of the levels or ratios 
normally found in tea in our diet, which tend to be in the region of 2 to 1 in favour of 
caffeine.  Similarly, the lowest dose of L-theanine explored previously in terms of 
behaviour (100 mg) is equivalent to ~4 cups of tea.  The doses used in the present study 
(75 mg caffeine, 50 mg L-theanine and a combination of 75 mg caffeine and 50 mg L-
theanine) therefore more closely reflect the ratios found in tea and represent the levels 
found in approximately 2 cups.  The decision to include both habitual and non-habitual 
caffeine consumers was taken based on previous research documenting differences in 
CBF as a result of consumer status (Addicott et al., 2009; Field et al., 2003).  It would also 
allow assessment of the impact of status on CBF effects following caffeine/L-theanine 
within the present study.   To be consistent with chapter 3, and specifically following 
findings of an antagonistic interaction between L-theanine and caffeine on this measure 
(Rogers, 2007), blood pressure and heart rate readings were also monitored, pre and 
post-treatment. 
This double-blind, placebo-controlled, balanced, crossover study aimed to address 
these issues using NIRS to measure CBF in the pre-frontal cortex during cognitive task 
performance following caffeine and L-theanine both alone and in combination.  The cohort 
included both habitual tea drinking consumers and non-habitual consumers of caffeine, 
and involved administration of doses and ratios of caffeine and L-theanine that more 
closely reflect those present in tea.  It is hypothesised that administration of caffeine alone 
will lead to a reduction in CBF and that this effect will be attenuated when administered in 
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the presence of L-theanine.  It is also predicted that this combination will enhance the 
effects of caffeine on behaviour. 
 
4.2 Method 
4.2.1 Participants 
Twenty-four healthy young participants (10 males, 14 females) between the ages 
of 18 and 35 (mean age 21.8, SD 3.19; BMI 22.8, SD 3.1) were recruited.  Volunteers 
were recruited to take part in the study if they fell into one of two pre-defined categories; 
‘habitual consumers’ (those who drank tea and consumed more than 150 mg caffeine per 
day) or ‘non-habitual consumers’ (those who consumed less than 60 mg caffeine per day 
and no more than two cups of tea/coffee per week).  Twelve participants were classified 
as habitual consumers (5 males; mean age 23.3, SD 3.65) and 12 as non-habitual 
consumers (5 males; mean age 20.4, SD 1.88).  From the self-report caffeine 
consumption questionnaire (see appendix C), habitual consumers reported drinking 
between 163 mg to 432 mg caffeine per day (mean 252.2, SD 74.3).  Non-habitual 
consumers reported drinking between 0 and 56 mg caffeine per day (mean 16.7, SD 15.6).  
With regards tea consumption, habitual consumers reported consuming between 1 to 6 
cups per day (mean 3.50, SD 1.46) and non-habitual consumers reported consuming 
between 0 and 2 per week (mean 0.45, SD 0.62).  The study was approved by 
Northumbria University’s School of Psychology and Sport Sciences’ ethics committee and 
conducted in accordance with the Declaration of Helsinki.  Prior to participation, 
volunteers were required to sign an informed consent form (see appendix A for example 
of information sheet) and complete the aforementioned caffeine consumption 
questionnaire that assessed their daily level of caffeine intake.  A general health screen 
(see appendix A) informed volunteers that they would not be eligible to take part if they 
had a history of neurological, vascular or psychiatric illness.  Participants would also be 
excluded if they had a history or current diagnosis of drug or alcohol abuse, a current 
diagnosis of depression or anxiety, anaemia, high blood pressure, a heart or respiratory 
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disorder, type 1 diabetes, phenylketonuria, a history of head trauma, migraines, learning 
difficulties, dyslexia or ADHD.  All participants reported that they were in good health, had 
normal or corrected-to-normal vision and had no known allergies to the treatment 
ingredients.  They also reported that they were not currently taking any dietary 
supplements or medication, including the contraceptive pill as intake of oral contraceptives 
has been shown to increase the half-life of caffeine (Patwardhan, Desmond, Johnson, & 
Schenker, 1980).  Additionally, they were not colour-blind, did not smoke and in the case 
of female volunteers that they were not pregnant or seeking to become pregnant. 
 
4.2.2 Design and treatment 
A double-blind, counter-balanced, within subjects, placebo-controlled design was 
utilised.  Participants attended 4 study visits and at each received one of the following 
treatments: 75 mg caffeine (pharmaceutical grade caffeine powder, Blackburn 
Distributions Ltd); 50 mg L-theanine (pharmaceutical grade L-theanine powder, 
Suntheanine, Taiyo Europe, Germany); 75 mg caffeine and 50 mg of L-theanine in 
combination, or placebo.  The doses selected roughly equate to the levels of L-theanine 
found in 2 cups of tea.  These were chosen in an attempt to extend previous findings 
exploring 100 mg L-theanine (Einother et al., 2010; Kelly et al., 2008; Owen et al., 2008) 
whilst more closely reflecting the ratio of L-theanine to caffeine found in tea.  Each 
treatment was administered in the form of 2 capsules in order to mask any taste 
differences and ensure participants remained blind to the treatment they had received.  
The order in which participants received each treatment was determined by Latin square 
and random allocation to treatment order for each group (habitual consumers and non-
habitual consumers). 
4.2.3 Salivary caffeine levels 
Saliva samples were obtained using salivettes (Sarstedt Ltd).  One sample was 
taken upon arrival and one immediately following the post-dose cognitive assessment.  
This was to ensure overnight caffeine abstinence and to confirm caffeine absorption 
following caffeinated treatments (no analysis of post-treatment caffeine levels were made 
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following placebo or L-theanine).  Once taken, samples were frozen at -20ºC.  The 
samples were then thawed and the caffeine levels in the saliva samples were measured 
using an Emit® Caffeine Assay (Dade Behring Ltd). 
 
4.2.4 Physiological, cognitive and mood measures 
4.2.4.1 Near infrared spectroscopy measurements 
Please see chapter 2 for a full description of the NIRS method used, which is 
identical to that used in the present chapter. 
4.2.4.2 Cognitive and mood measures 
All cognitive and mood measures were delivered using COMPASS which has 
previously been shown to be sensitive to caffeine (Kennedy & Haskell, 2011).  Please see 
chapter 2 for a description of COMPASS and an explanation of tasks listed here but not 
described in full below.  The tasks were chosen based on their ability to activate the pre-
frontal cortex (Drummond et al., 1999; Lawrence et al., 2002; Schroeter et al., 2002) or 
their known sensitivity to one or both of the nutritional interventions under investigation 
(Haskell et al., 2008b; Kennedy & Haskell, 2011; Lieberman, Wurtman, Emde, Roberts, & 
Coviella, 1987).  The tasks completed at baseline and post-dose were identical with the 
exception of duration (all baseline tasks were 2 minutes).  Tasks were presented in the 
following order (post-dose duration in parentheses) serial 3s subtractions (4 minutes), 
serial 7s subtractions (4 minutes), simple reaction time (SRT), (8 minutes), RVIP (8 
minutes), choice reaction time (CRT), (8 minutes) and Stroop (8 minutes).  Prior to 
baseline task completion and following completion of post-dose tasks participants 
completed a subjective assessment of their mood in the form of the caffeine research 
visual analogue scales. 
4.2.4.2.1 Serial 3s: 
 Please see chapter 2 for a description of this task.  This task was scored for 
percentage accuracy and percentage errors. 
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4.2.4.2.2 Serial 7s: 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage accuracy and percentage errors. 
4.2.4.2.3 Simple reaction time: 
An upwards pointing arrow appears on the screen at a random inter-stimulus 
duration of between 1 and 3.5 seconds.  Participants have to respond as quickly as they 
can when they see a stimulus appear by pressing the space bar.  One hundred and ninety 
stimuli were presented and the task was scored for reaction time. 
4.2.4.2.4 RVIP: 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage of target strings correctly detected, average reaction time and percentage of 
false alarms. 
4.2.4.2.5 Choice reaction time: 
An arrow pointing either left or right is presented in the middle of the screen at a 
random inter-stimulus duration of between 1 and 3.5 seconds.  As soon as participants 
see an arrow appear on the screen they are required to press the ‘Z’ key if the arrow is 
pointing left or the ‘M’ key if the arrow is pointing right.  One hundred and eighty-five 
stimuli were presented and the task was scored for percentage of correct responses and 
reaction time. 
4.2.4.2.6 Stroop: 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage accuracy and reaction time. 
4.2.4.2.7 Caffeine research visual analogue scales: 
Caffeine research visual analogue scales adapted from Rogers et al. (2003) that 
have previously been used in caffeine and L-theanine research were also included 
(Haskell et al., 2008b; Haskell et al., 2005; Kennedy & Haskell, 2011) and were presented 
on-screen.  Participants were shown the following descriptors “relaxed”, “alert”, “jittery”, 
“tired”, “tense”, “headache”, “overall mood”, “mentally fatigued” and asked to rate how 
much they matched their current state by placing an ‘x’ on a 100 mm line with the end 
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points labelled ‘not at all’ (left hand end) and ‘extremely’ (right hand end), with the 
exception of “overall mood”, which was labelled ‘very bad’ and ‘very good’.  Alert and tired, 
then tense and relaxed scores were combined to create respective factors of “alertness” 
and “tension” as recommended by the authors. 
4.2.4.3 Blood pressure and heart rate 
Please see chapter 3 for details of equipment used.  Readings were taken from 
the upper left arm following 5 minutes seated rest at each visit upon arrival and following 
post-dose completion of the cognitive tasks. 
 
4.2.5 Procedure 
Participants were required to attend the laboratory on 5 separate occasions.  The 
first visit was a screening session where participants were informed about the nature of 
the study, its requirements and its restrictions.  Informed consent was obtained and their 
eligibility to participate was confirmed.  Habitual caffeine intake and source were assessed 
via questionnaire and familiarisation with the tasks to be administered on the study days 
was conducted.  The remaining 4 study visits were identical to each other, with the 
exception of the treatment administered.  On each day, participants attended the lab at 8 
am following an overnight 12-hour fast where they were permitted only to drink water.  
Upon arrival heart rate and blood pressure readings were taken following 5 minutes of 
seated rest.  Following a baseline completion of the mood scales, salivary caffeine levels 
were taken to ensure caffeine abstinence.  Following this, the NIRS headband was fitted.  
Participants initially sat quietly for 5 minutes, then made a baseline completion of the 
cognitive tasks, this was followed by a 2-minute rest period where they sat quietly.  The 
rest period was included to reduce the haemodynamic impact of the baseline cognitive 
tasks upon the pre-treatment, resting baseline measure.  Upon completion of the tasks 
participants were required to sit quietly for a 2 minute NIRS resting baseline period.  
Participants were then required to take their treatment for the day.  Following a 30-minute 
absorption period (during which time NIRS recording continued whilst participants 
watched a non-stimulating wildlife DVD), participants completed a second set of the 
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cognitive tasks and a final rest period (8 minutes; included to allow an assessment of 
whether any CBF effects apparent after the absorption period are as a result of increased 
neural demand during tasks or are simply due to the time-course of effects of treatment).  
They then had their blood pressure and heart rate measured for a second time, rated their 
mood for a second time, and gave a second saliva sample, which was used to confirm 
caffeine absorption following caffeinated treatment (see fig 4.1 for more details of 
procedure and task duration).  Participants returned for their next study visit within 7 days, 
following (at least) a 48-hour washout period.  
 
 
Fig 4.1. Timeline representing flow of study day. 
 
4.2.6 Statistics 
 Two paired sample t-tests were utilised to analyse baseline and post-caffeinated 
treatment salivary caffeine levels to confirm caffeine absorption for caffeine containing 
treatments (caffeine, combination).  To determine if any differences existed in salivary 
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caffeine levels following caffeine and combination treatment, ‘change from baseline’ data 
were analysed by 2-way repeated measures ANOVA (treatment X consumer status).   
Prior to the primary NIRS analysis a within subjects ANOVA was carried out with 
left/right optode included as a factor to examine any treatment related hemispheric 
differences in response.  As there were no interpretable interactions involving this factor 
the data from the two channels were averaged for the analysis. 
For the primary NIRS analysis, the question under investigation was how caffeine, 
L-theanine and the combination treatment would modulate haemodynamics over time, 
during the course of the study visit (throughout the absorption period and during overall, 
individual task performance) in comparison to placebo and if consumer status would be a 
factor in this response.  Data for oxy-Hb, deoxy-Hb and total-Hb was averaged across the 
4 minute (absorption period) and 8 minute (individual tasks) epochs and baseline adjusted 
to the 2-minute post-task resting pre-treatment period.  To account for disruption in NIRS 
readings as a result of consumption of treatment, the first 2 minutes of the absorption 
period was omitted from the analysis.  Data was analysed by 3-way repeated measures 
ANOVA (treatment (75 mg caffeine, 50 mg L-theanine, 75 mg caffeine and 50 mg L-
theanine in combination or placebo) X epoch (absorption period - 7 x 4 minute epochs, 
task period – 6 x 8 minute epochs) X consumer status (habitual consumers, non-habitual 
consumers)).  Significant treatment related interactions were then described with 
reference to a priori planned comparisons, where each active treatment was compared to 
placebo at each epoch utilising t-tests calculated with the Mean Squares Error from the 
ANOVA (Keppel, 1991).  In order to reduce the potential for Type I errors only those 
planned comparisons associated with a statistically significant difference on the initial 
ANOVA are reported.  In addition, only those instances where a consistent pattern of 
significant differences are maintained across epochs are identified as reportable 
significant effects. 
In order to further explore the haemodynamic effect during the task period alone, 
to identify if effects were specific to task performance, separate analysis of the task period 
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was conducted by 3-way repeated measures ANOVA (treatment (as above) X task (serial 
subtractions, SRT, RVIP, CRT, Stroop, rest period) X consumer status (as above).  
Planned comparisons were conducted as per primary analysis, documented above. 
Secondary NIRS analysis was aimed at assessing the effects of treatment in more 
detail through the use of shorter-duration epochs and identifying any treatment-related 
haemodynamic effects over the first and second half of each task.  NIRS data was 
averaged across 4 minute epochs and baseline adjusted to the 2-minute post-task resting 
pre-treatment period.  Separate analysis of the task period was conducted by 3-way 
repeated measures ANOVA (treatment (as per primary analysis) X (12 x 4 minute epochs) 
X consumer status (as per primary analysis)).  Planned comparisons were conducted as 
per primary analysis, documented above.   
To assess the possibility of any on-day or consumer status differences in cognitive 
performance, mood, blood pressure and heart rate prior to treatment, 2-way repeated 
measures ANOVAs were conducted (treatment X consumer status) on baseline data.  Any 
significant differences were further explored with Bonferroni corrected pairwise 
comparisons.   
Cognitive performance, subjective mood, heart rate and blood pressure data were 
analysed as ‘change from baseline’ by 2-way repeated measures ANOVA (treatment X 
consumer status).  Significant treatment related effects were described with reference to a 
priori planned comparisons (as above) where each active treatment was compared to 
placebo or, in the case of interactions, each active treatment was compared to placebo in 
each consumer group. 
 
4.3 Results 
4.3.1 Salivary caffeine levels 
Prior to analysis, baseline scores were examined, and it was confirmed that they 
were in accordance with levels of caffeine that would reflect overnight caffeine abstinence.  
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Mean baseline values were 0.34 µg/ml, consumers and non-habitual consumers levels 
were 0.44 µg/ml and 0.25 µg/ml respectively and confirmed overnight abstinence [levels 
below 1 µg/ml have previously been reported for overnight caffeine abstinence  (Evans & 
Griffiths, 1999)].   Following caffeinated treatment, salivary caffeine levels were 2.25 µg/ml 
(combination) and 2.33 µg/ml (caffeine).  Analysis of the results confirmed that in 
comparison to baseline levels, salivary caffeine was significantly higher following caffeine 
[t(23) = -8.55, p<0.001] and combination treatments [t(23) = -5.54, p<0.001, (see fig. 4.2).  
There was no significant difference between caffeinated treatments (caffeine and 
combination) for salivary caffeine levels post-treatment. 
 
Fig 4.2.  Mean (and SEM) salivary caffeine values at baseline and post-dose following a 
combination of 50 mg L-theanine and 75 mg caffeine and 75 mg caffeine in isolation.  
Paired sample t-test significance levels are shown (**** p<0.001). 
 
4.3.2 Near infrared spectroscopy 
4.3.2.1 Primary analysis 
Effects of treatment on cerebral blood flow over time. 
4.3.2.1.1 Oxygenated haemoglobin 
A significant interaction effect (epoch X treatment) was observed for oxy-Hb [F(36, 
792)=1.50, p<0.05].  Planned comparisons revealed that following caffeine as compared 
to placebo, oxy-Hb was significantly reduced during minutes 3-6 [t(792)=2.05, p<0.05, 
d=0.32] and 11-18 of the absorption period (minutes 11-14 [t(792)=2.21, p<0.05, d=0.33], 
Caff Combi Caff Combi 
0
1
2
3
Baseline Postdose
****
****
Salivary Caffeine
µg
/m
l
117 
 
15-18 [t(792)=2.15, p<0.05, d=0.29]) and during SRT [t(792)=2.67, p<0.01, d=0.31], RVIP 
[t(792)=3.63, p<0.001, d=0.38], CRT [t(792)=3.55, p<0.001, d=0.35] and Stroop tasks 
[t(792)=4.26, p<0.001, d=0.41] and the rest period [t(792)=3.98, p<0.001, d=0.44], see fig 
4.3a.  This effect was not evident following L-theanine or when caffeine was combined 
with L-theanine, in fact, oxy-Hb was significantly increased following the combination 
during minutes 23-30 of the absorption period as compared to placebo (minutes 23-26 
[t(792)=2.82, p<0.005, d=-0.37], 27-30 [t(792)=2.19, p<0.05, d=-0.27]), see fig. 4.3a.   
4.3.2.1.2 Deoxygenated haemoglobin 
In relation to deoxy-Hb, a significant interaction effect (epoch X treatment) was 
also evinced [F(36, 792)=1.62, p<0.05].  Planned comparisons revealed that following 
caffeine as compared to placebo, deoxy-Hb was significantly increased during serial 
subtractions [t(792)=2.72, p<0.01, d=-0.39], SRT [t(792)=2.07, p<0.05, d=-0.32], RVIP 
[t(792)=2.19, p<0.05, d=-0.30] and Stroop tasks [t(792)=2.52, p<0.05, d=-0.31] and during 
the rest period [t(792)=2.47, p<0.05, d=-0.30], see fig. 4.3b.  Following the combination 
deoxy-Hb was significantly increased during serial subtractions [t(792)=2.31, p<0.05, d=-
0.36], CRT [t(792)=2.05, p<0.05, d=-0.30] and Stroop tasks [t(792)=1.97, p<0.05, d=-0.25] 
as compared to placebo, see fig 4.3b.  There was also a significant treatment by 
consumer interaction for deoxy-Hb [F(3, 792)=3.25, p<0.05].  Planned comparisons 
revealed that non-habitual consumers had significantly higher deoxy-Hb throughout the 
absorption and task periods following caffeine as compared to placebo [t(792)=2.93, 
p<0.005, d=-0.85], see fig. 4.5. 
4.3.2.1.3 Total haemoglobin 
There were no treatment related differences in total-Hb, see fig. 4.4. 
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Fig. 4.3.  Concentration changes of (a) oxy-Hb and (b) deoxy-Hb represented in 4 minute 
epochs during absorption period and 8 minute epochs during cognitive task period 
following placebo (), 50 mg L-theanine (), 75 mg caffeine () and a combination of 50 
mg L-theanine and 75 mg caffeine ().  Means and SEM are presented as change from 
pre-treatment, resting baseline.  Treatment x epoch interaction effects are shown.  
Significance is compared to placebo (t-tests calculated with the Mean Squares Error from 
the ANOVA) (* p<0.05, ** p<0.01, *** p<0.005, **** p<0.001). 
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 Fig. 4.4.  Concentration change of total-Hb represented in 4 minute epochs during 
absorption period and 8 minute epochs during cognitive task period following placebo (), 
50 mg L-theanine (), 75 mg caffeine () and a combination of 50 mg L-theanine and 75 
mg caffeine ().  Means and SEM are presented as change from pre-treatment, resting 
baseline. 
 
Fig. 4.5.  Concentration change of deoxy-Hb overall (absorption and cognitive task period) 
following placebo, 50 mg L-theanine, 75 mg caffeine and a combination of 50 mg L-
theanine and 75 mg caffeine.  Means and SEM are presented as change from pre-
treatment, resting baseline.  Treatment x consumer status interaction effects are shown 
for deoxy-Hb (t-tests calculated with the Mean Squares Error from the ANOVA) (*** 
p<0.005). 
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4.3.2.1.4 Further primary analysis 
Effects of treatment on cerebral blood flow during performance of individual 
tasks. 
4.3.2.1.4.1 Oxygenated haemoglobin 
There were no treatment related differences in oxy-Hb.   
4.3.2.1.4.2 Deoxygenated haemoglobin 
There were no treatment related differences in deoxy-Hb.   
4.3.2.1.4.3 Total haemoglobin 
There were no treatment related differences in total-Hb.   
 
4.3.2.2 Secondary analysis 
Effects of treatment on cerebral blood flow during task performance using 
smaller duration (4 minute) epochs. 
4.3.2.2.1 Oxygenated haemoglobin 
There were no treatment related differences in oxy-Hb. 
4.3.2.2.2 Deoxygenated haemoglobin 
There were no treatment related differences in deoxy-Hb. 
4.3.2.2.3 Total haemoglobin 
There were no treatment related differences in total-Hb. 
 
4.3.3 Cognitive performance and mood 
4.3.3.1 Baseline scores 
There was a significant main effect of treatment on baseline Stroop % accuracy 
[F(3, 66)=3.28, p<0.05].  However, this effect was not related to placebo and was 
therefore not explored further.  There were no other significant on-day or consumer status 
differences in cognitive performance, mood or autonomic measures prior to treatment. 
121 
 
4.3.3.2 Choice reaction time 
There was a significant main effect of treatment on choice reaction time [F(3, 
66)=2.99, p<0.05].  Planned comparisons revealed that reaction time was significantly 
faster following caffeine compared to placebo [t(66)=2.92, p<0.005, d=0.60], see fig.4.6a.  
However, there was also a significant treatment X consumer interaction effect [F(3, 
66)=2.82,  p<0.05] whereby this effect was found to be predicated on significantly faster 
responses in the non-habitual consumers following caffeine [t(66)=4.10, p=<0.001, d=0.97] 
and combination treatments [t(66)=2.30, p<0.05, d=0.62] as compared to placebo, see fig 
4.6b.   
4.3.3.3 Stroop 
There was a significant main effect of treatment on Stroop % accuracy [F(3, 
66)=5.52, p<0.005].  Planned comparisons revealed that participants were significantly 
more accurate following L-theanine [t(66)=2.67, p<0.01, d=-0.57] and caffeine [t(66)=3.34, 
p<0.005, d=-0.75] as compared to placebo, see fig 4.6c. 
 
Fig. 4.6.  Mean (and SEM) change from baseline scores on cognitive performance 
following placebo, 50 mg L-theanine (L-thea), 75 mg caffeine (Caff) and a combination of 
50 mg L-theanine and 75 mg caffeine (Combi).  Main effects of treatment are shown for (a) 
choice reaction time; interaction effects of treatment x consumer status are shown for (b) 
choice reaction time; main effects of treatment are shown for (c) Stroop % accuracy (* 
p<0.05, ** p<0.01, *** p<0.005, **** p<0.001). 
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4.3.3.4 ‘Overall mood’ 
There was a significant main effect of treatment on ratings of mood [F(3, 66)=3.00, 
p<0.05].  Planned comparisons revealed that participants’ overall mood was significantly 
improved following caffeine in isolation as compared to placebo [t(66)=3.00, p<0.005, d=-
0.69], see fig. 4.7a. 
4.3.3.5 ‘Alertness’ factor 
There was a significant main effect of treatment on the alertness factor [F(3, 
66)=3.16, p<0.05].  Planned comparisons revealed alertness was significantly increased 
following caffeine in isolation as compared to placebo [t(66)=2.48, p<0.05, d=-0.47], see 
fig. 4.7b. 
4.3.3.6 ‘Tired’ 
The effect on alertness was largely as a result of a significant main effect of 
treatment on ratings of tiredness [F(3, 66)=3.03, p<0.05].  Planned comparisons revealed 
that participants were significantly less tired following caffeine in isolation as compared to 
placebo [t(66)=2.46, p<0.05, d=0.52], see fig. 4.7c. 
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 Fig. 4.7.  Mean (and SEM) change from baseline scores for mood following placebo, 50 
mg L-theanine (L-thea), 75 mg caffeine (Caff) and a combination of 50 mg L-theanine and 
75 mg caffeine (Combi).  Higher values represent more of each mood state, in the case of 
(a) this reflects better overall mood.  Main effects of treatment are shown for (a) overall 
mood, (b) an alertness factor and (c) tiredness ratings (* p<0.05, ***p<0.005). 
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Table 4.1.  Baseline and change from baseline scores for serial subtractions, SRT, RVIP 
and CRT tasks for each treatment.  Means ± SEM values are presented with F and p 
values from the primary ANOVA of treatment effects and treatment x consumer 
interactions.  Significant measures are shown in bold.  
 
Measure 
 
Treatm
ent 
 
n 
Pre-dose baseline score Post-dose change from 
baseline score 
Treat 
effect 
Treat x 
cons 
interact Consumers Non-
consumers 
Consumers Non-
consumers 
Serial 3s 
subs 
correct 
(%) 
Pla  
12 
 
95.41±1.54 97.07±1.26 -1.50±1.11 -1.98±2.21 F=2.24                     
p>0.05 
F<1
L-thea 95.43±1.61 95.71±1.76 0.65±0.94 -1.97±1.68 
Caff 93.94±1.47 95.92±1.11 1.55±1.69 -0.27±1.52 
Combi 92.36±2.09 96.30±1.10 4.15±1.67 0.50±1.40 
Serial 3s 
subs 
errors 
(%) 
Pla  
12 
4.59±1.54 2.93±1.26 1.50±1.11 1.38±1.93 F<1 F<1 
L-thea 4.42±1.58 4.29±1.76 -0.50±0.85 1.74±1.82 
Caff 6.06±1.47 4.09±1.11 -1.55±1.69 0.27±1.52 
Combi 7.40±2.06 3.34±0.85 -3.91±1.68 -0.14±1.13 
Serial 7s 
subs 
correct 
(%) 
Pla  
12 
93.30±1.48 92.18±3.55 -0.81±2.26 -0.54±4.59 F<1 F<1 
L-thea 94.31±1.79 85.54±5.82 0.45±1.83 5.31±4.14 
Caff 92.75±3.19 90.26±3.24 1.41±3.38 -0.91±2.21 
Combi 92.57±2.41 89.60±3.42 1.05±1.89 2.87±3.56 
Serial 7s 
subs 
errors 
(%) 
Pla  
12 
6.70±1.48 7.22±3.39 0.81±2.26 1.14±4.36 F<1 F<1 
L-thea 5.69±1.79 14.46±5.82 -0.45±1.83 -5.31±4.14 
Caff 7.25±3.19 9.19±3.18 -1.74±3.36 0.92±1.99 
Combi 7.43±2.41 9.94±3.45 -1.05±1.89 -2.55±3.61 
SRT 
(RT) 
Pla  
12 
294.00±11.19 326.54±16.59 14.39±5.59 17.55±7.89 F=1.68 
p>0.1 
F<1 
 L-thea 288.71±11.38 329.85±19.73 19.65±8.24 35.46±7.47 
Caff 304.90±9.96 308.08±9.96 7.31±7.40 12.12±11.00 
Combi 290.87±9.64 322.86±24.60 13.73±6.63 17.87±11.00 
RVIP 
Acc 
(%) 
Pla  
12/11 
70.83±6.17 62.50±4.30 -11.33±3.24 -9.80±3.90 F<1 
 
F=1.67 
p>0.1 
 
 
L-thea 68.23±5.63 67.05±4.85 -9.90±3.34 -10.37±3.20 
Caff 75.52±7.20 62.50±6.31 -13.28±2.90 -1.56±3.67 
Combi 68.75±8.43 67.05±5.34 -4.56±3.79 -6.82±3.58 
RVIP 
false 
alarms 
(%) 
Pla  
12/11 
0.79±0.25 1.09±0.26 -0.24±0.28 -0.41±0.19 F<1 F<1 
L-thea 0.58±0.15 0.86±0.24 -0.09±0.19 0.02±0.30 
Caff 0.42±0.12 0.96±0.25 0.01±0.12 -0.28±0.21 
Combi 0.42±0.15 0.64±0.19 0.06±0.17 0.17±0.22 
RVIP 
(RT) 
Pla  
12/11 
502.55±18.02 481.36±15.76 10.82±8.55 1.18±19.36 F<1 F<1 
L-thea 501.75±18.82 480.71±13.99 9.30±9.01 -8.83±10.44 
Caff 510.43±18.23 487.52±12.52 2.32±7.29 -13.33±9.41 
Combi 499.29±27.41 471.37±14.31 -0.46±13.98 -6.22±12.38 
CRT 
Acc 
(%) 
Pla  
12 
96.17±0.87 96.67±0.79 -0.13±1.09 -0.59±0.68 F<1 F<1 
L-thea 96.33±0.69 95.33±1.68 -0.03±0.38 0.88±1.30 
Caff 96.83±0.72 94.50±0.82 -0.44±0.64 1.76±0.49 
Combi 96.50±0.96 95.17±1.19 0.21±0.71 1.23±0.74 
CRT 
(RT) 
Pla  
12 
425.90±15.09 437.36±18.00 -2.80±9.34 59.50±22.27 F=2.99 
p=0.037 
F=2.82 
p=0.046 L-thea 420.64±10.14 448.00±24.75 -0.20±7.11 32.83±11.25 
Caff 410.14±10.90 453.22±27.21 -3.30±8.44 -10.63±19.28 
Combi 409.81±10.06 428.49±25.41 -3.10±3.84 20.06±13.08 
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Table 4.2.  Baseline and change from baseline scores for the Stroop task and measures 
derived from the caffeine research visual analogue scales for each treatment.  Means ± 
SEM values are presented with F and p values from the primary ANOVA of treatment 
effects and treatment x consumer interactions.  Significant measures are shown in bold.  
 
Measure 
 
Treatm
ent 
 
n 
Pre-dose baseline score Post-dose change from 
baseline score 
Treat 
effect 
Treat x 
cons 
interact Consumers Non-consumers Consumers Non-
consumers 
Stroop 
Acc 
(%) 
Pla 12 98.22±0.47 97.38±0.655 -1.44±0.84 -1.12±0.71 F=5.52 
p=.002 
F<1 
L-thea 12 97.26±0.71 96.86±0.574 -0.23±0.58 0.35±0.63  
Caff 12 96.70±1.05 95.88±1.048 0.29±0.23 0.52±0.72  
Combi 12 97.36±1.06 97.44±0.823 -1.28±0.52 -0.93±0.57  
Stroop 
(RT) 
Pla 12 651.67±26.36 628.92±26.501 -10.42±19.32 31.42±17.75 F=1.35 
p>0.1 
F<1 
L-thea 12 659.50±49.91 692.92±57.087 -22.42±33.08 -20.75±24.57  
Caff 12 633.67±23.40 643.17±40.669 -25.83±12.89 -30.08±28.23  
Combi 12 615.67±22.50 651.33±31.572 -10.00±15.68 -29.25±30.65  
Relaxed Pla 12 64.75±2.73 63.83±3.643 -12.92±5.41 -8.50±4.84 F=1.49 
p>0.1 
F<1 
L-thea 12 55.83±5.76 63.50±4.762 0.17±5.81 -0.92±5.68  
Caff 12 58.83±6.63 62.25±6.095 -7.33±4.38 -7.83±5.49  
Combi 12 61.17±4.24 67.92±4.642 -6.42±8.31 -3.50±5.38  
Alert Pla 12 57.17±5.63 50.17±6.068 -5.33±7.08 1.33±6.38 F=1.49 
p>0.1 
F<1 
L-thea 12 51.50±4.10 58.42±6.344 -3.58±5.35 -3.67±7.58  
Caff 12 55.83±4.65 49.17±6.977 2.58±6.51 8.75±5.74  
Combi 12 59.25±3.12 54.75±6.301 -2.33±4.99 3.00±7.18  
Jittery Pla 12 28.92±5.51 17.75±3.856 8.83±6.55 5.25±5.24 F=3.03 
p=0.035 
F<1 
L-thea 12 26.92±3.59 24.25±6.273 9.17±6.65 1.67±4.77  
Caff 12 33.33±4.32 27.17±5.328 2.92±6.18 3.75±5.78  
Combi 12 26.50±5.26 26.58±6.405 9.17±6.82 -1.50±6.21  
Tired Pla 12 46.25±7.87 54.25±6.703 5.42±7.06 -0.92±5.99 F<1 F=1.58 
p>0.1 L-thea 12 45.75±6.44 42.83±4.355 -0.08±6.79 6.42±6.47 
Caff 12 50.92±5.83 53.92±6.407 -10.67±7.76 -9.25±6.46 
Combi 12 39.08±6.37 49.67±5.875 7.75±7.23 -5.83±5.23 
Tense Pla 12 28.50±4.27 24.42±4.892 7.67±3.51 -1.00±6.56 F<1 F=1.29 
p>0.1 L-thea 12 34.00±5.56 25.83±5.348 4.83±5.73 -2.92±5.67  
Caff 12 32.17±4.50 26.08±6.011 2.92±5.82 3.50±7.00  
Combi 12 31.75±6.20 18.67±3.281 1.17±3.69 6.92±4.24  
Headach
e 
Pla 12 16.50±6.34 18.00±5.392 12.08±4.04 18.83±8.44 F<1 F=1.14 
p>0.1 L-thea 12 16.00±4.57 20.50±5.927 12.42±4.34 10.33±5.83  
Caff 12 19.83±6.58 14.83±3.790 11.42±5.73 13.08±6.93  
Combi 12 12.75±3.59 17.92±4.803 13.50±3.79 3.08±3.64  
Overall 
Mood 
Pla 12 67.33±4.43 59.83±4.026 -8.00±3.23 -3.92±4.94 F=3.00 
p=0.037 
F<1 
L-thea 12 58.50±4.04 66.08±4.081 -0.17±2.66 -2.42±4.51  
Caff 12 61.50±3.98 59.25±4.340 0.50±3.00 5.58±3.67  
Combi 12 66.33±4.02 66.50±3.967 -5.17±2.15 1.92±3.98  
Mental 
Fatigue 
Pla 12 35.83±7.27 30.50±5.590 16.92±7.80 17.75±7.19 F<1 F<1 
L-thea 12 39.25±5.38 35.00±5.003 14.75±6.88 11.17±6.77  
Caff 12 29.25±5.20 33.83±6.338 15.17±7.03 11.33±8.68  
Combi 12 30.58±6.34 31.67±6.132 14.58±5.92 5.67±5.81  
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4.3.3.7 Consumer related effects 
Those outcomes that demonstrated a significant between subjects effect of 
consumer status are reported below. 
4.3.3.7.1 Serial 3s 
There was a significant effect of consumer status on accuracy of serial 3s 
subtractions, which demonstrated that overall and irrespective of treatment, habitual 
consumers were significantly more accurate than non-habitual consumers [F(1, 22)=5.45, 
p<0.05], see fig. 4.8a. 
4.3.3.7.2 Choice reaction time 
There was a significant effect of consumer status on choice reaction time, which 
demonstrated that irrespective of treatment, habitual consumers were significantly faster 
than non-habitual consumers [F(1, 22)=6.06, p=0.05], see fig. 4.8b. 
 
 
Fig. 4.8.  Mean (and SEM) change from baseline scores for cognitive performance.  Main 
effects of consumer status are shown for (a) serial 3’s accuracy, (b) choice reaction time 
(* p<0.05). 
 
4.3.4 Blood pressure and heart rate 
4.3.4.1 Systolic blood pressure 
Analysis of blood pressure levels revealed a significant main effect of treatment for 
systolic [F(3, 66)=4.41, p<0.01].  Planned comparisons demonstrated that following the 
combination treatment systolic blood pressure was significantly elevated [t(66)=2.03, 
p<0.05, d=-0.57] as compared to placebo, see fig. 4.9a. 
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4.3.4.2 Diastolic blood pressure 
A significant main effect of treatment was observed for diastolic blood pressure 
[F(3, 66)=3.87, p<0.05].  Planned comparisons revealed that diastolic blood pressure was 
significantly elevated in comparison to placebo following the combination [t(66)=2.75, 
p<0.01, d=-0.76], caffeine in isolation [t(66)=3.10, p<0.005, d=-0.72] and L-theanine in 
isolation [t(66)=2.19, p<0.05, d=-0.60], see fig. 4.9b. 
4.3.4.3 Heart rate 
There were no significant effects of treatment on heart rate. 
 
 
Fig. 4.9.  Mean (and SEM) change from baseline blood pressure readings following 
placebo, 50 mg L-theanine (L-thea), 75 mg caffeine (Caff) and a combination of 50 mg L-
theanine and 75 mg caffeine (Combi).  Main effects of treatment are shown for (a) systolic 
and (b) diastolic   (* p<0.05, ** p<0.01, *** p<0.005). 
 
 
4.4 Discussion 
The results here demonstrate that, compared to placebo, caffeine administered 
alone leads to a significant reduction in oxygenated haemoglobin in the pre-frontal cortex 
during minutes 3-6 and 11-18 of the absorption period and during task performance 
commencing at 39 minutes post-dose until the end of testing.  This effect of caffeine was 
abolished by combining it with L-theanine, despite no effects of L-theanine in isolation on 
this measure.  Conversely, the expected reduction in deoxygenated haemoglobin during 
the task period was attenuated following both of the treatments that contained caffeine, as 
compared to placebo.  Following caffeine alone this effect reached significance during 
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serial subtractions, SRT, RVIP, Stroop and the rest period; following the combination this 
effect reached significance during serial subtractions, CRT and Stroop.  In addition, there 
was a significant treatment x consumer interaction, whereby the effects on deoxygenated 
haemoglobin following caffeine alone were predicated on an exaggerated increase in non-
habitual consumers throughout the entire testing session. 
In relation to the behavioural effects, caffeine significantly reduced reaction time on 
the CRT task (predominantly in non-habitual consumers) and improved performance 
accuracy on the Stroop task.  It also led to improved subjective ratings of overall mood 
and alertness (largely due to a reduction in tiredness).  The combination treatment was 
found only to significantly reduce CRT in non-habitual consumers. L-theanine 
administration also only led to a single effect, manifest as an increase in accuracy of 
Stroop responses, irrespective of consumer status.  Overall and irrespective of treatment 
habitual consumers were found to be significantly more accurate on the serial threes 
subtraction task and significantly faster on the CRT task as compared to non-habitual 
consumers.   
In terms of peripheral effects, diastolic blood pressure was significantly elevated 
following all three active treatments, whereas systolic blood pressure was significantly 
elevated following the combination treatment only.   
In terms of the effects on CBF, in the present study, the expected task-related 
increase in oxy-Hb was observed following all treatments, for the majority of tasks.  
However, there was a significant attenuation of this effect following caffeine.  Caffeine is a 
known vasoconstrictor and its effects on cerebral blood flow have been documented 
previously in imaging studies using higher doses (Chen & Parrish, 2009b; Rack-Gomer et 
al., 2009) and more recently in a study utilising NIRS that administered the same, 
comparatively low dose of caffeine as here (Kennedy & Haskell, 2011).  However, despite 
a similar pattern of effects, the previously observed reduction in total levels of 
haemoglobin following caffeine (Kennedy & Haskell, 2011) failed to reach significance in 
the current study.  Since the total level of haemoglobin is the sum of oxy-Hb and deoxy-
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Hb, this is most likely due to a pattern of higher deoxy-Hb and possibly relates to small 
differences in the levels of caffeine consumed by the non-habitual consumers across the 
two studies.  Of particular interest, the effects of caffeine on oxy-Hb, but not deoxy-Hb 
were abolished by co-administration with L-theanine.  This pattern of effects is consistent 
with those previously observed on blood pressure by Rogers et al. (2008), showing 
attenuation of the rise in blood pressure following caffeine in isolation when it was 
combined with L-theanine.  Although higher doses of caffeine and L-theanine were used 
in that study (250 mg and 200 mg respectively), the ratio of compounds was more 
comparable to those used here than other studies in this area and the post-treatment 
assessment took place within a similar time frame (45 minutes post-dose). 
The significant increase in deoxy-Hb observed during the task period following 
caffeine relative to placebo is contrary to the expected increase in oxy-Hb and, or, 
corresponding decrease in deoxy-Hb generally observed in NIRS assessments during 
cognitively demanding tasks (Fallgatter & Strik, 1998; Izzetoglu et al., 2004; Izzetoglu et 
al., 2003; Kennedy, Wightman, et al., 2010; Shibuya-Tayoshi et al., 2007) taken to be 
indicative of neuronal activation.  It is, however not unexpected given the previously 
observed neurovascular uncoupling following caffeine (Laurienti et al., 2003; Mulderink et 
al., 2002; Perthen et al., 2008).  Previous calibrated (to hypercapnia) BOLD fMRI studies 
have shown that a high single dose of caffeine (~200 mg+), administered to habitual 
consumers uncouples the relationship between CBF and local oxygen consumption by 
reducing blood flow, but increasing oxygen consumption in response to task/stimulation 
(Chen & Parrish, 2009a; Perthen et al., 2008).  This suggests that the increase in deoxy-
Hb may be indicative of neural activation.  Laurienti et al. (2002) also showed that the 
effects of 250 mg caffeine administration on fMRI BOLD were correlated to dietary 
caffeine use with high consumers (mean 648 mg/day), tending to show increased 
activation and lower consumers (mean 41 mg/day) showing decreased activation.   The 
differential effect of consumer status on deoxy-Hb in the current study reflecting a 
significant increase in deoxy-Hb across tasks following caffeine in non-habitual consumers 
only, suggests that the disparity of effects of caffeine on BOLD activation are the result of 
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varying deoxy-Hb rather than oxy-Hb response.  Given the lack of interaction effect on 
oxy-Hb in the current study, this may point to a specific tolerance to the effects on deoxy-
Hb in habitual caffeine consumers.  As the effects on deoxy-Hb suggest increased neural 
activation in non-consumers, this would indicate an upregulation of A1 receptors (Laurienti 
et al., 2003), as has previously been demonstrated (Johansson et al., 1993).  Interestingly 
no differential effects on deoxy-Hb as a function of consumer status were observed 
following the combination of caffeine and L-theanine, with both groups showing an 
increase.   
Turning to the behavioural findings, the relative lack of effects following the 
combination of caffeine and L-theanine in the current study is contrary to previous findings.  
Combinations of caffeine and L-theanine have previously been shown to improve 
performance on SRT and RVIP tasks and improve subjective alertness, tiredness, mental 
fatigue and headache ratings (Einother et al., 2010; Haskell et al., 2008b; Kelly et al., 
2008; Owen et al., 2008); however, in the present study no such improvements were 
observed.  It is somewhat surprising given that the combination showed a similar but 
lesser modulation of deoxy-Hb to caffeine, but did not decrease oxy-Hb (in fact this was 
increased during the final two epochs of the absorption period).  The lack of behavioural 
effects may be due to the lower doses used here in addition to the ratios of caffeine and L-
theanine administered (in the aforementioned studies the combinations comprised ratios 
of caffeine and L-theanine, that were more in favour of L-theanine).  However, despite the 
different ratios and lower doses used in the current study, the improvements seen as a 
result of the combination treatment on choice reaction time are consistent with those 
observed previously (Haskell et al., 2008b; Owen et al., 2008).  These effects were, 
however, dependent upon a participant’s level of caffeine consumption, as reaction time 
was only improved in non-habitual consumers.  An effect of consumer status was also 
observed following the caffeine-in-isolation treatment, as an improvement in choice 
reaction time was similarly, only observed in non-consumers.  These effects of consumer 
status were largely due to there being very little difference in reaction times across 
treatments for the habitual consumer group, with one explanation being that the doses 
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used in the present study were too low to elicit an effect in habitual consumers.  However, 
this justification seems unlikely, as previous studies have demonstrated significant 
improvements in reaction time of this and lower doses in both habitual consumers and 
habitual non-consumers (Haskell et al., 2005; Richardson, Rogers, Elliman, & Odell, 1995; 
Smit & Rogers, 2000).  An alternative explanation is that habitual consumers were the 
subject of ceiling effects, indicated by an almost identical level of performance on this task 
following all treatments.  This is supported by an overall consumer status effect showing 
habitual consumers to be significantly faster on the CRT task as compared to non-habitual 
consumers, irrespective of treatment; as well as being more accurate on the serial 3s 
subtraction task.  The demonstration of an improvement in CRT in non-habitual 
consumers (in the absence of significant differences between consumer groups at 
baseline), in addition to significant differences in favour of habitual consumers, would 
seem to indicate that these were net effects of treatment (Haskell et al., 2005; Hewlett & 
Smith, 2006; Smith, Christopher, & Sutherland, 2013) and not those of a reversal of 
withdrawal (Rogers et al., 2003).  Indeed, better performance on the serial 3s subtraction 
task for habitual consumers has previously been demonstrated (Haskell et al., 2005).  
However, it is not clear whether differing responses of habitual and non-habitual 
consumers of caffeine are the consequence of chronic caffeine consumption or are 
related to underlying differences.  Caffeine in isolation also improved alertness and overall 
mood, both of which have been previously reported (Childs & de Wit, 2006; Haskell et al., 
2005; Rogers et al., 2008) and improved accuracy on the Stroop task, a finding not 
unexpected considering caffeine’s known, positive effects on attention (Haskell et al., 
2005).  L-theanine in isolation was also found to improve accuracy on the Stroop task.  In 
contrast to those following caffeine, this finding could be described as unexpected, as 
although no other studies to date have assessed the effects of L-theanine alone on the 
performance of this task, previous research has only reported decrements or no effects on 
performance when L-theanine is administered in isolation (Gomez-Ramirez et al., 2007; 
Gomez-Ramirez et al., 2009; Haskell et al., 2008b; Kelly et al., 2008; Owen et al., 2008).  
Once again, the dose used here may provide an explanation for this, as the majority of 
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studies to date have administered doses of L-theanine much higher than used in the 
current study. 
In terms of the peripheral effects, the combination treatment was found to increase 
systolic blood pressure and all three active treatments increased diastolic blood pressure.  
The ability of caffeine to raise blood pressure has been documented previously (James, 
2004; Rogers et al., 2008; Umemura et al., 2006) and the rise seen in the present study is 
as expected.  In contrast, the increase seen following L-theanine is perhaps counter-
intuitive based on L-theanine’s purported historic use as a relaxing agent (Heese et al., 
2009) its ability to reduce induced stress responses (Kimura et al., 2007) and evidence 
that it is capable of reducing blood pressure in rats (Yokogoshi et al., 1995).  It should be 
noted that this effect in rats was only observed following very high doses (1500 and 
2000mg/kg), in spontaneously hypertensive rats, not normotensive Wistar Kyoto rats.  An 
effect of L-theanine in isolation on blood pressure in humans has only been demonstrated 
in ‘high-responders’ as determined by placebo blood pressure response to a mental task 
(Yoto, Motoki, Murao, & Yokogoshi, 2012).  In terms of the combination, this treatment 
was found to significantly increase both systolic and diastolic blood pressure.  This is in 
contrast to the findings of Rogers et al., (2008), who found that when caffeine was 
combined with L-theanine it was able to attenuate the rise in blood pressure seen 
following caffeine in isolation.  However, Geisbrecht et al. (2010) found that 40 mg 
caffeine combined with 97 mg L-theanine led to significant increases in systolic blood 
pressure with a trend towards the same for diastolic.  These contrasting effects of 
caffeine/L-theanine combinations on blood pressure may be indicative of differential 
effects of different doses on this parameter.  Other methodological differences should also 
be noted; Rogers et al. (2008) did not restrict intake of caffeine/L-theanine whereas in the 
current study and that of Geisbrecht et al. (2010) caffeine and theanine intake was 
prohibited for 12 hours prior to study visits.  The tasks employed by Rogers et al. (2008) 
could also be said to be of a lower complexity than those administered in the latter studies 
prior to blood pressure recording.   
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The present study has demonstrated that caffeine and L-theanine at doses 
equivalent to 1 to 2 cups of tea are capable of modulating cerebral haemodynamics, 
cognitive performance, mood and autonomic measures.  When combined with 75 mg 
caffeine, 50 mg L-theanine antagonised the effects on oxy-Hb observed during cognitive 
tasks following 75 mg caffeine in isolation.  As the attenuation of the reduction in oxy-Hb 
continued until the end of testing, future studies should aim to determine the duration of 
these effects on caffeine by L-theanine by extending the post dose testing period.  This 
study also provides partial replication of a previous study showing modulation of the CBF 
effects of 75mg caffeine as a function of habitual caffeine consumption (Kennedy & 
Haskell, 2011).  In the current study, the combination of caffeine and L-theanine also 
resulted in a reduction in the effectiveness of caffeine to modulate behaviour, but it should 
be noted that when consumed in the form of tea there are many other compounds present 
with the potential to interact with the two compounds explored here.  Once again the 
technique of NIRS has demonstrated its ability to identify cerebral oxygenation changes 
following administration of a nutritional intervention, this time one known for its ability to 
reduce cerebral blood flow.  However, it has also demonstrated this it is sensitive enough 
to detect an attenuation of these parameters when a second intervention is introduced. 
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Chapter 5: An assessment of energy expenditure and cerebral 
haemodynamics during cognitive performance, following two doses of 
caffeine. 
 
5.1 Introduction 
 Caffeine’s impact on metabolism is an area that has received attention in the 
literature in both healthy and obese populations due to its thermogenic effects.   Acheson 
et al. (1980) observed that caffeine (in the form of caffeinated coffee) significantly 
increased metabolic rate in both normal weight (8 mg/kg administered) and obese 
participants (4 mg/kg administered).  Similarly, Dulloo et al. (1989) demonstrated an 
increase in resting metabolic rate in both lean participants and those who were 
categorised as being pre-disposed to obesity and were previously overweight, following a 
100 mg dose of caffeine.  In further studies of normal weight participants, an increase in 
energy expenditure has been demonstrated at rest following 100 mg caffeine (Astrup et al., 
1990; Hollands et al., 1981), 400 mg caffeine (Astrup et al., 1990) and a larger dose of 10 
mg/kg caffeine (Acheson et al., 2004), with increased fat oxidation demonstrated following 
8 mg/kg (Acheson et al., 1980) and 10 mg/kg (Acheson et al., 2004).  Research has also 
extended to exercise models due to caffeine’s purported ergogenic effects and the 
potential for caffeine to enhance exercise performance.  One of the first studies to 
demonstrate the beneficial effects of caffeine during exercise was research conducted by 
Costill et al. (1978).  They observed that coffee containing 330 mg caffeine (as compared 
to decaffeinated coffee), when administered 60 minutes prior to exercise (bicycle 
ergometer at 80 % of Vo2 max), not only increased the rate of lipid metabolism and 
significantly increased fat oxidation, but also significantly increased time to exhaustion.  
Although the findings in terms of increased time to exhaustion have been demonstrated 
since (Greer, Friars, & Graham, 2000; Pasman, Vanbaak, Jeukendrup, & Dehaan, 1995; 
Simmonds, Minahan, & Sabapathy, 2010; Spriet et al., 1992), the findings in relation to 
substrate metabolism have been equivocal (Graham, Battram, Dela, El-Sohemy, & Thong, 
2008).  Animal research has shown that the means by which caffeine is thought to 
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increase time to fatigue is, similar to caffeine’s cognitive and haemodynamic effects,  via 
antagonism of adenosine receptors (Davis et al., 2003).   
Indirect calorimetry is a method of determining energy expenditure, and 
carbohydrate and fat oxidation through the measurement of inhaled and exhaled gas.  
The majority of research that has used ICa to assess the impact of nutritional 
interventions on metabolism has been conducted using resting or exercise protocols.  To 
date there have been three studies that have used ICa to determine the metabolic impact 
of cognitive task performance (Kennedy et al., 2016; Seematter et al., 2000; Troubat, 
Fargeas-Gluck, Tulppo, & Dugue, 2009), only one of which has been in the presence of a 
nutritional intervention (Kennedy et al., 2016).  Seematter et al. (2000) demonstrated that 
performance of cognitive tasks (arithmetic tasks and Stroop) led to an increase in overall 
energy expenditure in both lean and obese women.  During performance of an hour long 
game of chess, Troubat et al. (2009) did not observe an effect on energy expenditure; 
however, there were changes in substrate metabolism.  An initial increase in carbohydrate 
oxidation (with a corresponding reduction in fat oxidation, which failed to reach 
significance), followed by a significant increase in fat oxidation, with a significant decrease 
in carbohydrate oxidation during the middle and end of the task was observed.  This was 
taken as an indication of switching substrate oxidation as a function of the demands of the 
task over time.  A study by Kennedy et al. (2016) that looked at the CBF (using NIRS) and 
metabolic effects of performing cognitive tasks of differing difficulty following the 
administration of multivitamins and minerals, found that fat oxidation and energy 
expenditure were significantly increased during cognitive task performance.  This effect 
was observed following acute and (in the case of energy expenditure only) chronic (56 
days) supplementation with micronutrients.  Cerebral blood flow was also increased 
during task performance following acute supplementation. 
As discussed in chapter 4, the behavioural effects of caffeine have been well 
documented, with the most consistent effects being increased ratings of alertness as well 
as improvements in measures of reaction time and vigilance (Haskell et al., 2008b; 
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Haskell et al., 2005; Quinlan et al., 2000; Rogers et al., 2008).  Caffeine’s ability to restrict 
cerebral blood flow is also well established and has been demonstrated via neuroimaging 
methodologies (Chen & Parrish, 2009a; Laurienti et al., 2003; Mathew & Wilson, 1991; 
Rack-Gomer et al., 2009) including NIRS (Kennedy & Haskell, 2011).  The findings of 
chapter 4 contributed to this area through the demonstration that NIRS is sensitive 
enough to detect changes in blood oxygenation during cognitive tasks following the 
administration of 75 mg caffeine.  The evidence from ICa studies suggests that cognitive 
task performance leads to increases in energy expenditure and may also modulate fat and 
(to some extent) carbohydrate oxidation during certain tasks.  In light of caffeine’s 
influence on metabolism and taking into consideration its cerebro-vascular and cognitive 
effects, it would be interesting to conduct parallel assessments of both metabolic rate 
(measured via ICa), and the delivery of metabolic substrates/oxygen extraction (as 
measured by NIRS).   
The present study therefore intended to build on the findings of chapter 4 in 
relation to cerebral oxygenation by introducing a measure of metabolism during task 
performance in the presence of caffeine.  The completion of cognitive tasks of varying 
difficulty was intended to delineate any changes in metabolic demand and oxygen 
delivery/utilisation.  It was anticipated that an increase in task demand would be reflected 
by an increase in energy expenditure and a concomitant increase in blood flow and 
oxygen extraction, with caffeine potentially interacting with both measures as a result.  
This double-blind, placebo-controlled, balanced, crossover study aimed to assess the 
impact of two doses of caffeine on cerebral haemodynamics and whole-body metabolism 
whilst simultaneously performing of a range of cognitive tasks that differed in their level of 
demand.  The second aim of the study was to explore the impact of tasks of different 
levels of subjective difficulty on physiological measures (CBF and metabolism), 
irrespective of the treatment administered.  
 
137 
 
5.2 Method 
5.2.1 Participants 
Twenty-four healthy young participants (13 males, 11 females) between the ages 
of 18 and 35 (mean age 23.5, SD 3.8; BMI 23.0, SD 2.6) were recruited.  The study was 
approved by Northumbria University’s School of Psychology and Sport Sciences’ ethics 
committee and conducted in accordance with the Declaration of Helsinki.  Prior to 
participation, volunteers were required to sign an informed consent form and complete a 
self-report caffeine consumption questionnaire (appendix C) that assessed their daily level 
of caffeine intake.  Volunteers were recruited to take part in the study if they were ‘habitual 
consumers’ (those who drank tea and/or coffee and consumed more than 150 mg caffeine, 
but no more than 600 mg per day).  The decision to only recruit habitual consumers was 
taken to remove any impact of consumption status, as identified in chapter 4.  From the 
self-report caffeine consumption questionnaire, participants reported drinking between 
156 mg to 555 mg caffeine per day (mean 327.0, SD 90.2).  A general health screen 
(appendix B) informed volunteers that they would not be eligible to take part if they had a 
history of neurological, vascular or psychiatric illness or a history or current diagnosis of 
drug or alcohol abuse.  They would also not be eligible if they had a current diagnosis of 
depression or anxiety, anaemia, high blood pressure, a heart or respiratory disorder, type 
1 diabetes, phenylketonuria, a history of head trauma, migraines, learning difficulties, 
dyslexia or ADHD.  All participants reported that they were in good health, had normal or 
corrected-to-normal vision and had no known allergies to the treatment ingredients.  
Additionally, they were not currently taking any dietary supplements or medication 
(including the contraceptive pill), were not colour-blind, did not smoke and in the case of 
female volunteers, were not pregnant or seeking to become pregnant.   
5.2.2 Design and treatment 
A randomised, double-blind, counter-balanced, within subjects, placebo-controlled 
design was utilised.  Participants attended 3 study visits and at each received 1 of the 
following treatments: 75 mg caffeine (pharmaceutical grade caffeine powder, Blackburn 
Distributions Ltd); 150 mg caffeine or placebo.  Each treatment was administered in the 
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form of a capsule in order to mask any taste differences and ensure participants remained 
blind to the treatment they had received.  The order in which participants received each 
treatment was determined by Latin square and random allocation to treatment order. 
 
5.2.3 Salivary caffeine levels 
Saliva samples were obtained using salivettes (Sarstedt Ltd).  One sample was 
taken upon arrival and one immediately following the post-dose assessment.  This was to 
ensure overnight caffeine abstinence and to confirm caffeine absorption following 
treatment.  Once taken, samples were frozen at -80 ºC.  The samples were then thawed 
and the caffeine levels in the saliva samples were measured using an Emit® Caffeine 
Assay (Dade Behring Ltd). 
 
5.2.4 Physiological, cognitive and mood measure 
5.2.4.1 Near infrared spectroscopy measurements 
Please see chapter 2 for a full description of the NIRS method used, which is 
identical to that used in the present chapter. 
5.2.4.2 Cognitive and mood measures 
Please see chapters 2 and 3 for a description of COMPASS and an explanation of 
tasks and mood assessments listed here but not described in full below.  The tasks were 
chosen based on their ability to activate the pre-frontal cortex (Cohen et al., 1997; 
Drummond et al., 1999; Lawrence et al., 2002) or their known sensitivity to caffeine 
(Haskell et al., 2008b; Kennedy & Haskell, 2011).  In an attempt to avoid any effects of 
task order in relation to metabolic parameters, the order in which the tasks were 
completed at baseline and post-dose were determined by a counterbalancing Latin square 
and randomly allocated for each participant.  This order was consistent at each study visit 
and for baseline and post-dose sessions.  All baseline tasks were 2 minutes and all post-
dose tasks were 5 minutes in duration, with a 2-minute rest period observed after each 
post-dose task in order to limit any overlapping metabolic effects of the previous task.   
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5.2.4.2.1 Serial 3s: 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage accuracy and percentage errors. 
5.2.4.2.2 Serial 7s: 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage accuracy and percentage errors. 
5.2.4.2.3 Serial 17s: 
Please see chapter 3 for a description of this task.  This task was scored for 
percentage accuracy and percentage errors. 
5.2.4.2.4 RVIP: 
 Please see chapter 2 for a description of this task.  This task was scored for 
percentage of target strings correctly detected, average reaction time for correct 
detections, and number of false alarms. 
5.2.4.2.5 3-back: 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage of correct responses and reaction time. 
5.2.4.2.6 Key tapping control: 
This task was included as a control to account for physical activity required during 
task performance in relation to metabolism and CBF.  It was therefore somatically 
matched to the task that required the most physical movement (in this instance, serial 3s). 
It also provided a comparator for the tasks in terms of subjective difficulty.  To the sound 
of a metronome (set at 84 beats per minute; derived from the average frequency of key 
strokes during the serial 3s task) participants are instructed to alternately press the ‘C’ key 
and the ‘N’ key on the keyboard using their left and right forefingers respectively.  This 
task is not scored. 
5.2.4.2.7 Subjective mental fatigue visual analogue scale: 
 Following completion of each task at post-dose, participants rated their level of 
mental fatigue.  Please see chapter 2 for a description of this task. 
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5.2.4.2.8 Subjective difficulty visual analogue scale: 
Following completion of each task at post-dose, participants rated the difficulty of 
each task by placing an ‘x’ on a 100 mm line with the end points labelled ‘not at all’ (left 
hand end) and ‘extremely’ (right hand end).   
5.2.4.2.9 Caffeine research visual analogue scales: 
 Following completion of all tasks at the baseline and post-dose sessions, 
participants completed these scales.  Please see Chapter 4 for a description of this task. 
5.2.4.2.10 Subjective energy measures: 
Following completion of all tasks at the baseline and post dose sessions, scales 
which assessed the participants’ self-ratings of ‘concentration’, ‘mental stamina’ and 
‘physical stamina’ were completed.  Participants were asked to rate how much they 
matched their current state by placing an ‘x’ on a 100 mm line, with ‘very low’ labelled at 
the left-hand end and ‘very high’ labelled at the right-hand end.  Participants’ self-rated 
levels of being ‘mentally tired’ and ‘physically tired’ were then completed in the same way, 
with the scales labelled ‘not at all’ and ‘extremely’. 
 
5.2.4.3 Indirect calorimetry 
During completion of cognitive tasks, pulmonary (minute) ventilation (VE), oxygen 
uptake (VO2), carbon dioxide production (VCO2) and respiratory exchange ratio (RER) 
were determined from breath-by-breath expired gases, measured using indirect open 
circuit calorimetry (Cortex Metalyzer 3B, Cranlea, UK).  Participants breathed as normal 
into a mask that covered the nose and mouth, which was connected using falconia tubing 
to the Metalyzer. This data was then used to determine measures of energy expenditure 
(kcal/min), carbohydrate oxidation (g/min) and fat oxidation (g/min), using standard 
formulae, as described by Frayn (1983). 
 
141 
 
5.2.4.4 Blood pressure and heart rate 
Please see chapter 3 for details of equipment used.  Readings were taken from 
the upper left arm following 5 minutes seated rest at each visit upon arrival and following 
post-dose completion of the cognitive tasks. 
 
5.2.5 Procedure 
Participants were required to attend the laboratory on 4 separate occasions.  The 
first visit was a screening session where participants were informed about the nature of 
the study, its requirements and its restrictions.  Informed consent was obtained and their 
eligibility to participate was confirmed.  Habitual caffeine intake and source were assessed 
via questionnaire and familiarisation with the tasks to be administered on the study days 
was conducted.  The remaining 3 study visits were identical to each other, with the 
exception of the treatment administered.  On each day, participants attended the lab at 
9.30 am following an overnight 12-hour fast where they were permitted to only drink water.  
Upon arrival, salivary caffeine levels were taken to ensure caffeine abstinence and 
following 5 minutes of seated rest heart rate and blood pressure readings were taken.  
Following this, the ICa face mask and the NIRS headband were fitted.  At this point NIRS 
recording began.  Participants then made a baseline completion of the cognitive tasks, the 
caffeine visual analogue scales and the subjective energy measures.  The gas turbine 
was then inserted into the face mask and recording of respiratory gas analysis began.  
Participants were required to sit quietly for a 10 minute NIRS and gas analysis resting 
baseline period (during which time participants watched a non-stimulating home 
improvement DVD).  Gas analysis was then stopped, the turbine was removed and 
participants were required to take their treatment for the day.  Following a 30-minute 
absorption period (during which time NIRS recording continued whilst participants 
watched the DVD), the gas turbine was re-inserted into the face mask and post-dose 
resting gas analysis readings were taken for a further 5 minutes whilst participants 
continued to watch the DVD.  Participants then completed a second set of the cognitive 
tasks.  Following each of the post-dose tasks participants were required to rate their level 
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of mental fatigue and the subjective difficulty of each task.  A 2-minute resting period was 
also completed between each task, to minimise any carry-over effects on CBF from the 
previous task.  Following the cognitive tasks, the caffeine visual analogue scales and the 
subjective energy measures were completed for a second time, blood pressure and heart 
rate were measured and a final saliva sample was taken and used to confirm caffeine 
absorption (see fig 5.1 for more details of procedure and task duration).  Participants 
returned for their next study visit following (at least) a 48-hour washout period.  
 
Fig. 5.1. Timeline representing flow of study day. 
 
5.2.6 Statistics 
Two paired sample t-tests were utilised to analyse baseline and post-dose salivary 
caffeine levels to confirm caffeine absorption.  To determine if any differences existed in 
salivary caffeine levels following the 75 mg and 150 mg caffeine treatments, ‘change from 
baseline’ data were analysed by paired samples t-test. 
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Prior to the primary NIRS analysis a within subjects ANOVA was carried out with 
left/right optode included as a factor to examine any treatment related hemispheric 
differences in response. As there were no interpretable interactions involving this factor 
the data from the two channels were averaged for the analysis. 
For the primary NIRS analysis, the question under investigation was how the two 
doses of caffeine would modulate the haemodynamic response over time as compared to 
placebo, irrespective of which task was being completed at that time.  Data for oxy-Hb, 
deoxy-Hb and total-Hb was averaged across 5 minute epochs during the absorption and 
task period and baseline adjusted to the last 5 minutes of the post-task resting pre-
treatment period.  Data was then analysed by 2-way repeated measures ANOVA 
(treatment (75 mg caffeine, 150 mg caffeine or placebo) X epoch (13 x 5 minute epochs)).  
Significant treatment related interactions were then described, with reference to a priori 
planned comparisons, where each active treatment was compared to placebo at each 
epoch utilising t tests calculated with the Mean Squares Error from the ANOVA (Keppel, 
1991).  In order to reduce the potential for Type I errors only those planned comparisons 
associated with a statistically significant difference on the initial ANOVA are reported.  In 
addition, only those instances where a consistent pattern of significant differences are 
maintained across epochs are identified as reportable significant effects. 
In order to identify the specific effects of task performance, a further analysis was 
conducted whereby the task period was analysed alone by 2-way repeated measures 
ANOVA (treatment (as above) X task (serial 3s, serial 7s, serial 17s, 3-back, RVIP, 
control).  Planned comparisons were conducted as per primary analysis, documented 
above.  
Secondary analysis was aimed at assessing in more detail the effect of treatment 
on tasks through the use of shorter-duration epochs.    In order to identify the course of 
treatment-related haemodynamic effects over the first and second half of each task, data 
was baseline adjusted to the last 5 minutes of the post-task resting pre-treatment period.  
Analysis of the task period was conducted by two-way repeated measures ANOVA 
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(treatment (as per primary analysis) X (12 x 2.5 minute epochs)).  Planned comparisons 
for secondary analysis were conducted as per primary analysis, documented above.   
The primary analysis of indirect calorimetry data aimed to identify treatment-
related effects of individual task performance.  Measures of energy expenditure, 
carbohydrate oxidation and fat oxidation were calculated and averaged across each 5-
minute task period.  Raw data was then analysed by 2-way repeated measures ANOVA 
(treatment (75 mg caffeine, 150 mg caffeine or placebo) X task (as per NIRS 
assessment)).  The rest period was analysed alone by 1-way repeated measures ANOVA.  
Significant treatment related interactions were described with reference to a priori planned 
comparisons as per NIRS assessment.   
The secondary aim of the study was to explore the effects of task performance 
(irrespective of treatment) on measures of metabolism and CBF.  Therefore, where a 
significant main effect of task was observed during the 2-way repeated measures ANOVA 
(treatment X task) from the primary analysis for NIRS and ICa measures, pairwise 
comparisons (partial Bonferroni corrections) were conducted on each task as compared 
to the control. 
To assess the possibility of any on-day differences in cognitive performance, ICa, 
mood, blood pressure and heart rate pre-treatment, repeated measures ANOVAs were 
conducted on baseline data.  Any significant differences were further explored with 
Bonferroni corrected pairwise comparisons.   
Cognitive performance, subjective mood, heart rate and blood pressure data were 
analysed as ‘change from baseline’ by repeated measures ANOVA (apart from post-
individual-task subjective measures of difficulty and mental fatigue, where raw data was 
used).  Significant treatment related effects were described with reference to a priori 
planned comparisons (as above) where each active treatment was compared to placebo. 
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5.3 Results 
5.3.1 Salivary caffeine levels 
Prior to analysis, baseline salivary caffeine levels were examined and it was 
confirmed that they were in accordance with levels of caffeine that would reflect overnight 
caffeine abstinence.  Mean baseline values were 0.65 µg/ml [levels below 1 µg/ml have 
previously been reported for overnight caffeine abstinence  (Evans & Griffiths, 1999)].  
Following caffeinated treatment, salivary caffeine levels were 1.42 µg/ml (75mg caffeine) 
and 2.92 µg/ml (150 mg caffeine).  Analysis of the results confirmed that in comparison to 
baseline levels, salivary caffeine was significantly higher following 75 mg caffeine [t(23) = -
4.05, p<0.001] and 150 mg caffeine [t(23) = -14.69, p<0.001], (see fig. 5.2).  There was 
also a significant difference between salivary caffeine levels post-treatment, whereby the 
150 mg dose elicited a significantly greater rise in salivary caffeine levels than the 75 mg 
dose [t(23) = -6.08, p<0.001]. 
 
 
 
Fig. 5.2.  Mean (and SEM) salivary caffeine values at baseline and post-dose following 75 
mg caffeine and 150 mg caffeine.  Paired sample t-test significance levels are shown (**** 
p<0.001). 
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5.3.2 Treatment related effects  
5.3.2.1 Near infrared spectroscopy; primary analysis 
Effects of treatment on cerebral blood flow over time, irrespective of task 
performed. 
5.3.2.1.1 Oxygenated haemoglobin 
 There were no treatment related differences in oxy-Hb over time, see fig. 5.3a. 
5.3.2.1.2 Deoxygenated haemoglobin 
There were no treatment related differences in deoxy-Hb over time, see fig. 5.3b. 
5.3.2.1.3 Total haemoglobin 
A significant interaction effect (treatment x epoch) was observed for total-Hb [F(24, 
552)=1.65, p<0.05].  Planned comparisons revealed that total-Hb was significantly 
increased during minutes 6-10 [t(552)=2.238, p<0.05, d=0.52], 16-20 [t(552)=2.130, 
p<0.05, d=0.42] and 26-30 [t(552)=2.331, p<0.05, d=0.40] of the absorption period 
following 75 mg caffeine as compared to placebo, see fig. 5.4. 
147 
 
 Fig. 5.3.  Concentration changes of oxy-Hb (a) and deoxy-Hb (b) represented in 5 minute 
epochs during absorption and cognitive task period over time (irrespective of task 
performed) following placebo, 75 mg caffeine and 150 mg caffeine.  Means and SEM are 
presented as change from pre-treatment, resting baseline. 
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 Fig. 5.4.  Concentration change of total-Hb represented in 5 minute epochs during 
absorption and cognitive task period over time (irrespective of task performed) following 
placebo, 75 mg caffeine and 150 mg caffeine.  Means and SEM are presented as change 
from pre-treatment, resting baseline.  Treatment x epoch interaction effects are shown.  
Significance is compared to placebo (t-tests calculated with the Mean Squares Error from 
the ANOVA) (* p<0.05). 
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5.3.2.2 Near infrared spectroscopy; secondary analysis 
Effects of treatment on cerebral blood flow during first and second half of 
individual task performance. 
5.3.2.2.1 Oxygenated haemoglobin 
There were no treatment related differences in oxy-Hb specific to task 
performance.   
5.3.2.2.2 Deoxygenated haemoglobin 
There were no treatment related differences in deoxy-Hb specific to task 
performance.   
5.3.2.2.3 Total haemoglobin 
 There were no treatment related differences in total-Hb specific to task 
performance. 
 
5.3.2.3 Indirect calorimetry 
Effects of treatment on metabolism during performance of individual tasks 
and during rest period. 
5.3.2.3.1 Baseline scores 
There were no significant on-day differences in measures of energy expenditure, 
carbohydrate oxidation or fat oxidation prior to treatment.  Due to data capture errors, only 
data from 13 participants is included the primary analysis. 
5.3.2.3.2 Energy expenditure 
 There was a significant main effect of treatment on energy expenditure during task 
performance [F(2, 120)=3.803, p<0.05].  Planned comparisons revealed that energy 
expenditure was significantly higher following 75 mg [t(120)=2.48, p<0.05, d=0.40] and 
150 mg caffeine [t(120)=3.81, p<0.001 d=0.59] as compared to placebo, see fig. 5.5a.  
There were no treatment related effects on energy expenditure during the rest period. 
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5.3.2.3.3 Carbohydrate oxidation 
 There was a significant main effect of treatment on carbohydrate oxidation during 
task performance [F(2, 120)=8.099, p<0.005].  Planned comparisons revealed that 
carbohydrate oxidation was significantly higher following 75 mg [t(120)=3.89, p<0.001, 
d=0.77] and 150mg caffeine [t(120)=5.90, p<0.001, d=0.95], as compared to placebo, see 
fig. 5.5b.  There was a significant main effect of treatment on carbohydrate oxidation 
during the rest period [F(2, 24)=11.33, p<0.001].  Planned comparisons revealed that 
during the rest period, carbohydrate oxidation was significantly higher following 75 mg 
[t(24)=4.13, p<0.001, d=1.19] and 150 mg caffeine [t(24)=4.40, p<0.001, d=1.12], as 
compared to placebo, see fig. 5.6a. 
5.3.2.3.4 Fat oxidation 
There were no treatment related effects on fat oxidation during task performance, 
see fig. 5.5c.  There was a significant main effect of treatment on fat oxidation during the 
rest period [F(2, 24)=7.58, p<0.005].  Planned comparisons revealed that during the rest 
period, fat oxidation was significantly lower following 75 mg [t(24)=3.62, p<0.005, d=-.93] 
and 150 mg caffeine [t(24)=3.06, p<0.01, d=-0.73], as compared to placebo, see fig. 5.6b. 
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 Fig. 5.5.  Raw mean (and SEM) values for (a) energy expenditure, (b) carbohydrate 
oxidation and (c) fat oxidation following placebo, 75 mg caffeine and 150 mg caffeine. 
Main effects of treatment are shown, significance is compared to the placebo (t-tests 
calculated with the Mean Squares Error from the ANOVA) (* p<0.05, **** p<0.001). 
 
 
 
Fig. 5.6.  Raw mean (and SEM) values for (a) carbohydrate oxidation and (b) fat oxidation 
during the post-treatment rest, following placebo, 75 mg caffeine and 150 mg caffeine.  
Main effects of treatment are shown, significance is compared to the placebo (t-tests 
calculated with the Mean Squares Error from the ANOVA) (** p<0.01, *** p<0.005, **** 
p<0.001). 
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5.3.2.4 Cognitive performance and mood 
Effects of treatment on measures of cognitive performance and mood. 
5.3.2.4.1 Baseline scores 
There were no significant on-day differences in cognitive performance, mood or 
autonomic measures prior to treatment.  Due to an oversight when programming 
COMPASS, the alertness scale was absent from the configuration for the post-dose 
subjective assessment for the first 11 participants.  Therefore, data from only 13 subjects 
is included for ‘alert’ and the ‘alertness’ factors. 
5.3.2.4.2 Mental stamina 
There was a significant main effect of treatment on ratings of mental stamina [F(2, 
46)=3.98, p<0.05].  Planned comparisons revealed that participants’ rated their level of 
mental stamina as being significantly greater following 75 mg caffeine as compared to 
placebo [t(46)=2.75, p<0.001, d=0.74], see fig. 5.7a. 
5.3.2.4.3 Physical stamina 
There was a significant main effect of treatment on ratings of physical stamina [F(2, 
46)=3.60, p<0.05].  Planned comparisons revealed that participants’ rated their level of 
physical stamina as being significantly greater following 75 mg caffeine as compared to 
placebo [t(46)=2.60, p<0.05, d=0.59], see fig. 5.7b 
5.3.2.4.4 Post-individual-task mental fatigue 
There was a significant main effect of treatment on ratings of post-individual-task 
mental fatigue [F(2, 230)=8.25, p<0.001].  Planned comparisons revealed that participants’ 
rated their level of mental fatigue as being significantly lower following 75 mg caffeine 
[t(230)=4.93, p<0.001, d=-0.83] and 150 mg caffeine as compared to placebo [t(230)=4.47, 
p<0.001, d=-0.69], see fig 5.7c. 
5.3.2.4.5 Post-individual-task difficulty 
There was a significant main effect of treatment on ratings of post-individual-task 
difficulty [F(2, 230)=6.985, p<0.005].  Planned comparisons revealed that participants’ 
rated tasks overall as being less difficult following 75 mg caffeine [t(230)=2.72, p<0.01 d=-
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0.62] and 150 mg caffeine as compared to placebo [t(230)=3.10, p<0.005 d=-0.73], see fig. 
5.7d. 
 
Fig. 5.7.  Mean (and SEM) change from baseline scores on mood parameters following 
placebo, 75 mg caffeine and 150 mg caffeine.  Main effects of treatment are shown for (a) 
mental stamina, (b) physical stamina, (c) mental fatigue and (d) task difficulty significance 
is compared to the placebo (t-tests calculated with the Mean Squares Error from the 
ANOVA) (* p<0.05, *** p<0.005, **** p<0.001). 
 
5.3.3 Task related effects 
5.3.3.1 Near infrared spectroscopy 
Effects of task performance on measures of cerebral blood flow, irrespective 
of treatment received. 
5.3.3.1.1 Oxygenated haemoglobin 
A significant main effect of task was observed for oxy-Hb [F(5, 230)=11.14, 
p<0.001].  Pairwise comparisons of each task to the control revealed that during the 
control task oxy-Hb was significantly lower as compared to serial 3s (p<0.005), serial 7s 
(p<0.005), serial 17s (p<0.001), see fig.  
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5.3.3.1.2 Deoxygenated haemoglobin 
A significant main effect of task was observed for deoxy-Hb [F(5, 230)=9.704, 
p<0.001].  Pairwise comparisons (partial Bonferroni corrections) of each task to the control 
revealed that during the control task deoxy-Hb was significantly lower than during serial 3s 
(p<0.01) and serial 7s (p<0.05), see fig. 5.8. 
5.3.3.1.3 Total haemoglobin 
 A significant main effect of task was observed for total-Hb [F(5, 230)=15.14, 
p<0.001].  Pairwise comparisons (partial Bonferroni corrections) of each task to the control 
revealed that during the control task total-Hb was significantly lower than during serial 3s 
(p<0.001), serial 7s (p<0.005) and serial 17s (p<0.001), see fig. 5.8. 
 
5.3.3.2 Indirect calorimetry 
Effects of task performance on metabolism measures, irrespective of 
treatment received. 
5.3.3.2.1 Energy expenditure 
 A significant main effect of task was observed for energy expenditure [F(5, 
120)=8.470, p<0.001].  Pairwise comparisons (partial Bonferroni corrections) of each task 
to the control revealed that during the control task, energy expenditure was significantly 
lower than during serial 3s (p<0.05), serial 7s (p<0.05) and serial 17s (p<0.05), see fig. 
5.8. 
5.3.3.2.2 Carbohydrate oxidation 
 A significant main effect of task was observed for carbohydrate oxidation [F(5, 
120)=3.935, p<0.005].  However, pairwise comparisons (partial Bonferroni corrections) of 
each task to the control revealed no significant differences between tasks for 
carbohydrate oxidation, see fig. 5.8. 
5.3.3.2.3 Fat oxidation 
 There were no significant task related effects for fat oxidation, see fig. 5.8. 
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5.3.3.3 Subjective mental fatigue and difficulty 
Subjective ratings of mental fatigue and difficulty following individual task 
performance, irrespective of treatment received. 
5.3.3.3.1 Post-individual-task mental fatigue 
There was a significant main effect of task on ratings of post-individual-task mental 
fatigue [F(5,230)=8.78, p<0.001].  Pairwise comparisons (partial Bonferroni corrections) of 
each task to the control revealed that participants rated themselves as being significantly 
less mentally fatigued following the control task as compared to the 3-back (p<0.005) and 
RVIP (p<0.001), see fig. 5.8. 
5.3.3.3.2 Post-individual-task difficulty 
There was a significant main effect of task on ratings of post-individual-task 
difficulty [F(5, 230)=40.03, p<0.001].  Pairwise comparisons (partial Bonferroni corrections) 
of each task to the control revealed that participants rated the control task as being 
significantly less difficult than serial 3s (p<0.005), serial 7s (p<0.001), serial 17s (p<0.001), 
3-back (p<0.001) and RVIP (p<0.001), see fig. 5.8. 
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 Fig. 5.8.  Mean change (and SEM) during each task period, main effects of task are 
shown for metabolic measures (raw data), cerebral oxygenation (change from baseline) 
and subjective measure of task difficulty and mental fatigue (raw data).  Pairwise 
comparisons (partial Bonferroni corrections) are shown where each task is compared to 
the control (*p<0.05, **p<0.01, ***p<0.005, ****p<0.001). 
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Table 5.1.  Baseline and change from baseline scores for serial subtractions, RVIP and 3-
back tasks for each treatment.  Means ±SEM values are presented with F and p values 
from the primary ANOVA for main treatment effects.  Significant measures are shown in 
bold. 
Measure n Treatment Baseline Post-dose 
change from 
baseline score 
Treatment 
effect 
Serial 3s  
subtraction 
correct (%) 
 
24 
 Placebo 92.0±1.70 2.46±1.47 F=1.40 
p>0.1 
 
75mg 94.6±1.14 -0.58±1.19 
150mg 95.4±1.22 0.39±1.19 
Serial 3s 
subtraction errors 
(%) 
 
24 
 Placebo 8.04±1.70 -2.46±1.47 F=1.40 
p>0.1 
 
75mg 5.38±1.14 0.58±1.19 
150mg 4.57±1.22 -0.39±1.19 
Serial 7s  
subtraction 
correct (%) 
 
24 
 Placebo 94.0±1.19 -3.68±1.81 F<1 
 75mg 90.4±1.61 -0.79±1.74 
150mg 91.4±2.87 0.07±2.96 
Serial 7s 
subtraction errors 
(%) 
 
24 
 Placebo 6.04±1.19 3.68±1.81 F<1 
75mg 9.60±1.61 0.79±1.74 
150mg 8.60±2.87 -0.07±2.96 
Serial 17s  
subtraction 
correct (%) 
 
23 
 Placebo 89.0±1.95 -0.57±2.04 F<1 
 75mg 83.9±2.77 2.62±2.92 
150mg 85.1±2.46 0.71±2.18 
Serial 17s 
subtraction errors 
(%) 
 
23 
 Placebo 11.0±1.95 0.57±2.04 F<1 
75mg 16.1±2.77 -2.62±2.92 
150mg 14.9±2.46 -0.71±2.18 
RVIP correct  
(%) 
 
23 
 Placebo 65.6±4.52 -6.76±3.87 F<1 
75mg 70.4±3.54 -8.97±3.02 
150mg 65.8±4.06 -2.72±3.43 
RVIP RT 
(ms) 
 
 
23 
 Placebo 484±10.5 11.1±11.8 F=1.10 
p>0.1 
 
75mg 493±12.1 -8.20±10.4 
150mg 494±13.4 -3.23±9.13 
RVIP  
false alarms (%) 
 
 
23 
 Placebo 16.0±4.36 -1.94±4.15 F<1 
75mg 10.6±2.20 -1.68±2.34 
150mg 12.5±2.91 -1.85±1.88 
3-back 
overall correct 
(%) 
 
24 
 Placebo 85.6±2.27 -4.53±3.95 F<1 
75mg 89.1±1.66 -5.59±1.95 
150mg 88.6±1.28 -8.37±3.13 
3-back 
overall RT (ms) 
 
24 
 Placebo 744±54.6 -18.4±32.2 F<1 
75mg 766±52.7 -13.8±27.6 
150mg 787±52.0 -40.9±35.3 
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Table 5.2.  Baseline and change from baseline scores for caffeine research visual  
analogue scales and subjective energy measures for each treatment.  Means ±SEM  
values are presented with F and p values from the primary ANOVA for main treatment  
effects.  Significant measures are shown in bold. 
Measure n Treatment Baseline Post-dose 
change from 
baseline 
score 
Treat 
effect 
 
 
 
 
 
 
 
 
 
 
 
Caffeine 
research 
visual 
analogue 
scales 
(mm) 
 
Relaxed 
 
 
24 
 Placebo 54.6±2.85 -14.2±4.06 F=1.61 
p>0.1 75mg 53.2±2.55 -6.25±3.43 
150mg 58.3±2.56 -12.3±3.34 
 
Alert 
 
13 
 Placebo 52.4±3.21 -10.4±6.66 F<1 
75mg 51.9±2.88 -2.54±4.59 
150mg 56.3±2.87 -4.85±5.06 
 
Jittery 
 
 
24 
 Placebo 27.2±3.26 17.8±5.80 F=1.19 
p>0.1 75mg 28.8±2.70 9.33±4.38 
150mg 27.8±3.21 8.75±4.97 
 
Tired 
 
24 
 Placebo 44.7±3.70 5.17±5.65 F=2.91 
p=0.065 
 
75mg 47.0±3.73 -8.08±5.12 
150mg 39.4±3.86 2.38±4.14 
 
Tense 
 
 
24 
 Placebo 30.8±3.52 15.0±5.48 F=1.22 
p>0.1 
 
75mg 34.1±2.94 5.04±4.46 
150mg 31.7±3.35 9.21±3.42 
 
Headache 
 
 
24 
 Placebo 23.3±3.95 27.7±4.85 F=1.69 
p>0.1 
 
75mg 24.4±4.18 22.9±5.07 
150mg 21.8±3.92 18.8±4.17 
 
Overall mood 
 
24 
 Placebo 58.6±2.16 -11.9±2.87 F=1.69 
p>0.1 
 
75mg 58.5±2.39 -4.17±3.16 
150mg 63.2±2.37 -9.83±3.19 
 
Mental fatigue 
 
24 
 Placebo 35.2±3.67 19.9±4.19 F=2.28 
p>0.1 75mg 31.5±2.50 9.79±3.82 
150mg 33.0±3.04 12.9±3.40 
 
 
 
Energy 
measures 
(mm) 
 
Concentration 
 
24 
 Placebo 56.9±2.42 -14.4±3.41 F=2.42 
p=0.1 
 
75mg 56.0±3.04 -3.29±4.20 
150mg 57.8±2.94 -6.29±4.38 
Mental 
stamina 
 
24 
 Placebo 57.0±2.42 -15.1±3.19 F=3.98 
p=0.026 
 
75mg 54.7±3.02 -2.04±3.95 
150mg 57.3±2.19 -6.00±3.80 
Physical 
stamina 
 
24 
 Placebo 56.8±3.14 -11.2±4.01 F=3.60 
p=0.035 75mg 57.6±2.71 -0.75±3.17 
150mg 60.3±2.56 -3.62±2.59 
 
Mentally tired 
 
24 
 Placebo 40.3±3.76 13.5±4.50 F<1 
75mg 35.0±2.47 9.58±4.15 
150mg 36.7±2.85 11.50±3.36 
 
Physically 
tired 
24  Placebo 37.5±3.77 9.00±4.83 F=1.66 
p>0.1 
 
75mg 35.7±3.15 0.87±4.88 
150mg 34.4±3.60 0.71±3.48 
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5.3.4 Blood pressure and heart rate 
5.3.5.1 Systolic blood pressure 
 There were no significant treatment related differences in systolic blood pressure. 
5.3.5.2 Diastolic blood pressure 
 There were no significant treatment related differences in diastolic blood pressure. 
5.3.5.2 Heart rate 
 There were no significant treatment related differences in heart rate. 
 
 
5.4 Discussion 
The findings here demonstrate that 75 mg caffeine leads to a significant increase 
in total-Hb during minutes 6-10, 16-20 and 26-30 of the absorption period prior to task 
performance.  In relation to exhaled gas analysis, as compared to placebo, both 75 mg 
and 150 mg caffeine led to a significant increase in energy expenditure and carbohydrate 
oxidation during task performance, which increased incrementally with dose.  At rest, 75 
mg and 150 mg caffeine led to a significant increase in carbohydrate oxidation and a 
significant decrease in fat oxidation as compared to placebo.  The only significant 
treatment related behavioural effects were on mood measures.  The 75 mg dose led to 
significant increases in ratings of mental and physical stamina and both the 75 mg and 
150 mg doses resulted in significant reductions in post-individual-task ratings of mental 
fatigue and task difficulty. 
 In terms of haemodynamics, the findings of the present study largely reflected the 
pattern of change in cerebral oxygenation expected in the face of a cognitive challenge.  
Here, the observed increase in oxy-Hb coupled with a corresponding decrease in deoxy-
Hb relative to the baseline and/or absorption periods (both of which are essentially rest 
phases here) is consistent with previous NIRS research that has looked at the effects of 
task performance (Fallgatter & Strik, 1998; Schroeter et al., 2002).  However, what is less 
consistent is that a 75 mg dose of caffeine should lead to a significant increase in total-Hb, 
during the absorption period, when previous caffeine research consistently reports a 
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reduction in CBF following caffeine ingestion (Chen & Parrish, 2009a; Laurienti et al., 
2003; Mathew & Wilson, 1991; Rack-Gomer et al., 2009).  Indeed, in chapter 4, a 
significant reduction in oxy-Hb was observed as soon as 3 minutes post-treatment with 
the same dose as used here.  In the present study, there was also an absence of an effect 
of caffeinated treatment following both doses during task performance.  This is also 
surprising as chapter 4 demonstrated that a 75 mg dose engendered a significant 
reduction in oxy-Hb and a corresponding increase in deoxy-Hb almost throughout the 
entire task period.  One possible explanation for the absence of an effect is the decision to 
use only habitual caffeine consumers in the present study.  In chapter 4 both habitual and 
non-habitual consumers were recruited and further analysis of the findings on deoxy-Hb in 
that study revealed that the increase seen was largely as a result of the non-habitual 
consumer group.  Similarly, decreased total-Hb previously shown following 75 mg caffeine 
was also due to exaggerated effects in the non-consumers, whilst there were no effects in 
the habitual consumers (Kennedy & Haskell, 2011). 
 Turning to the treatment related effects on exhaled gas analysis, this is the first 
study to demonstrate that caffeine administration leads to a significant increase in energy 
expenditure and carbohydrate oxidation during the completion of cognitive tasks, and that 
these effects increase incrementally with dose.  Caffeine’s ability to increase metabolic 
rate (Acheson et al., 1980; Dulloo et al., 1989) and energy expenditure (Arciero, Gardner, 
Callesescandon, Benowitz, & Poehlman, 1995; Astrup et al., 1990; Hollands et al., 1981) 
during periods of rest has been demonstrated previously (although interestingly not in the 
present study), so too its dose-dependent manner (Astrup et al., 1990).  That this effect 
should also occur during performance of cognitive tasks is therefore unsurprising although 
hitherto unexplored.  With regards the observed significant increase in carbohydrate 
oxidation during task performance and at rest; previous research has demonstrated that 
caffeine in combination with glucose leads to an increase in carbohydrate oxidation during 
exercise (as compared to the administration of glucose alone) (Yeo, Jentjens, Wallis, & 
Jeukendrup, 2005).  However, where caffeine has been administered alone during 
exercise (Costill et al., 1978), and at rest (Acheson et al., 2004; Acheson et al., 1980), an 
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increase in fat oxidation has been reported.  In the present study, although no effect on fat 
oxidation was observed during task performance, a significant decrease was seen at rest 
following caffeine.  These inconsistencies may reflect differences in the energy 
requirements of the brain and muscle as well as dose response effects at rest, given that 
previous studies administered much higher doses of caffeine than those used here.  It is 
also important to note that the effects at rest in the present study may reflect carryover 
effects from the baseline cognitive assessment, with caffeine aiding in the preferential 
oxidation of carbohydrate over fat in order to replenish stores. 
 The relative absence of treatment effects on cognition is not entirely unexpected 
as the tasks were selected on the basis of their potential to induce differing levels of 
metabolic demand, rather than their sensitivity to caffeine. The RVIP task has previously 
shown sensitivity to caffeine but the demanding paradigm employed may have served to 
increase arousal to such a level that effects of caffeine were negated, as has previously 
been observed with a demanding paradigm (Kennedy & Haskell, 2011).  In terms of mood, 
beneficial effects were observed on mental fatigue and ratings of physical and mental 
stamina as a result of treatment.  Improvements to feelings of fatigue and vigour as well 
as mental energy and energetic arousal have been reported previously as a result of 
caffeine administration (Lieberman, 2001; Quinlan et al., 2000; Smit & Rogers, 2000).  
Furthermore, with studies demonstrating that caffeine leads to increased time to 
exhaustion (Greer et al., 2000; Pasman et al., 1995; Simmonds et al., 2010; Spriet et al., 
1992), the increase in feelings of physical stamina observed here, are not counter to 
expectations.  It is unfortunate that in the present study, subjective measures of alertness 
were only obtained for 13 participants.  The small sample size may provide some 
explanation for the absence of an effect on this measure, since positive effects on 
measures of alertness have been demonstrated previously, albeit at different doses to 
those administered here (Quinlan et al., 2000; Rogers et al., 2008). 
In addition to treatment related effects, there were also a number of task-related 
effects.  Irrespective of treatment, serial 3s, serial 7s and serial 17s led to a significant 
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increase in oxy-Hb and total-Hb as compared to the control.  Correspondingly, there was 
a significantly smaller decrease in deoxy-Hb during performance of the serial 3s and serial 
7s tasks as compared to the control.   In relation to exhaled gas analysis, there was a 
significant increase in energy expenditure during the serial 3s, serial 7s and serial 17s 
subtraction tasks as compared to the control.  However, participants rated the 3-back and 
RVIP tasks subjectively as being significantly more mentally fatiguing than the control.  In 
relation to task difficulty, the serial 3s, serial 7s, serial 17s, 3-back and RVIP tasks were all 
rated as being significantly more difficult than the control.  
These task related effects (irrespective of treatment) are of particular interest in 
that NIRS and ICa findings presented a similar pattern of effects.  Overall and irrespective 
of treatment, the serial subtractions tasks led to the most pronounced increases in oxy-Hb, 
the smallest reductions in deoxy-Hb and augmented energy expenditure and 
carbohydrate oxidation levels to the highest degree (although the findings in terms of 
carbohydrate oxidation failed to reach significance).  By comparison, both the 3-back and 
RVIP tasks led to changes in the above parameters that were more in-keeping with those 
of the control task.  The study by Kennedy et al. (2016) (supplemental data) found a 
strikingly similar pattern of effects using a similar methodology as here.  They observed 
that the 3-back task was found to elicit metabolic changes (to total energy expenditure 
and carbohydrate oxidation), and cerebral blood flow changes (oxy-Hb), that were in-
keeping with those of the control task as compared to that of the serial 3s, serial 7s and 
serial 17s.  Importantly, this finding was despite the 3-back task being subjectively rated 
as more difficult and mentally fatiguing than the subtractions tasks (just as they were in 
the present study, with the addition of the RVIP).  In the case of energy expenditure, this 
demonstrated that not only the somatic demands of the task had bearing on the increase 
observed, but also the cognitive demands, since the control task was matched to the most 
somatically demanding serial 3s subtraction task.  The changes with regards carbohydrate 
and fat oxidation also followed a very similar pattern to that of Kennedy et al. (2016).  As 
with energy expenditure, the 3-back (and also in the present study the RVIP task) was 
more closely matched to that of the control and there was an increase in carbohydrate 
164 
 
oxidation and a decrease in fat oxidation as the difficulty of the serial subtraction 
calculations increased, despite the somatic demands of the subtraction tasks decreasing 
(fewer key presses per minute).  In the present study, however, the findings failed to reach 
significance.  With regards to the CBF effects, again for oxy-Hb a similar pattern to that of 
Kennedy et al. (2016) was observed with the serial subtractions tasks eliciting a 
significantly greater increase as compared to the control and the 3-back, despite being 
rated as less cognitively demanding than the 3-back task.   
When task related findings are considered in conjunction with the subjective 
assessments of task difficulty and ratings of mental fatigue engendered by each task, 
these findings are perhaps, contrary to expectation.  Although all of the tasks were rated 
as being significantly more difficult than the control task, it was the 3-back and RVIP tasks 
that elicited the highest subjective difficulty rating.  In addition, the 3-back and RVIP tasks 
were the only two tasks rated as being significantly more mentally fatiguing than the 
control.  That the subjective and physiological assessments of a task should provide such 
contrasting results could, in part, be due to the nature of the tasks themselves.  A previous 
study undertaken in the same research facility (Jackson et al., 2012, internal 
communication) that looked at the subjective ratings of Serial 3s, Serial 7s and the RVIP 
task demonstrated that whilst the RVIP was rated as requiring significantly more hard 
work and mental effort than the serial 3s task, it required significantly less focus.  
Unfortunately continuous heart rate measurements were not taken in the present study, 
as this may have provided a further physiological measure of the level of demand each 
task was placing on the subject (Mehler, Reimer, & Coughlin, 2012).  Despite this, the 
findings of the present study clearly demonstrate that the serial subtractions tasks are the 
most physiologically demanding (in terms of energy expenditure) and neurally demanding 
as they elicit the greatest increase in oxygenated haemoglobin and total haemoglobin as 
well as the greatest increase in deoxygenated haemoglobin, which taken together could 
reflect both an increase in cerebral blood flow and oxygen extraction.  These findings 
suggest that measuring CBF in conjunction with the metabolic effects provide a more 
comprehensive overview of the resources required during cognitive task performance and 
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indeed complement each other in their analysis of the demands of individual tasks.  They 
have also demonstrated that subjective measures are not always accurate in determining 
specific features of task difficulty and should ideally, be used alongside a physiological 
measure of demand. 
There were some limitations to the present study, however.  Data from only 13 
participants was included in the metabolism analysis.  This was because participants were 
excluded as their respiratory exchange ratio (RER) values fell outside of the expected 
range for a fasted, resting state.  The expected value for this state is usually between 0.7-
0.9 (calculated as the ratio between the amount of carbon dioxide produced and the 
amount of oxygen consumed).  Indeed, for many of the excluded participants, values 
were >1, which would normally be observed during intense exercise.  The exact reason 
for these anomalous values is not wholly apparent; however, it may relate to the nature of 
the study and the equipment used.  During indirect calorimetry measurements, 
participants are required to wear a mask over their nose and mouth and to breathe 
through their mouth (expelled gas is collected into a turbine which is housed within the 
mask and positioned directly in front of the mouth).  There are two issues with this; the 
mask may not securely fit the face, thereby leaving gaps for expired air to escape (despite 
every attempt to avoid this through the use of differing mask sizes and plugging gaps in 
the mask manually).  The second is that breathing through their mouth is a counterintuitive 
action, since at rest breathing through the nose would be a more natural response.  It is 
possible that in the present study participants forgot to breathe through their mouth or 
simply chose not to (the monitoring of this was made difficult as participants were facing 
away from the researcher).  This could lead to build-up and false elevation of VCO2 
readings.  The significance of both of these factors therefore is the influence they bear on 
the RER readings, since this, as previously explained, is calculated using the values of 
expired CO2 and inspired O2.  Another possibility is that the participants may not have 
fasted as this would also lead to an elevation of the RER value.  Although participants 
were asked upon the morning of their visit if they had remembered to abstain from eating 
or drinking anything other than water and all confirmed that they had, there is always the 
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possibility that this procedure was not adhered to.  Future studies looking at the metabolic 
effects of task performance may benefit from the use of a mouthpiece and nose clip that 
directs participants to breathe through their mouth and removes the need for a facemask.  
The issue of fasting could be addressed by requesting that participants give a blood 
sample upon arrival, allowing glucose levels to be determined in order to confirm that 
participants are fasted. 
The absence of heart rate readings during performance of each task meant that 
there was no objective measure of demand.  Previous research has observed that heart 
rate is able to differentiate between levels of demand, with more cognitively demanding 
tasks leading to an increase in heart rate (Mehler et al., 2012).  Using this measure during 
tasks in the present study could have gone further to provide a clearer picture in terms of 
which tasks were found the most demanding. 
This is the first study to use NIRS and indirect calorimetry in conjunction with an 
assessment of cognitive performance in the presence of caffeine.  It has demonstrated 
that a 75 and a 150 mg dose of caffeine leads to an incremental increase in energy 
expenditure and carbohydrate oxidation during cognitive task performance.  It has also 
demonstrated that irrespective of treatment, the metabolism of central and peripheral 
substrates follow a similar pattern of effects during specific task performance.  Future 
studies would benefit from including a continuous measure of heart rate as well as 
subjective measures of task ‘experience’ that provide a clearer distinction of the of level of 
effort/demand that a task requires. 
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Chapter 6: Effects of dietary nitrate supplementation (beetroot juice) 
during incremental exercise, on cerebral haemodynamics, cognitive 
performance and subjective fatigue. 
 
6.1 Introduction  
Nitric oxide (NO), an autocrine and paracrine signalling molecule, is an important 
modulator of a number of physiological processes, such as platelet function (Radomski, 
Palmer, & Moncada, 1990), host defence, neurotransmission, peripheral vasodilation 
(Moncada & Higgs, 1993) and cerebral vasodilation (Toda et al., 2009).  Endogenously, 
NO is generated through the oxidation of L-arginine by a family of enzymes known as NO 
synthases (NOSs) (Knowles & Moncada, 1994; Knowles, Palacios, Palmer, & Moncada, 
1989; Palmer, Ashton, & Moncada, 1988).  NO can also be generated via an alternative 
pathway, independent of NOS, either in vivo under hypoxic conditions (Lundberg & 
Weitzberg, 2010) or following the intake of supplementary nitrate (NO3-) in its 
pharmacological form (Lundberg & Govoni, 2004). NO can also be stimulated through the 
intake of foods (predominantly fruit and vegetables) containing high levels of nitrate 
(Webb et al., 2008).  Via this route, nitrate is reduced to nitrite (NO2-) in the mouth by oral 
bacteria on the posterior of the tongue.  Nitrite is then reduced to NO in the stomach and 
the remainder alongside the remaining nitrate is absorbed by the small intestine into 
circulation.  The nitrate that is not excreted in urine (approx. 25 %) is then taken up by 
salivary glands and concentrated into saliva, reduced to nitrite and absorbed once again 
from the intestine, where it is reduced to NO (Lundberg, Weitzberg, & Gladwin, 2008). 
Beetroot is a member of the chenopodiaceae family, a class of vegetables that has 
been shown to accumulate comparatively large levels of nitrate, with beetroot itself 
containing 1727 mg/kg (Santamaria et al., 1999).  Following consumption of nitrate-rich 
food (500 ml beetroot juice), a 16 fold increase in nitrate has been demonstrated, peaking 
at 90 minutes post-consumption, with a corresponding 2-fold increase in plasma nitrite 
levels, peaking at 3 hours post-consumption (Webb et al., 2008).  Supplementation of 
dietary nitrate in humans (in the form of beetroot juice) has led to effects consistent with 
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those observed as a result of increases in endogenous NO synthesis, such as 
improvements in the vasculature.  Joris and Mensink (2013) observed that beetroot juice 
led to a reduction of post-prandial impairment in flow-mediated dilation in healthy 
overweight and slightly obese men.  In healthy populations, reductions in blood pressure 
have been observed (Kapil et al., 2010; Vanhatalo et al., 2010; Webb et al., 2008; Wylie et 
al., 2013) with nitrate supplementation also leading to protection against endothelial 
dysfunction in the forearm, and inhibition of platelet aggregation (Webb et al., 2008).  
Evidence from animal studies have also supported the nitrite-NO pathway as a means of 
positively modulating CBF (Rifkind et al., 2007) and neurovascular coupling after a 
challenge (Piknova, Kocharyan, Schechter, & Silva, 2011).  It is believed this method of 
NO production supplements the oxygen dependent L-arginine/NO pathway and may 
prevail under conditions of hypoxia (Lundberg & Weitzberg, 2010), such as is observed in 
skeletal muscle during exercise.  
Recently there have been a number of studies assessing the impact of dietary nitrate 
supplementation during the implementation of exercise protocols.  Bailey et al. (2009) 
administered 500 ml of beetroot juice (BR) per day (nitrate 5.5 mmol per 500 ml) over a 
period of 6 consecutive days to young recreationally active males.  They demonstrated 
that beetroot juice leads to a significant reduction in the amplitude of pulmonary VO2 
during moderate intensity exercise, alongside a significant (13 %) reduction in the 
amplitude of muscle deoxy-Hb (as measured by NIRS); inferred as being indicative of 
reduced oxygen extraction.  BR also increased time to exhaustion during severe exercise.  
The attenuation of deoxy-Hb, in conjunction with the change in VO2, was taken as 
evidence of reduced aerobic energy turnover or muscle energy utilisation.  Increases in 
the time to exhaustion following BR during high intensity exercise have since been 
demonstrated (Bailey et al., 2010; Breese et al., 2013; Wylie et al., 2013), so too 
reductions in the oxygen cost of sub-maximal exercise following both chronic (Bailey et al., 
2010; Lansley, Winyard, Fulford, et al., 2011; Vanhatalo et al., 2010) and acute 
(Vanhatalo et al., 2010; Wylie et al., 2013) BR supplementation.  It has also been shown 
to improve cycling performance (Lansley, Winyard, Bailey, et al., 2011), rowing 
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performance (Bond, Morton, & Braakhuis, 2012) and aspects of exercise recovery 
following a bout of eccentric exercise (Clifford, Bell, West, Howatson, & Stevenson, 2016). 
However, the effects of BR are not confined to the periphery as modulation of the 
cerebral vasculature has also been observed.  Presley et al. (2011) looked at the effects 
of a high nitrate diet (including 500 ml BR) on cerebral perfusion (via arterial spin labelling 
magnetic resonance imaging) in older adults.  In this crossover study, participants 
received a diet high in fruits and vegetables plus 500 ml of BR at breakfast (providing a 
high nitrate diet of 12.4 mmol nitrate) or a diet low in fruits and vegetables with no 
supplementary BR (providing a low nitrate diet of 0.089 mmol nitrate).  In addition to 
significantly elevated nitrate and nitrite levels, the high nitrate diet led to a significant 
increase in cerebral perfusion in the white matter of the frontal lobe as compared to that 
following the low nitrate diet.  The effects of BR supplementation have also been 
assessed on cerebral perfusion during cycling at 40 %, 60 % and 80 % VO2peak, in healthy 
young adults.  Following 500 ml acute beetroot supplementation, a significant reduction in 
cerebrovascular resistance index (CRI) (calculated as middle cerebral artery mean blood 
velocity (MCA Vmean)/mean arterial blood pressure, as measured by Transcranial 
Doppler) was observed, at rest and during all workout intensities (Bond et al., 2013).  
Rattray et al. (2015) assessed the effects of an acute low dose (140 ml) of BR 
supplementation on MCA Vmean (via Transcranial Doppler), during cycling performance 
whilst simultaneously measuring cognitive performance on the Stroop task.  They 
demonstrated that MCA Vmean was significantly elevated during higher intensity exercise 
performance (75 % and 85 % of heart rate reserve), but particularly so during 
performance of the cognitive task.  Although no significant behavioural effects were 
observed, there was an improvement in performance accuracy on the Stroop task that just 
failed to reach significance (p=0.059).  The CBF velocity (via Transcranial Doppler) effects 
of BR administration have also been assessed during cognitive task (Stroop) performance 
in hypoxia in healthy young males.  However, here, Lefferts et al. (2015) observed no 
effects on neurovascular coupling or cognitive performance following acute beetroot (70 
ml) supplementation.  
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A study by Wightman et al. (2015) assessed the cognition and cerebral oxygenation 
enhancing effects of dietary nitrate supplementation in healthy young adults.  It was 
observed that 450 ml BR led to an initial increase in CBF (total-Hb) at the onset of the task 
period during an assessment of mental arithmetic (serial 3s subtractions), with a 
subsequent reduction in CBF during RVIP, a task that has been associated with smaller 
changes in CBF in previous studies (Kennedy, Wightman, et al., 2010) as well as in 
chapter 5 of this thesis.   As the task period progressed, however, CBF was also reduced 
for a later completion of serial 3s.  In terms of cognitive performance, the only finding was 
that BR led to a significant improvement in performance of serial 3s subtractions.  Other 
studies that have assessed the effect of BR on cognitive performance, have demonstrated 
mixed results.  Supplementation has led to improvements in reaction time on the Stroop 
task during exercise (Thompson et al., 2015), but also no effect on performance (on tasks 
including the Stroop and RVIP tasks), in the presence (Rattray et al., 2015) and absence 
of exercise in healthy older adults (Kelly et al., 2013).  Beetroot supplementation has also 
led to an absence of effects on the Stroop task under hypoxic conditions (Lefferts et al., 
2015). 
The purpose of the present study was therefore to extend the methodological 
approach used in previous chapters by measuring the haemodynamic effects of cognitive 
task performance, but introducing an element of exercise to the protocol, with the aim of 
increasing levels of demand both peripherally and centrally.  It was also anticipated that 
this methodology would further current knowledge of the peripheral and central effects of 
BR by combining exercise and cognitive function protocols, in order to determine if one 
impacts upon the other in the presence of BR.  This would be achieved through 
measurement of NIRS-related cerebral haemodynamics, cognitive function and subjective 
mental fatigue and energy levels, taken before during and after simultaneous exercise at a 
range of intensities (50 %, 70 % and 90 % VO2peak).  It was hypothesised that, in 
comparison to placebo, BR supplementation would elevate plasma nitrite levels, positively 
modulate cerebral oxygenation during exercise and at rest and improve subjective mental 
fatigue and energy levels. 
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6.2 Method 
6.2.1 Participants 
Sixteen healthy young, recreationally active male participants between the ages of 
18 and 35 (mean age 23, SD 4.1; BMI 24.2, SD 2.9) were recruited.  The study was 
approved by Northumbria University’s School of Psychology and Sport Sciences’ ethics 
committee and conducted in accordance with the Declaration of Helsinki.  Prior to 
participation, volunteers were required to sign an informed consent form.  A general health 
screen (appendix B for example) informed volunteers that they would not be eligible to 
take part if they had a history of neurological, vascular or psychiatric illness or a history or 
current diagnosis of drug or alcohol abuse.  They would also be ineligible if they had a 
current diagnosis of depression or anxiety, anaemia, high blood pressure, a heart or 
respiratory disorder, type 1 diabetes, phenylketonuria, a history of head trauma, migraines, 
learning difficulties, dyslexia or ADHD.  As blood samples would be taken as part of the 
study, volunteers were informed they would not be eligible to take part if any of the 
following applied; they had an active infection, were HIV antibody positive, they had a past 
or present diagnosis of hepatitis, had jaundice within the last year, haemophilia or any 
similar blood clotting disorder.  All participants reported that they were in good health, had 
normal or corrected-to-normal vision and had no known food intolerances or sensitivities.  
Additionally, they were not currently taking any dietary supplements or medication, were 
not colour-blind and did not smoke. 
6.2.2 Design and treatment 
A randomised, double-blind, counter-balanced, within subjects, placebo-controlled 
design was utilised.  Participants attended two study visits and at each received one of the 
following: 450 ml organic beetroot juice, containing 5 mmol nitrate (Beet It, James White 
Drinks, Ipswich, UK) and 50 ml low calorie blackcurrant cordial or placebo (50 ml low 
calorie blackcurrant cordial, 45 ml pressed apple juice and 405 ml water).  Pressed apple 
juice was added to the placebo as Beet It contains 10 % apple juice (and there was no 
interest in the effects of apple juice on performance of any of the measures in the current 
study).  Each treatment was administered in the form of a drink.  The order in which 
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participants received each treatment was determined by Latin square and random 
allocation to treatment order. 
 
6.2.3 Blood plasma nitrite levels 
 Venous blood samples were collected into lithium heparin tubes for determination 
of plasma nitrite.  Samples were centrifuged at 4000 rpm for 10 minutes at 4 °C within 3 
minutes of collection.  Plasma was collected and stored at -80 °C until further analysis for 
nitrite by chemiluminescence using the procedures described by Bailey et al. (2009).  
Samples were taken upon arrival, following the 90-minute post-treatment absorption 
period and immediately after cycling to 90 % VO2peak. 
 
6.2.4 Physiological, cognitive and mood measures 
 The present chapter formed part of a larger study and consequently data was 
collected that will not be reported here.  These included measures of electromyography 
(EMG), muscle oxygenation (via NIRS), heart rate, pulmonary ventilation, VO2, VCO2 and 
RER (via indirect calorimetry) all of which were taken during exercise performance.  Blood 
lactate and ratings of perceived exertion, which were taken before, during and after 
exercise.  Measurements of blood pressure and assessments of mood via the Brunel 
Mood Scale, which were taken at various stages before and after exercise. 
6.2.4.1 Near infrared spectroscopy measurements 
Please see chapter 2 for a full description of the NIRS method used, which is 
identical to that used in the present chapter. 
6.2.4.2 Cognitive and subjective fatigue assessment 
All cognitive measures were delivered using COMPASS.  Please see chapters 2 
and 3 for a description of COMPASS and an explanation of tasks and mood assessments 
listed here but not described in full below.  The tasks were chosen based on their ability to 
activate the pre-frontal cortex (Lawrence et al., 2002; Schroeter et al., 2002).  A response 
pad was used for participant responses to all tasks and during exercise was securely 
173 
 
mounted onto the handle bars of the cycle ergometer.  The tasks were completed once at 
baseline and four times post-dose; during a pre-exercise period, whilst cycling at 50 % 
VO2peak, whilst cycling at 70 % VO2peak and after exercise.  The tasks were identical at each 
period and followed the same order; RVIP, Stroop.  They differed only in their duration 
(baseline tasks were 2 minutes and all post dose tasks were 9 minutes).  After the 
completion of each set of tasks at each period, participants were required to complete 
subjective mental fatigue and energy level ratings. 
6.2.4.2.1 RVIP 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage of target strings correctly detected, average reaction time for correct 
detections and percentage of false alarms. 
6.2.4.2.2 Stroop 
Please see chapter 2 for a description of this task.  This task was scored for 
percentage accuracy and reaction time. 
6.2.4.2.3 Subjective fatigue 
Following completion of each set of cognitive tasks, participants were presented 
with the questions “how mentally fatigued do you feel right now” and “how energetic do 
you feel right now” and asked to rate their current state by marking a vertical line on a 100 
mm line on an A4 piece of paper with the end points labelled ‘not at all’ (left hand end) and 
‘extremely’ (right hand end). 
 
6.2.5 Procedure 
Participants were required to attend the laboratory on three separate occasions.  
The first visit was a screening session where participants were informed about the nature 
of the study, its requirements and its restrictions.  Informed consent was obtained and 
eligibility to participate was confirmed and familiarisation with the tasks to be administered 
on the study days was conducted.  At this visit participants also completed an incremental 
exercise test to determine VO2peak.  Following a 5-minute rest period, participants 
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completed 3 minutes of ‘unloaded’ (20 W) cycling, after which the work rate was increased 
by 30 W/min until volitional exhaustion.  VO2peak was determined as the highest 30 second 
mean VO2 value achieved prior to exercise termination.  The remaining two study visits 
were identical to each other, with the exception of the treatment administered.  On each 
day, participants attended the lab at 8 am following an overnight 12-hour fast.  
Participants were required to abstain from alcohol for 24 hours and they were also 
expected to avoid strenuous exercise for 24 hours prior to each assessment. In addition, 
participants were provided with a list of nitrate rich foods which they were asked to avoid 
for 36 hours prior to each visit.  Upon arrival, baseline blood plasma nitrite samples were 
taken.  Following this, the NIRS headband was fitted and NIRS recording began.  
Participants initially sat quietly for 5 minutes whilst NIRS readings stabilised, before 
making a baseline completion of the cognitive tasks, and subjective mental fatigue/energy 
level measures.  A 10-minute baseline assessment of NIRS readings were then taken 
whilst participants sat quietly and watched a non-stimulating home improvement DVD.  
Participants were then required to take their treatment for the day.  Due to the treatment 
being administered as a 500 ml drink, 10 minutes was allowed for treatment consumption.  
Following a (further) 80-minute absorption period (during which time NIRS recording 
continued whilst participants watched the DVD), participants completed a second set of 
the cognitive tasks and subjective measures.  Blood plasma nitrite samples were taken for 
a second time before the exercise test began.  During the test, participants were required 
to cycle on a cycle ergometer (Velotron, Dynafit Pro, RacerMate Inc, Seattle, USA), 
initially for 3 minutes ‘unloaded’ (20 W), followed by two, 20 minute incremental stages at 
work rates required to elicit ~50 % and ~70 % VO2peak and a final work rate corresponding 
to 90 % VO2peak which was continued to task failure (defined as a fall in pedal rate of >10 
rpm below self-selected cadence).  Whilst cycling during the 50 % and 70 % VO2peak 
stages, participants performed a set of the cognitive tasks and immediately upon 
completion of each stage, the subjective measures.  Following the 90 % VO2peak, no 
cognitive tasks were performed; however, subjective measures were still obtained upon 
completion of this stage.  A final blood plasma nitrite sample was then taken, followed by 
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a final completion of the cognitive tasks (in the absence of exercise) and subjective 
measures before participants were able to leave (see fig 6.1 for more details of procedure 
and task duration).  Participants returned for their next study visit following (at least) a 1-
week washout period. 
 
Fig. 6.1. Timeline representing flow of study day. 
 
6.2.6 Statistics 
Blood plasma nitrite was analysed by 2-way repeated measures ANOVA 
(treatment; (beetroot juice or placebo) X epoch (pre-supplementation, post-
supplementation/pre-exercise, post-exercise)).  Significant differences were further 
explored by Bonferroni adjusted pairwise comparisons. 
Prior to the primary NIRS analysis a within subjects ANOVA was carried out with 
left/right optode included as a factor to examine any treatment related hemispheric 
differences in response. As there were no interpretable interactions involving this factor 
the data from the two channels were averaged for the analysis.   
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For the primary NIRS analysis, the question under investigation was how beetroot 
juice would modulate cerebral oxygenation parameters over time as compared to placebo.  
Data for oxy-Hb, deoxy-Hb and total-Hb was averaged across 10 minute epochs during 
the absorption period and 9 minute epochs during the task period and baseline adjusted 
to the last 5 minutes of the post-task resting pre-treatment period.  Data was then 
analysed by 2-way repeated measures ANOVA (treatment (beetroot juice or placebo) X 
epoch (9 x 10 minute epochs for absorption period and 8 x 9 minute epochs for task 
period)).  Significant treatment related interactions were described with reference to a 
priori planned comparisons, where the active treatment was compared to placebo at each 
epoch utilising t tests calculated with the Mean Squares Error from the ANOVA (Keppel, 
1991).  In order to reduce the potential for Type I errors only those planned comparisons 
associated with a statistically significant difference on the initial ANOVA are reported.  In 
addition, only those instances where a consistent pattern of significant differences are 
maintained across epochs are identified as reportable significant effects. 
In order to identify if effects were specific to task performance, a further analysis 
was conducted whereby the task period was analysed alone by 2-way repeated measures 
ANOVA (treatment (as above) X task (RVIP before exercise, Stroop before exercise, 
RVIP 50% VO2peak, Stroop 50% VO2peak, RVIP 70% VO2peak, Stroop 70% VO2peak, RVIP 
after exercise, Stroop after exercise).  Planned comparisons were conducted as per 
primary analysis, documented above.  
Secondary analysis of the data focused on the task period, included exercise level 
as a factor and was aimed at assessing the effects of treatment in more detail.  This was 
achieved through the use of shorter-duration epochs in order to identify if treatment 
related effects were confined to a specific stage within the study and/or a specific time-
point within a task.  For oxy-Hb, deoxy-Hb and total-Hb, data was averaged across 3 
minute epochs within each task and baseline adjusted to the last 5 minutes of the post-
task resting pre-treatment period.  It was then analysed by repeated measures ANOVA 
(treatment (as above) X task (RVIP, Stroop) X exercise level (prior to exercise, 50% 
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VO2peak, 70% VO2peak, after exercise) X epoch (3-minute time points)).  Planned 
comparisons for secondary analysis were conducted as per primary analysis, 
documented above.   
To assess the possibility of any on-day differences in cognitive performance, 
subjective mental fatigue and energy level measures, paired samples t-tests were 
conducted on baseline data.  Any significant differences were further explored with 
Bonferroni corrected pairwise comparisons. 
Cognitive performance, subjective ratings of mental fatigue and energy levels were 
analysed as ‘change from baseline’ by 2-way repeated measures ANOVA (treatment 
(beetroot juice or placebo) X repetition (before exercise, 50% VO2peak, 70% VO2peak, after 
exercise)).  Significant treatment related effects were described with reference to a priori 
planned comparisons (as above) where the active treatment was compared to placebo. 
 
6.3 Results 
6.3.1 Plasma nitrite 
Due to missing data points and one instance of anomalous data, only 13 data sets 
are included in this analysis.   
There was a significant treatment x time point interaction, whereby plasma nitrite 
was significantly elevated pre and post-exercise following beetroot supplementation as 
compared to placebo (F (1,12)=30.96, p<0.005).  Bonferroni corrected pairwise 
comparisons revealed that post-dose/pre-exercise dietary nitrite values were significantly 
elevated as compared to placebo (p=0.001), so too were post-dose/post-exercise nitrite 
values (p=<0.01).  There was no significant difference between pre-dose dietary nitrite 
values for beetroot and placebo treatments, see fig. 6.2. 
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 Fig.6.2. Mean (and SEM) nitrite values pre-dose, pre-exercise (post-dose) and post-
exercise (post-dose) following either beetroot juice or placebo.  Treatment x time point 
effects are shown, significance is compared to placebo (**** p<0.001, ** p<0.01). 
 
6.3.2 Near infrared spectroscopy 
6.3.2.1 Primary analysis 
Effects of treatment on cerebral blood flow over time. 
6.3.2.1.1 Oxygenated haemoglobin 
 A significant main effect of treatment was observed for oxy-Hb [F(1, 240)=6.29, 
p<0.05, d=0.18] whereby beetroot juice led to significantly increased oxy-Hb overall as 
compared to placebo, see fig. 6.3a.  A significant interaction effect (treatment x epoch) 
was also observed [F(16, 240)=2.09, p<0.05].  Planned comparisons revealed that oxy-Hb 
was significantly higher following beetroot as compared to placebo during the absorption 
period at minutes 1-10 [t(240)=3.90, p<0.001, d=1.18], 11-20 [t(240)=4.92, p<0.001, 
d=1.48], 21-30 [t(240)=4.79, p<0.001, d=1.61], 31-40 [t(240)=3.60, p<0.001, d=1.14], 41-
50 [t(240)=3.64, p<0.001, d=1.0], 51-60 [t(240)=2.54, p<0.05, d=0.63], 61-70 [t(240)=2.91, 
p<0.005, d=0.63].  It was also significantly higher during RVIP 50 % VO2peak [t(240)=2.63, 
p<0.01, d=0.24] and during RVIP [t(240)=3.69, p<0.001, d=0.36] and Stroop [t(240)=5.33, 
p<0.001, d=0.56] after exercise completion, see fig. 6.4a. 
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6.3.2.1.2 Deoxygenated haemoglobin 
A significant main effect of treatment was observed for deoxy-Hb [F(1, 240)=8.24, 
p<0.05, d=-0.21] whereby beetroot juice led to a significant reduction in deoxy-Hb overall 
as compared to placebo, see fig. 6.3b.  For graph representing treatment X epoch effects 
see fig. 6.4b, there were no significant effects of this interaction. 
6.3.2.1.3 Total haemoglobin 
A significant main effect of treatment was observed for total-Hb [F(1, 240)=4.63, 
p<0.05, d=0.14] whereby beetroot juice led to significantly increased total-Hb overall as 
compared to placebo, see fig. 6.3c.  A significant interaction effect (treatment x epoch) 
was also observed [F(16, 240)=2.26, p<0.005].  Planned comparisons revealed that total-
Hb was significantly higher following beetroot as compared to placebo during the 
absorption period at minutes 1-10 [t(240)=3.55, p<0.001, d=1.18], 11-20 [t(240)=4.70, 
p<0.001, d=1.51], 21-30 [t(240)=4.65, p<0.001, d=1.53], 31-40 [t(240)=3.21, p<0.005, 
d=1.0], 41-50 [t(240)=3.33, p<0.005, d=0.92], 51-60 [t(240)=1.99, p<0.05, d=0.51], 61-70 
[t(240)=2.31, p<0.05, d=0.48].  It was also significantly higher during RVIP 50 % VO2peak 
[t(240)=2.23, p<0.05, d=0.16] and during RVIP [t(240)=3.44, p<0.001, d=0.30] and Stroop 
[t(240)=5.27, p<0.001, d=0.50] after exercise completion, see fig. 6.5. 
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Fig. 6.3 Concentration changes of (a) oxy-Hb, (b) deoxy-Hb and (c) total-Hb overall 
(absorption and cognitive task period) following placebo and beetroot supplement.  Means 
and SEM are presented as change from pre-treatment, resting baseline.  Main effects of 
treatment are shown (t-tests calculated with the Mean Squares Error from the ANOVA) (* 
p<0.05). 
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 Fig. 6.4.  Concentration changes of (a) oxy-Hb and (b) deoxy-Hb represented in 10 minute 
epochs during absorption period and 9 minute epochs during cognitive task period 
following placebo and beetroot supplement.  Means and SEM are presented as change 
from pre-treatment, resting baseline.  Treatment x epoch interaction effects are shown.  
Significance is compared to placebo (t-tests calculated with the Mean Squares Error from 
the ANOVA) (* p<0.05, ** p<0.01, *** p<0.005, **** p<0.001). 
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 Fig. 6.5.  Concentration change of total-Hb represented in 10 minute epochs during 
absorption period and 9 minute epochs during cognitive task period following placebo and 
beetroot supplement.  Means and SEM are presented as change from pre-treatment, 
resting baseline.  Treatment x epoch interaction effects are shown.  Significance is 
compared to placebo (t-tests calculated with the Mean Squares Error from the ANOVA) (* 
p<0.05, *** p<0.005, **** p<0.001). 
 
6.3.2.1.4 Further primary analysis 
Effects of treatment on cerebral blood flow during performance of individual 
tasks. 
6.3.2.1.4.1 Oxygenated haemoglobin 
There were no treatment related differences specific to task performance for oxy-
Hb.   
6.3.2.1.4.2 Deoxygenated haemoglobin 
There were no treatment related differences specific to task performance for 
deoxy-Hb.   
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6.3.2.1.4.3 Total haemoglobin 
There were no treatment related differences specific to task performance for total-
Hb.   
6.3.2.2 Secondary analysis 
Effects of treatment on cerebral blood flow during task performance using 
smaller duration (3 minute) epochs. 
6.3.2.2.1 Oxygenated haemoglobin 
 There were no treatment related differences in task performance for oxy-Hb. 
6.3.2.2.2 Deoxygenated haemoglobin 
A significant interaction effect (treatment X task X exercise level X epoch) was 
observed for deoxy-Hb [F(6, 90)=2.29, p<0.05].  Planned comparisons revealed that 
deoxy-Hb was significantly reduced across both the RVIP and Stroop tasks, before 
exercise commenced (all p<0.05), during 50 % VO2peak (all p<0.005), 70 % VO2peak (all 
p<0.05) and following exercise completion (all p<0.001), see fig. 6.6 for full details of 
significance values.   
6.3.2.2.3 Total haemoglobin 
 There were no treatment related differences in task performance for total-Hb. 
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 Fig. 6.6.  Concentration change of deoxy-Hb during cognitive task periods, represented in 
3 minute epochs following placebo and beetroot supplement.  Means and SEM are 
presented as change from pre-treatment, resting baseline.  Treatment x task x exercise 
level x epoch interaction effects are shown.  Significance is compared to placebo (t-tests 
calculated with the Mean Squares Error from the ANOVA) (* p<0.05, *** p<0.005, **** 
p<0.001). 
 
6.3.3 Cognitive performance and subjective fatigue 
6.3.3.1 Baseline measures 
Due to a data capture error, only 15 participants were included in the cognitive and 
subjective analysis. There were no significant on-day differences in cognitive performance, 
subjective mental fatigue or energy level measures prior to treatment. 
6.3.3.2 Cognitive performance 
There were no treatment related significant differences in performance on 
cognitive tasks. 
6.3.3.3 Subjective mental fatigue and energy levels 
There were no treatment related significant differences in subjective mental fatigue 
or energy level measures. 
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6.4 Discussion 
The initial findings of the study were that acute consumption of 500 ml BR led to a 
significant increase in plasma nitrite levels that were observed at 90 minutes and 
maintained at ~ 180 minutes post-dose.  In terms of cerebral oxygenation, following BR 
supplementation there was a significant increase in oxy-Hb during the first 70 minutes of 
the absorption period that was followed by a significant increase during the RVIP task at 
50 % VO2peak and post-exercise during both the RVIP and Stroop tasks, these findings 
were largely mirrored for total-Hb.  BR supplementation also led to a significant reduction 
in deoxy-Hb during performance of the RVIP and Stroop tasks pre and post exercise and 
during exercise at 50 and 70 % VO2peak.  Overall, BR supplementation significantly 
increased oxy-Hb and total-Hb and led to a significant decrease in deoxy-Hb.    
There were no effects of BR supplementation on cognition or measures of 
subjective fatigue.  
The demonstration that an acute 500 ml dose of BR leads to an elevation in 
plasma nitrite levels at 90 and 180 minutes post-consumption is a finding that has been 
documented previously and within similar time-scales (Kenjale et al., 2011; Vanhatalo et 
al., 2010; Webb et al., 2008; Wightman, Haskell-Ramsay, Thompson, et al., 2015).  In 
relation to cerebral blood flow, a principal finding of the present study was that following 
BR supplementation during exercise and concomitant performance of cognitive tasks, 
cerebral haemodynamics were modulated.  The initial change in oxy-Hb and total-Hb was 
observed during the absorption period within the first 10 minutes and lasted until 
approximately 70 minutes post-dose, when levels returned to those similar to the placebo 
treatment.  That these effects should be observed so soon following treatment suggests it 
is unlikely that they are as a direct consequence of nitrate supplementation and its 
subsequent reduction to nitrite and NO.  Previous research of the time course of dietary 
nitrate has observed that peak plasma concentrations of nitrate and nitrite have not been 
demonstrated until approximately 90 and 180 minutes post-dose, respectively (Webb et 
al., 2008).  An alternative explanation for the augmentation seen following BR could be 
the sensory properties of the drink.   Functional magnetic imaging research has 
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established that activation of the frontal cortex can occur as a direct result of the sensory 
properties of food and this has been demonstrated for different tastes (Kringelbach, de 
Araujo, & Rolls, 2004; Smits, Peeters, van Hecke, & Sunaert, 2007) as well as the valence 
of taste (its pleasant or unpleasantness) (Small et al., 2003).  This is perhaps 
corroborated by the fact that after this initial elevation, and prior to the onset of the 
cognitive and exercise interventions, the difference between the treatments for oxy-Hb, 
deoxy-Hb and total-Hb no longer remains.  In the present study, during the subsequent 
cognitive task period, the only treatment related significant increases in oxy-Hb and total-
Hb that occurred were during the RVIP task at 50 % VO2peak and once exercise had 
ceased.  Masschelein et al. (2012) studied the haemodynamic effects of 500 ml dietary 
nitrate during exercise in hypoxia using NIRS and concluded that supplementation did not 
lead to any augmentation in cerebral oxygenation levels.  However, studies that used TCD 
to measure CBF during exercise have reported significant reductions in cerebrovascular 
resistance index following 500 ml BR at 40 %, 60 % and 80 % VO2 peak (Bond et al., 2013) 
and increases in MCA Vmean following a smaller BR dose (140ml) during exercise at 70 % 
and 85 % alongside simultaneous cognitive task (Stroop) performance (Rattray et al., 
2015).  Why nitrate should lead to an increase in oxy-Hb and total-Hb during the RVIP 
task in the initial stages of exercise, in the absence of any other exercise/task related 
effect, is therefore unclear.   The only other effect of BR on oxy-Hb and total-Hb was 
observed during the recovery period, once exercise had ceased.  In the absence of 
exercise intervention, BR supplementation has been shown to increase cerebral blood 
flow at rest in healthy older adults (Presley et al., 2011) and during performance of 
mentally demanding tasks in healthy young adults (Wightman, Haskell-Ramsay, 
Thompson, et al., 2015).  The presence of an effect on oxy-Hb and total-Hb during the 
recovery period but not consistently prior to exercise performance may reflect the ability of 
BR/nitrate supplementation to modulate levels of total-Hb and oxy-Hb when it is needed 
most.  With reference to the present study; when the participant is mentally and physically 
fatigued after a bout of intense exercise and cognitively demanding tasks. 
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Turning to the effects of BR on deoxy-Hb, although there was no change in deoxy-Hb 
during the absorption period, before, during and after exercise performance there was a 
significant reduction in deoxy-Hb.  Recently a study by Aamand et al. (2013) identified that 
following dietary nitrate (in the form of sodium nitrate) a faster and smaller BOLD signal 
was observed, but only in response to visual stimuli.  It was suggested that this reflected 
enhanced haemodynamic coupling as a result of increased nitrate intake.  It is possible 
that in the present study, under similar circumstances (increased nitrate intake in the 
presence of a stimulus; with the stimulus in the current study being increasing exercise 
load and simultaneous performance of cognitive tasks), the same enhancement of 
haemodynamic coupling occurred.  In the present study this was represented by a 
reduction in deoxy-Hb in the absence of a consistent increase in oxy-Hb across the 
cognitive task period as compared to placebo. 
NIRS assessments of cerebral oxygenation during incremental exercise performance 
have observed that acute sub-maximal exercise leads to an increase in cerebral 
oxygenation in the PFC, but at maximal exercise oxy-Hb falls and deoxy-Hb increases 
(Rooks, Thom, McCully, & Dishman, 2010).  In the present study, irrespective of treatment 
during initial task performance (before exercise had begun), oxy-Hb and total-Hb were at 
levels similar to the absorption period; however, once exercise commenced cerebral 
oxygenation rose incrementally with exercise level, before dropping off once exercise had 
ceased.  Although the effects on deoxy-Hb began in the same manner, with levels during 
initial task performance similar to that of the absorption period, they then became more 
complex.   During RVIP performance at 50 % VO2peak there was an increase in deoxy-Hb 
followed by a reduction in deoxy-Hb during the second half of exercise performance 
(during Stroop) at 50 % VO2peak, which was maintained during RVIP at 70 % VO2peak, 
before peaking during Stroop at 70 % VO2peak and then dropping to levels similar to the 
onset of task performance.  This perhaps reflects a pattern of effects whereby the 
reduction in deoxy-Hb (as a consequence of the increase in oxy-Hb as task/exercise 
demands increase) is overridden when the demands of the task peak and resources are 
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required most, demonstrated by an increase in deoxy-Hb in the presence of an increase 
of oxy-Hb.  
The current study failed to demonstrate an effect of BR supplementation on 
performance of cognitive tasks.  The absence of an effect of BR supplementation on 
cognitive performance, specifically during RVIP and Stroop tasks which were used here, 
is one that has been observed previously in an older cohort (Kelly et al., 2013) as well as 
in healthy young populations (Rattray et al., 2015; Wightman, Haskell-Ramsay, Thompson, 
et al., 2015).  It could be argued this may have been due to the sensitivity of the tasks and 
their ability to detect an effect in the present study during exercise.  However, previous 
research of cognitive tasks in the presence of exercise has demonstrated that BR 
supplementation improved reaction time on the Stroop task during intermittent sprint 
performance (Thompson et al., 2015).  A further explanation could have been the overly 
demanding nature of the protocol and the excessive equipment participants were required 
to wear (ICa face mask and NIRS head band), whilst simultaneously exercising and 
completing tasks. 
There were some limitations to the present study.  Although every attempt was 
made to blind participants to the drink they were receiving it is highly likely that they were 
able to discern a difference in taste and mouthfeel of the drinks.  Further studies would 
benefit from better blinding of treatments, for example through the use of beetroot juice 
and placebo ‘shots’, which are currently available but were not at the time of testing.  
Although the integration of cognitive tasks and exercise performance was successful in 
the present study logistically, it may be that the method of delivery of the cognitive tasks 
and or the type of exercise intervention used, were not the most appropriate in order to 
obtain the most reliable results.  This is perhaps reflected by the absence of any effects 
on cognitive performance. 
Despite these limitations, the present study has demonstrated that NIRS is 
sensitive enough to detect changes in cerebral oxygenation during the performance of 
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cognitive tasks in the presence of incremental exercise and that BR supplementation via 
its conversion to nitrite can modulate these parameters.  
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Chapter 7. Discussion 
7.1 Summary of the objectives of the thesis 
 The primary aim of this thesis was to identify and validate new approaches for the 
assessment of cognitive and physiological effects of nutritional interventions.  This was 
achieved through the use of novel technologies and methodologies to expand upon 
existing knowledge of interventions and the methods by which these interventions can be 
measured.  In order to address this, Chapter 2 investigated the behavioural and 
neurophysiological effects of ginkgo and a ginkgo/ginseng combination (herbal extracts 
with vasodilating properties).  Here both electrophysiological and imaging techniques 
(EEG and NIRS) were used to measure cerebro-electrical and haemodynamic activity 
during the performance of a range of cognitive tasks.  Chapter 3 explored the cognitive 
and cerebral oxygenation effects of ginkgo further by introducing a level of mental fatigue 
to the protocol.  Chapter 4 aimed to identify the sensitivity of NIRS to assess the cognitive 
and cerebral haemodynamic effects of the vasoconstrictor caffeine in isolation and in 
combination with L-theanine.  These two compounds are commonly consumed together, 
but thought to possess disparate behavioural and physiological properties when 
consumed alone versus in combination.  Chapter 5 explored the impact of task difficulty 
on cerebral haemodynamics and whole body metabolism in the presence of two different 
doses of caffeine.  Chapter 6 introduced an exercise paradigm and explored the effects of 
beetroot juice during incremental cycling on haemodynamics and behavioural 
performance of prolonged cognitive tasks. 
 
7.2 General summary of the findings 
 The results of the studies making up this thesis have demonstrated that different 
technologies and methodologies can be implemented together successfully.  They have 
also provided meaningful contributions to existing knowledge of the central and peripheral 
impact of specific nutritional interventions.  Specifically, chapters 2, 3 and 4 demonstrated 
the sensitivity of NIRS in measuring cerebral oxygenation following the administration of 
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interventions with vasoconstrictive and vaso-relaxing properties.  In particular, that NIRS 
is sensitive enough to identify the ability of one intervention to augment another (chapter 
4).  Chapter 5 established that NIRS can be measured simultaneously with ICa and that a 
similar pattern of haemodynamic and metabolic effects is evoked during the performance 
of cognitive tasks, irrespective of treatment administered.  Finally, chapter 6 demonstrated 
that NIRS can be applied effectively during concurrent exercise and cognitive 
performance.  As well as being described in tables 7.1, 7.2, 7.3 and 7.4, a discussion of 
these findings is also included below. 
Table 7.1 Significant effects of treatment on oxy-Hb, deoxy-Hb and total-Hb during performance of cognitive tasks 
 
Measure 
 
Task 
Treatment 
180 
mg 
Gink 
360 
mg 
Gink 
207 
mg 
Gink 
207 mg 
Gink + 
207 mg 
Gins 
75 mg  
Caff 
(ch 4) 
50 mg  
L-thea 
75 mg 
Caff + 
50 mg  
L-thea 
75mg 
Caff 
(ch 5) 
150 
mg  
Caff 
500 
ml 
Beet 
 
 
 
 
Oxy-Hb 
SRT            
CRT           
Serial 3s           
Serial 7s           
Serial 13s           
Serial 17s           
Stroop           
RVIP           
3-Back           
 
 
 
 
Deoxy-Hb 
SRT           
CRT           
Serial 3s           
Serial 7s           
Serial 13s           
Serial 17s           
Stroop           
RVIP           
3-Back           
 
 
 
 
Total-Hb 
SRT           
CRT           
Serial 3s           
Serial 7s           
Serial 13s           
Serial 17s           
Stroop           
RVIP           
3-Back           
 
= not tested,    = increase/decrease during some time points within task                 
increase/decrease throughout duration of task. 
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Table 7.2 Significant effects of treatment on performance of cognitive tasks 
Task 180 
mg 
Gink 
360 
mg 
Gink 
207 
mg 
Gink 
207 mg 
Gink + 
207 mg 
Gins 
75 mg  
Caff 
(ch 4) 
50 
mg  
L-
thea 
75 mg 
Caff + 
50 mg  
L-thea 
75 mg 
Caff 
(ch 5) 
150 
mg  
Caff 
500 
ml 
Beet 
SRT           
CRT 
accuracy 
          
CRT                       
Serial 3s 
correct 
          
Serial 3s 
errors 
          
Serial 7s 
correct 
          
Serial 7s 
errors 
          
Serial 13s 
correct 
          
Serial 13s 
errors 
          
Serial 17s 
Correct 
          
Serial 17s 
errors 
          
Stroop % 
correct 
                     
Stroop RT           
RVIP % 
accuracy 
          
RVIP RT           
RVIP FA          
(acute) 
      
3-Back % 
correct 
          
3-back RT           
 
= not tested,   = increase/decrease during some time points within task            
increase/decrease throughout duration of task. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
195 
 
 
 
Table 7.3 Significant effects of treatment on subjective mood measures 
Measure 180 
mg 
Gink 
360 
mg 
Gink 
207 
mg 
Gink 
207 
mg 
Gink + 
207 
mg 
Gins 
75 mg  
Caff 
(ch 4) 
50 
mg  
L-
thea 
75 mg 
Caff + 
50 mg  
L-thea 
75 mg 
Caff 
(ch 5) 
150 
mg  
Caff 
500 
ml 
Beet 
Bond 
Lader 
Alertness           
Calmness           
Contented           
 
 
Caffeine 
research 
visual 
analogue 
scales 
Relaxed           
Alert           
Jittery           
Tired                      
Tense           
Headache           
Overall 
mood 
                        
‘Alertness’                         
‘Tension’           
Mental fatigue                                    
Concentration           
Mental stamina                         
Physical stamina                         
Mentally tired           
Physically tired           
Energetic           
 
 
 
Table 7.4 Significant effects of treatment on blood pressure and heart rate 
 180 
mg 
Ginkgo 
360 
mg 
Ginkgo 
207 
mg 
Ginkgo 
207 mg 
Ginkgo + 
207mg 
Ginseng 
75 mg  
Caffeine 
(chapter 
4) 
50 mg  
L-thea 
75 mg 
Caffeine 
+ 
50 mg  
L-thea 
75 mg 
Caffeine 
(chapter 
5) 
150 mg 
Caffeine 
Systolic 
BP 
                   
Diastolic 
BP 
                     
Heart 
Rate 
 
         
 
= not tested,   = increase/decrease during some time points within task            
increase/decrease throughout duration of task. 
 
 
7.3 The use of NIRS in the assessment of haemodynamic change during 
cognitive performance in interventional studies 
 The ability of NIRS to identify changes in cerebral oxygenation as a result of 
nutritional challenge has been validated in the current thesis following a range of different 
interventions, each known for their contrasting effects on CBF.  Chapter 2 established that 
a 207 mg dose of ginkgo attenuated the decrease in deoxy-Hb seen following placebo, 
during tasks that activate the pre-frontal cortex (Stroop, 3-back and to some extent, RVIP).  
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A similar pattern of effects was also observed in chapter 3, during performance of serial 
subtractions tasks (serial 7s and 13s) following a 180 mg but not a 360 mg dose of ginkgo.  
Following the 360 mg dose, deoxy-Hb was significantly reduced as compared to placebo.  
At the methodological level, this differential effect on deoxy-Hb is a good example of the 
sensitivity of this method to detect changes in the haemodynamic response as a 
consequence of different levels of the same active compound.  Chapter 4 highlighted that 
NIRS was also capable of detecting oxygenation changes when one intervention is 
combined with another.  A 75 mg dose of caffeine administered alone led to a significant 
reduction in oxy-Hb during simple (SRT, CRT) and complex frontal tasks (Stroop, RVIP) 
as well as a during a rest period.  This effect was abolished when the same caffeine dose 
was combined with 50 mg L-theanine (levels comparable to 1-2 cups of tea); an effect 
made more compelling by the absence of any effects when a 50 mg dose of L-theanine 
was administered in isolation.  The same study also demonstrated that the two caffeine 
containing treatments led to significant increases in deoxy-Hb (for the majority of tasks 
administered, with exceptions for each treatment, see table 7.1).  As discussed in chapter 
4, this increase in deoxy-Hb was potentially indicative of neuronal activation evidenced by 
caffeine’s propensity for neurovascular uncoupling as observed in previous fMRI studies 
(Chen & Parrish, 2009a; Perthen et al., 2008).  This is the first study to demonstrate such 
an effect using the technique of NIRS during performance of cognitive tasks.  Chapter 4 
also highlighted the ability of NIRS to detect variations within consumer groups as 
demonstrated by opposing effects of 75 mg on deoxy-Hb, irrespective of task, in habitual 
and non-habitual consumers.  The findings of chapter 5, however, were not consistent 
with those of chapter 4 with regards to caffeine’s effects on cerebral oxygenation.  
Counter to previous studies which have consistently reported a significant decrease in 
CBF following caffeine (Chen & Parrish, 2009a; Laurienti et al., 2003; Mathew & Wilson, 
1991; Rack-Gomer et al., 2009), 75 mg caffeine led to a significant increase in total-Hb 
during specific time points within the absorption period (starting at 6 minutes post-dose 
and continuing intermittently until the end of the absorption period).  This finding was 
particularly unexpected since the same dose in chapter 4 led to a significant decrease in 
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oxy-Hb, observed as early as 3 minutes post-dose.  In addition to this, neither the 75 mg 
nor 150 mg caffeine dose led to a significant change in cerebral haemodynamics during 
task performance.   Previous NIRS studies of cognitive performance in the presence of 
caffeine (including chapter 4 of this thesis) have demonstrated a significant decrease in 
oxy-Hb and or total-Hb in both the presence and absence of a corresponding increase in 
deoxy-Hb during performance of cognitive tasks (Heilbronner et al., 2015; Higashi et al., 
2004; Kennedy & Haskell, 2011; Niioka & Sasaki, 2003).  It is not abundantly clear why 
the present study failed to find an effect on CBF of these two doses, particularly since the 
doses in the aforementioned studies were either similar to or the same as those used here.  
One explanation is the decision in chapter 5 to use only habitual consumers since, in both 
the study by Kennedy and Haskell (2011) and in chapter 4 it was the non-habitual 
consumer group for whom total-Hb was decreased and deoxy-Hb was increased relative 
to placebo.  However, this does not account for the increase observed in total-Hb during 
the absorption period following 75 mg caffeine.  An alternative explanation could be that 
the 75 mg dose administered here was not enough to counteract the increase in CBF that 
is seen in habitual consumers following a period of caffeine withdrawal (Addicott et al., 
2009; Field et al., 2003).  However, when the findings in relation to placebo are 
considered, this also does not fully account for the differences observed. 
 The findings in relation to beetroot juice and its modulation of cerebral oxygenation 
go further to highlight the ability of NIRS to identify the effects of nutritional interventions, 
in this instance, one with vaso-relaxing properties.  Chapter 6 demonstrated that a 500 ml 
dose of beetroot juice led to a significant increase in oxy-Hb and total-Hb during the 
absorption period (intermittently during the first 70 minutes) and during performance of 
tasks in both the presence (RVIP) and absence (RVIP and Stroop) of exercise.  
Irrespective of epoch, it also led to a significant increase in oxy-Hb and total-Hb overall.  In 
terms of deoxy-Hb, beetroot caused a significant reduction during the entire task period 
(RVIP and Stroop) and before, during and after exercise at 50 and 70 % VO2peak, as 
compared to placebo.  There was also a significant reduction in deoxy-Hb overall, as 
compared to placebo, irrespective of epoch.  As discussed in chapter 6, the increases 
198 
 
observed during the absorption period are most likely related to the sensory properties of 
the drink, therefore of most interest here are the haemodynamic effects during 
performance of cognitive tasks.    Prior to and during exercise, the only effect observed in 
relation to oxy-Hb and total-Hb was a significant increase at 50 % VO2peak during the RVIP 
task.  Previous research of BR supplementation (doses equivalent to and less than those 
used here) has demonstrated that during exercise at 40, 60, 70, 80 and 85 % VO2peak, 
cerebrovascular resistance index CRI is reduced and middle cerebral artery mean blood 
velocity MCA Vmean is elevated (Bond et al., 2013; Rattray et al., 2015), but only at 70 
and 85 % VO2peak during the simultaneous performance of the Stroop task (Rattray et al., 
2015).  The absence of any further changes in oxy-Hb or total-Hb in the present study 
during simultaneous exercise/cognitive task performance may therefore relate to the 
specifics of the methodology used, since in the study by Rattray et al. (2015) cycling was 
conducted for only 8 minutes with the Stroop task completed over the last 3 minutes of 
this exercise bout and not throughout.  Based on previous research therefore, a protocol 
with a shorter bout of intense exercise and or a reduced cognitive workload may have 
been more successful in eliciting an effect of this measure.  Interestingly once exercise 
had ceased oxy-Hb and total-Hb were significantly elevated once more during the RVIP 
task and also the Stroop task.   This may reflect the ability of BR to augment cerebral 
oxygenation when it is needed most, in this case at the onset of simultaneous exercise 
and cognitive performance and then following extended periods of physical and mental 
fatigue.   Turning to the effects on deoxy-Hb, here a consistent decrease during task 
completion prior to, during and after exercise following BR supplementation, may 
represent enhanced haemodynamic coupling (Aamand et al., 2013).  It also demonstrates 
the capacity of the method adopted to detect modulation of cerebral haemodynamics in 
physiologically and cognitively demanding circumstances following nutritional intervention. 
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7.4 Integration of technologies in the assessment of nutritional interventions 
during cognitive challenge 
 One of the main aims of the current thesis was to identify technologies that could 
be used together in the assessment of nutritional interventions and their effects upon 
cognition.  Chapter 2 aimed to do this through the integration of NIRS and EEG in the 
assessment of two herbal extracts that had previously been shown to modulate EEG.  The 
intention being, that inclusion of NIRS would elucidate any haemodynamic effects of the 
extracts, whilst contributing to the understanding of the changes observed via EEG.  
Although EEG and NIRS were measured within the same study, it was not possible in the 
current thesis to integrate the two methods and simultaneously monitor both, despite this 
being the initial intention.  This was primarily due to the equipment available not allowing 
both devices to be secured to the head at the same time, without impacting on the quality 
of the data. 
Chapter 5, however, was more effective in this respect and the successful 
integration of NIRS with ICa led to some interesting findings, albeit irrespective of the 
treatment administered.  The subjective difficulty scales participants completed following 
each task revealed that numerically, participants found the least difficult task the control, 
followed by serial 3s, serial 7s, serial 17s and 3-back with RVIP rated as the most difficult.  
However, despite this, the assessments of cerebral oxygenation and metabolism during 
task performance revealed a different pattern of effects to the subjective assessment and 
a similar pattern of effects to each other.  The serial subtraction of 3s, 7s and 17s led to 
significantly greater increases in oxy-Hb and total-Hb compared to the control and 
correspondingly the smallest numerical reductions in deoxy-Hb.  The 3-back and RVIP 
task, however, were at levels similar to that of the control.  The same subtraction tasks 
(serial 3s, serial 7s and serial 17s) also led to significantly greater increases in energy 
expenditure and numerically greater carbohydrate oxidation, compared to control.  Once 
again, the 3-back and RVIP tasks were at levels more comparable to that of the control 
task.  Furthermore, the cognitive demands of the task were nicely demonstrated in the ICa 
data by comparing the metabolic effects of serial 3s to the somatically matched control.  
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These findings are a good example of how integrating technologies can provide a new 
insight into the physiological effects of task performance.  They also demonstrate how 
simultaneous assessments can validate the observed effects of each measure. 
7.5 Integration of methodologies in the assessment of nutritional 
interventions during cognitive performance 
7.5.1 Manipulating cognitive demand/fatigue 
 Chapter 3 used cognitive tasks to manipulate the level of cognitive demand and by 
consequence the level of fatigue experienced by participants.  This was achieved through 
the repeated administration of a block of tasks previously identified as being the most 
subjectively difficult within the COMPASS testing battery (Wightman, 2013).  It was 
anticipated that this method would protect against any ceiling effects likely to occur.  It 
would also highlight any behavioural and or physiological effects of the nutritional 
intervention (in this instance ginkgo) in the healthy young population being assessed.  
Unfortunately, however, no clear effects resulting from the manipulation of demand/fatigue 
were observed on behavioural performance.  As discussed in chapter 3 this may be due 
to the tasks not being difficult or fatiguing enough to elicit an effect.  However, this does 
not seem the most probable explanation since this approach (using similar but fewer tasks 
than those used in the aforementioned chapter), has previously been observed to elicit 
effects in the presence of a range of interventions (Kennedy & Scholey, 2004; Reay et al., 
2005, 2006; Scholey et al., 2009).  An alternative explanation is that repeated 
administration of this particular set of tasks was in fact found to be too demanding, leading 
participants to essentially ‘give up’ and thereby inadvertently removing the level of 
demand all together.    It should be noted that the tasks followed a 90-minute absorption 
period during which participants were required to wear the NIRS headgear and restrict 
body movement.   It seems, therefore, even more plausible that they may have found the 
entire testing period overly fatiguing and consequently disengaged in the tasks.  With 
regards the absence of an effect on cerebral oxygenation, the purpose of the repeated 
use of demanding tasks was to create an environment whereby any potential increase in 
CBF would be more readily apparent.  Unfortunately following ginkgo supplementation, 
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this was not the case.  Although changes in deoxy-Hb were observed, they were not as a 
consequence of the level of demand but of the dose administered.  The 180 mg led to an 
increase and the 360 mg dose lead to a decrease in deoxy-Hb overall during individual 
task performance, irrespective of task repetition.  This finding may also be explained by an 
unwillingness to engage once consistent repetition of tasks became too 
demanding/fatiguing.  Or, it may simply reflect that in young, healthy populations such as 
in the present study, CBF is not readily augmented as a consequence of demand.  
Chapter 5 aimed to measure the effects of cognitive demand in a different way, through 
the concomitant assessment of metabolism via ICa during performance of tasks with 
increasing ratings of subjective difficulty and mental fatigue.  This study was more 
successful in its approach and demonstrated that measuring energy expenditure during 
the performance of cognitive tasks allowed not only the identification of those that were 
the most metabolically demanding, but also those that were the most cognitively 
demanding.  Here, simultaneous measures of cerebral oxygenation (via NIRS), and 
metabolism (via ICa), identified the same serial subtraction tasks as requiring the most 
resources, both cognitively and physiologically.  This study also highlighted that subjective 
ratings of the level of demand/difficulty of a task may not always be the most reliable 
method of assessment of this measure.  Here the tasks rated as the least subjectively 
difficult led to increases in energy expenditure, oxy-Hb and total-Hb that were significantly 
greater than the control task and those that were identified as the most subjectively 
difficult (3-back and RVIP) led to changes in cerebral oxygenation and metabolism that 
were more in keeping with the control task.  It may be that what defines the ‘difficulty’ or 
level of ‘mental fatigue’ of a cognitive task is much more complex than the ratings a 
subjective measure can convey. 
7.5.2 Exercise, cognitive demand and fatigue 
 Chapter 6 introduced exercise to the protocol in an attempt to increase the 
demand/fatigue placed on participants during performance of cognitive tasks in the 
presence of BR juice.  The foremost indication of the impact of exercise can be seen in 
figures 6.4 and 6.5 where the effects of incremental exercise are clearly demonstrated 
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across oxy-Hb, deoxy-Hb and total-Hb.  Following placebo, prior to exercise during 
cognitive performance, both oxy-Hb and total-Hb are at levels comparable to those during 
the absorption period.  However, once exercise begins, the levels increase in line with 
intensity of exercise, before dropping off once exercise has ceased.  The effects on 
deoxy-Hb, however, are more complex.  There is an initial increase in deoxy-Hb in 
response to exercise performance at 50 % VO2peak, an effect which is potentially as a 
result of the concomitant increase seen in oxy-Hb, since there is an attenuation of the 
increase in deoxy-Hb during the second half of exercise performance at 50 % VO2peak and 
the first half performance at 70 % VO2peak.  This effect is subsequently overridden in the 
second half of performance at 70 % VO2peak (during the Stroop task) where once again 
there is an increase in deoxy-Hb.  This final increase in deoxy-Hb may be due to 
demand/fatigue being at its highest at this point – at the end of an intensive exercise bout 
and accompanying cognitive load.  However, some of the most interesting findings of this 
chapter in relation to exercise, cognitive demand and fatigue, were from the effects on 
cerebral oxygenation in the presence of BR.  Of most significance were those on deoxy-
Hb, since there was a consistent pattern of significant effects across the entire cognitive 
testing period in both the presence and the absence of exercise.  Here BR led to a 
significant decrease in deoxy-Hb as compared to placebo.  This decrease was consistent 
and sustained throughout exercise at intensities of 50 % and 70 % VO2peak during the 
RVIP and the Stroop tasks, as well as prior to and once exercise had ceased.  As 
previously discussed, it is suggested that this is demonstrative of enhanced 
haemodynamic coupling in the presence of a stimulus as a result of nitrate 
supplementation (Aamand et al., 2013).  That NIRS was capable of identifying an effect of 
BR supplementation in the presence of incremental exercise during the performance of 
cognitive tasks is particularly relevant here.  It demonstrates the ability and sensitivity of 
this technique to detect exercise-related manipulation of demand/fatigue during cognitive 
performance in the presence of an intervention.  Unfortunately, the present study revealed 
no effects of BR on behavioural performance in the presence of incremental exercise.  
However, the research to date pertaining to the effects of BR on performance of RVIP and 
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Stroop tasks administered here could be described as equivocal.  Previous research has 
documented positive effects in the presence of exercise (Thompson et al., 2015) as well 
as an absence of effects both with (Rattray et al., 2015) and without exercise (Kelly et al., 
2013; Wightman, Haskell-Ramsay, Thompson, et al., 2015).   
 
7.6 Cognitive and mood effects of nutritional interventions 
Ginkgo is a herbal extract that has led to a number of improvements in behavioural 
performance.  Those that are of relevance to findings in the present thesis include 
sustained attention, speed of performance on attentional tasks, reduction in errors in 
performance of a serial 3s task, an increase in the number of correct responses made on 
a serial 7s task and improvements in feelings of alertness and contentment (Elsabagh et 
al., 2005; Kennedy et al., 2000, 2002).  However, the only behavioural effects of ginkgo in 
isolation in the current thesis, were observed in chapter 3 following a 180 mg dose, where 
administration led to a reduction in the number of serial 13s errors.  This is despite 360 
mg (the same dose as administered in chapter 3) having been identified from a series of 
previous ginkgo assessments as the most beneficial in terms of its acute effects on 
cognition and mood in healthy young populations (Kennedy et al., 2002).  One potential 
explanation for the limited findings is the short duration of the absorption period in chapter 
3 and therefore the times at which testing took place.  Previous ginkgo research identified 
that despite initial testing taking place 1-hour post-dose, the first behavioural effects in 
terms of speed of attention and mental arithmetic were observed at 2.5 hours and were 
still apparent at 4 and 6 hours post-dose (Kennedy et al., 2000, 2002).  Practical 
limitations with continuous wave NIRS mean that removing the headband during testing is 
not possible.  Consequently, the duration of a testing session must be carefully 
considered to avoid discomfort to participants.  As previously discussed, the relative 
absence of effects in chapter 3 may also have been due to the increased cognitive 
demand placed on the participants, thereby masking any effects of treatment.  
Unfortunately, the explanation of demand does not extend to chapter 2 where a 207 mg 
ginkgo dose also failed to modulate behavioural performance as there was no extra 
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demand placed on the participant as a result of repeated administration of tasks, since 
they were only required to complete the tasks once.  However, the explanation in terms of 
timing of post-dose session may be of more relevance since here, although testing began 
at 2.5 hours it only continued until just under 3 hours post-dose. 
In chapter 2, 207 mg ginkgo was combined with 207 mg ginseng and this 
combination led to a significant increase in the number of RVIP false alarms following an 
acute dose.    This was the first study to assess the behavioural effects of a combination 
of ginkgo and ginseng at these doses.  The absence of any further findings than those 
reported here may be a reflection of the ratio of extracts used, and/or the comparatively 
low doses to previous research.  Cognitive effects of this combination have been reported 
following doses of 120 mg ginkgo/200 mg ginseng, 240 mg ginkgo/400 mg ginseng, 360 
mg ginkgo/600 mg ginseng (Kennedy et al., 2001a, 2002); in each case the ratio used has 
been more in favour of ginseng as opposed to ginkgo.  It may also arise from the timings 
of post-dose testing since the majority of behavioural effects have been reported at  4 or 6 
hours post-dose, with findings reported 1 and 2.5 hour(s) post-dose but only following the 
highest 960 mg combination (Kennedy et al., 2001a, 2002).   
 In chapters 4 and 5 the administration of caffeine in isolation at doses of 75 mg 
and (in chapter 5) 150 mg, led to fewer effects than perhaps expected given the known 
positive effects of caffeine on reaction time and vigilance (Childs & de Wit, 2006; Haskell 
et al., 2008b; Haskell et al., 2005; Quinlan et al., 2000; Rogers et al., 2008; Smit & Rogers, 
2000).  These effects have been observed across a range of studies and at similar doses 
and (in some instances) during the same tasks as those administered in chapters 4 and 5.  
Here, however, caffeine only led to a significant reduction in choice reaction time (largely 
as a result non-habitual caffeine consumers) and significantly improved performance 
accuracy on the Stroop task.  Both effects were observed in chapter 4 and as a 
consequence of the 75 mg dose.  That caffeine should lead to a reduction in reaction time 
and improve performance on what is largely an attentional task would therefore be as 
expected.  As discussed previously, the absence of treatment effects on cognition in 
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chapter 5 is not entirely unexpected as tasks were selected based upon their potential to 
induce differing levels of metabolic demand, rather than their sensitivity to caffeine.  
Therefore, the absence of an effect during specific tasks previously sensitive to caffeine, 
may have been due to the demanding paradigm employed.  In terms of the effects on 
mood, once again it was the 75 mg dose that led to the most prevalent effects; however, 
there were differences across the two studies despite the same dose and the same 
subjective assessment of mood being used in each.  In chapter 4 the 75 mg dose led to a 
significant reduction in subjective ratings of tiredness and a significant increase in overall 
mood and ratings on the alertness factor.  These subjective effects were not observed in 
chapter 5, even though the same 75 mg dose and caffeine research analogue scales 
were administered.  However, the absence of an effect in terms of alertness may relate to 
the small sample size for this measure.  In this chapter, the 75 mg and 150 mg dose of 
caffeine led to a significant reduction in subjective ratings of mental fatigue, with the 75 
mg dose also leading to a significant increase in subjective ratings of mental and physical 
stamina.  Once again that doses of 75 mg and 150 mg should lead to improvements in 
mood is consistent with previous caffeine research.   
Chapter 4 also assessed the cognitive effects of a 50 mg dose of L-theanine.  At 
this dose L-theanine led to a significant increase in performance accuracy on the Stroop 
task that was irrespective of caffeine consumer status.  Previous L-theanine research has 
tended to report decrements or an absence in effects on behavioural performance, 
therefore this study is the first to report a positive effect on performance of the Stroop task.  
This may be due to the lower dose used here, as previous studies have tended to use 
doses that are much higher, of between 100 mg and 250 mg.  There was also an effect of 
the combination of these two interventions.  Studies that have assessed the combination 
of caffeine and L-theanine have observed improvements on a number of tasks that were 
not seen when each treatment was administered in isolation.  Here 75 mg caffeine and 50 
mg L-theanine together led only to a significant decrease in choice reaction time, an effect 
that was dependent upon consumer status since it was only observed in the non-habitual 
caffeine consumer group.  Previous research has documented positive effects of this 
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combination on the same tasks as administered in this chapter (such as SRT, RVIP, 
alertness, tiredness, mental fatigue and headache ratings), meaning the relative paucity of 
effects observed here was unexpected.  However, the majority of these studies used 
higher does and ratios more in favour of L-theanine than caffeine and this may explain the 
comparative lack of effects seen here as a result of this combination. 
In chapter 6 the behavioural effects of 500 ml of BR were measured.  In this study, 
however, no significant effects were observed on cognitive performance in the presence 
or absence of exercise and no effects on measures of subjective fatigue.  Positive effects 
on cognitive performance during exercise such as those in the aforementioned study have 
only been demonstrated in one study to date (Thompson et al., 2015), other assessments 
of BR have reported no effects of cognitive performance in the presence (Rattray et al., 
2015) as well as the absence of exercise (Kelly et al., 2013; Wightman, Haskell-Ramsay, 
Thompson, et al., 2015). 
Cognitive and mood effects have been demonstrated in the present thesis as a 
result of the majority of the interventions assessed.  It could be argued, however, that the 
number of findings are relatively modest for interventions that have previously reported 
relatively robust behavioural effects, in particular caffeine.  This may be due in part to the 
relatively demanding nature of each protocol in that most required participants to remain 
seated for a lengthy period of time, during long absorption and cognitive tasks periods, 
wearing head gear that may have begun to feel uncomfortable.  These factors may also 
have contributed to the general paucity of effects observed. 
 
7.7 Concomitant changes in physiological and behavioural parameters 
following nutritional intervention 
 One of the main aims of the current thesis was integration of technologies and/or 
methodologies in the presence of nutritional interventions.  The purpose of this aim was to 
identify cognitive and physiological benefits and assess the ‘bigger picture’ in relation to 
the means by which these effects may occur.  There are 3 instances within this thesis 
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where a positive effect on behaviour is associated with a concomitant modulation of 
cerebral oxygenation in the presence of a nutritional intervention.   In chapter 3, the 
significant reduction in the number of false alarms during the serial 13s subtraction task 
occurred in the presence of a significant increase in deoxy-Hb.  Previous observations of 
increases in deoxy-Hb (in the presence of an increase in oxy-Hb) following interventions 
known to increase CBF have led authors to suggest that this may be indicative of 
increased oxygen extraction and utilisation (Bonoczk et al., 2002; Kennedy, Wightman, et 
al., 2010).  It is possible that here, the increase in deoxy-Hb following the 180 mg dose of 
ginkgo also reflects an increase in oxygen extraction (in the absence of oxy-Hb), leading 
to the improvement in task performance seen.  The two further concomitant changes in 
cerebral oxygenation and behaviour occurred in chapter 4 as a result of the 75 mg 
caffeine dose.  In this study a significant reduction in CRT and improvement in Stroop 
performance accuracy were observed alongside significant reductions in oxy-Hb, with a 
concomitant increase in deoxy-Hb during performance of the Stroop task only.  The 
increase in deoxy-Hb observed during the Stroop task in the presence of significantly 
reduced oxy-Hb, is reflective of caffeine’s known ability to uncouple the relationship 
between CBF and oxygen consumption, by reducing blood flow but increasing oxygen 
consumption in response to task stimulation (Chen & Parrish, 2009a; Perthen et al., 2008).  
Once again the findings in relation to the Stroop task in particular may be indicative of 
increased oxygen extraction, which in the current context has translated as an 
improvement in Stroop performance.  Unfortunately, there were no further associated 
effects on cerebral oxygenation and behavioural parameters.  Changes in cerebral 
oxygenation were frequently observed in the absence of any change in behavioural 
performance and vice versa (although this was much less common). 
 
7.8 Potential methodological limitations 
 Despite the novel and interesting findings observed as a consequence of the 
studies that make up this thesis, there were a number of methodological limitations that 
should be addressed. 
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 Chapter 2 presented the findings from the initial NIRS study within this thesis; 
however here, unfortunately, no baseline NIRS measure was made in the absence of 
treatment, an omission that also extends to the cognitive performance measures.  The 
CW-NIR technology used in the current thesis is one whereby the readings obtained are 
not absolute values, but are concentration change values.  In functional studies that 
include an intervention, the baseline measure is generally in the absence of treatment 
(Kennedy & Haskell, 2011; Kennedy et al., 2016; Kennedy, Wightman, et al., 2010; 
Wightman, Haskell-Ramsay, Reay, et al., 2015; Wightman, Haskell-Ramsay, Thompson, 
et al., 2015; Wightman et al., 2012).  However, the baseline data obtained in this study 
was after treatment had been administered.  Therefore, any early effects of treatment may 
have already occurred, potentially diluting any treatment related findings as a 
consequence.  There is also the possibility that they were missed altogether.  With 
regards to the cognitive performance data, on-day differences in cognitive performance 
were not accounted for either in chapter 2.  This was rectified in chapter 3 and the 
remaining 3 experimental chapters where baseline measures of cerebral oxygenation and 
cognitive performance in the absence of treatment were taken. 
The methodological approach of using the continuous repetition of cognitive tasks 
and incremental exercise in order to increase the level of demand experienced by the 
participants was adopted in chapters 2 (ginkgo) and 6 (beetroot) respectively.   
Unfortunately, however, neither paradigm was successful in prompting an effect of 
treatment on cognitive performance.  It is possible that the treatments administered and 
the doses selected were simply not capable of eliciting an effect.  However, it is also 
possible that the demand required of the participants was too high.  The use of the CDB 
within interventional studies has demonstrated how this approach (i.e. the use of demand) 
can be successful (Kennedy & Scholey, 2004; Reay et al., 2005, 2006; Scholey et al., 
2009).  Although the number and type of tasks used in chapter 3 was based upon the 
CDB, a more demanding schedule was presented.  This was achieved through the use of 
more difficult versions of serial subtractions (7s, 13s and 17s as compared to 3s and 7s).  
Plus, the addition of 2 further tasks to each ‘block’ (albeit leading to completion of each 
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block within a very similar time frame of 10 minutes here, as compared to 9 minutes for 
CDB).  This increase in difficulty, coupled with the extensive duration of each study visit, in 
addition to the equipment participants were required to wear, may have been overly 
demanding and participants may have, in effect, given up.  One method of addressing this 
in the future would be to marginally reduce the level of demand experienced by limiting 
the number of tasks and/or the number of times participants are required to repeat those 
tasks.  Another approach would be to use interventions with shorter absorption periods to 
avoid any additional means of tiring participants. 
The completion of baseline cognitive tasks immediately prior to the pre-treatment, 
resting NIRS baseline measure is an approach adopted throughout the thesis from 
chapter 3 onwards.  Following analysis of chapter 3, the carryover effects of cognitive 
performance on cerebral oxygenation were controlled for by using the last 5 minutes of 
the 10-minute baseline reading (chapters 5 and 6) or including a rest period prior to the 
baseline measure (chapter 4).  However, the time taken for CBF to return to resting values 
after a cognitive challenge is not one that can be readily determined when taking 
individual differences into account.  This coupled with the fact that CW-NIRS does not 
provide absolute quantifiable values, means there is no clear indication when oxygenation 
parameters have returned to values that reflect rest.  Therefore, future studies may benefit 
from measuring pre-dose, baseline NIRS values at the beginning of the study session 
(after a seated rest), rather than post-task, to avoid any carry over effects of those tasks. 
 
7.9 Future research 
Research into the methods by which nutritional interventions can be assessed 
would benefit from addressing some of the methodological limitations as identified 
previously as well as considering other issues in future research. 
 One of the most interesting findings within the current thesis was the concomitant 
effects observed on cerebral oxygenation and metabolism (energy expenditure) when 
NIRS was measured alongside ICa during cognitive task performance (chapter 5).  It is 
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unclear why this effect occurred in the absence of treatment when caffeine is known to 
impact both CBF and metabolism.  However, future research would benefit from using this 
protocol to assess the impact of other interventions, particularly those known to increase 
CBF.  Furthermore, with the identification that ICa measures detect not only the somatic 
effects of a task but also those of a cognitive nature, the inclusion of an element of 
demand to the protocol would also be of interest.  This could be achieved through the 
repeated administration of tasks (taking into consideration factors described within 
methodological limitations) in order to determine the impact upon metabolism.  
The finding from chapter 4 that a 50 mg dose of L-theanine administered in 
combination with 75 mg dose caffeine attenuated the oxy-Hb effects of 75 mg caffeine 
alone, also requires further investigation.  At the end of testing the effect of this 
combination could still be seen on oxy-Hb and future research should be aimed at 
determining how long this is sustained for.  This is particularly relevant since modulation of 
CBF as a consequence of caffeine has been seen as long as 90 minutes post dose (albeit 
following a larger, 250 mg dose than administered here) (Mathew & Wilson, 1985).  It 
would also be pertinent to observe the impact of different doses.  Previous research has 
documented a synergistic effect of L-theanine and caffeine on cognitive performance at 
higher doses and at ratios more in favour of L-theanine to that which was administered in 
the present study.  It would therefore be of interest to determine if the effects of this 
increased dose/ratio also extend to cerebral haemodynamics. 
 
7.10 General Conclusions 
The aims of this thesis were 3-fold, the first being the identification of technologies 
that could be used alone or together in the novel assessment of nutritional interventions 
and their effects upon cognition.  Each chapter addressed this aim in its own way, with the 
common theme throughout each being the application of the technique of NIRS (in the 
presence or absence of another technology).  Chapters 2-6 demonstrated that NIRS is 
sensitive enough to detect changes in cerebral oxygenation following administration of 
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nutritional interventions known for their differing effects on CBF.  Chapters 2 and 3 of this 
thesis were the first to use this technology to measure the acute effects of ginkgo on CBF 
and observe differences in the effects on deoxy-Hb as a function of dose.  Chapter 2 was 
also the first study to demonstrate that the chronic administration of a ginkgo and ginseng 
combination leads to modulation of cerebro-electrical activity.  Chapter 4 represented the 
first study to utilise NIRS in the assessment of L-theanine and an L-theanine and caffeine 
combination (interventions identified as having synergistic effects on cognitive 
performance when administered together).  This study demonstrated that there are also 
differences in cerebral oxygenation when these two interventions are administered alone 
and in combination.  The simultaneous measurement of NIRS and ICa in chapter 5 to 
identify the haemodynamic and metabolic impact of tasks of differing subjective difficulty, 
successfully demonstrated how two technologies can be effectively used together.  Not 
only did this allow an assessment of the ‘bigger picture’, it also provided a more 
comprehensive understanding of an outcome as compared to one measure alone.  
Irrespective of treatment, the findings in relation to oxy-Hb and total-Hb were confirmed by 
those on energy expenditure.  Here, the same tasks (serial subtractions) lead to increases 
across measures (NIRS and ICa) and a relative absence of an effect (when compared to 
the control task) during 3-back and RVIP across measures.  Furthermore, the tasks 
requiring the most resources were not those with the highest subjective difficulty rating, 
leading to the conclusion that subjective measures of difficulty may not always be that 
accurate in identifying the level of peripheral and central resources required of a task.  
Chapter 5 also revealed that the cognitive demands as well as the somatic demands of a 
task are measured via ICa since energy expenditure was significantly elevated during 
serial 3s subtractions as compared to the control task, despite being somatically matched. 
 The second aim was to identify methodologies that could be implemented 
concomitantly during the assessment of interventions of interest to cognition.  
Unfortunately, in chapter 2 the approach of using demand as a tool (in the presence 
ginkgo) to provide an opportunity to enhance performance (or protect against decrements 
in performance) was unsuccessful.  This may have been due to an overly demanding 
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protocol and future studies may be more successful in using a less demanding cognitive 
approach, as this method has proved effective previously.  The use of exercise as a 
means of increasing demand led to more positive findings, however.  In chapter 6, 
cerebral haemodynamics were augmented as a result of incremental exercise and the 
administration of beetroot juice led to a significant reduction in deoxy-Hb before during 
and after exercise performance.  However, there were no behavioural effects as a 
consequence of increased demand in the presence of BR supplementation. 
The third aim of this thesis was to expand the current knowledge base on the 
ability of specific nutritional supplements to benefit cognitive and physiological 
performance.  The findings of chapter 2 and 3 revealed that the haemodynamic effects of 
ginkgo administration may be dependent upon dose.  Acute administration of a ~200 mg 
and 180 mg dose of ginkgo led to a significant attenuation of the decrease in deoxy-Hb 
seen following placebo during the performance of tasks that activate the pre-frontal cortex.  
However, a 360 mg dose led to an opposing effect, whereby deoxy-Hb was significantly 
reduced.  This is the first study to document an effect of dose on cerebral haemodynamics 
following acute ginkgo administration.   In chapter 4, the significant reduction in oxy-Hb 
observed during task performance following 75 mg caffeine, was abolished when it was 
administered in combination with 50 mg L-theanine (doses equivalent to 1-2 cups of tea).  
This was despite no effects on this measure when L-theanine was administered in 
isolation.  This finding is a similar pattern of effects to those observed on blood pressure 
(Rogers et al., 2008) and contributes to caffeine/L-theanine research of a synergistic 
effect between these two interventions.  Chapter 6 demonstrated that BR supplementation 
can modulate cerebral haemodynamics during cognitive performance in the presence and 
absence of incremental exercise.  Here BR led to a significant reduction in deoxy-Hb as 
compared to placebo during performance of all cognitive tasks and a significant increase 
in oxy-Hb and total-Hb at the beginning of exercise and following exercise completion. 
 
The main findings of this thesis are therefore: 
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• That NIRS is sensitive enough to detect changes in cerebral oxygenation as a 
result of nutritional challenge; following differing doses of the same intervention; as 
a result of the synergistic effect of two different interventions and during 
incremental exercise whilst performing cognitive tasks. 
• The identification that NIRS and ICa can be measured concomitantly and are 
effective in simultaneously determining the somatic and cogntive demands of a 
task, irrespective of treatment. 
• That that this is the first study to demonstrate that caffeine administration leads to 
an increase in energy expenditure and carbohydrate oxidation during cogntive 
performance. 
• That L-theanine administered at a dose comparable to 1-2 cups of tea antagonises 
the effects of caffeine in isolation on oxy-Hb.  
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Appendix A 
 
 
    PARTICIPANT INFORMATION. 
TITLE OF PROJECT: __ Investigation of the acute effects of two doses of Ginkgo 
biloba on cerebral blood flow cognitive performance and mood. 
Participant ID 
Number:  
 
 
Principal Investigator: __Fiona Dodd________________ 
Investigator contact details:     Email: fiona.dodd@unn.ac.uk 
This project is funded by: BPNRC 
Number of participant points / payment: £72 
INFORMATION TO POTENTIAL PARTICIPANTS 
1. What is the purpose of the project? 
Ginkgo biloba is a common dietary supplement that has been taken historically to enhance 
alertness, is recognised as safe and can be obtained from most health food shops.  The aim 
of the proposed study is to assess the effects of single administration of two different doses of 
Ginkgo biloba on cerebral blood flow, cognitive performance and mood, in comparison to 
placebo.  Cerebral blood flow will be measured using Near Infrared Spectroscopy (NIRS).  
NIRS involves wearing a non-invasive headband across the forehead that uses light emission 
and absorption to measure blood flow (see diagram below).  Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with others if you wish. Ask if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
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2. Why have I been selected to take part? 
You have been selected because you are a healthy adult aged 18-40 years. You have 
indicated that you are healthy, do not habitually smoke (more than 3 cigarettes a day), are not 
currently taking any prescription or over-the-counter medicines (excluding the contraceptive 
pill) or illicit social drugs and you are not currently taking any dietary or herbal supplements. 
You are proficient in English equivalent to a native English speaker.  
 
3. What will I have to do? 
You will need to attend the laboratory on four separate days, each separated by a 1 week 
period. The first time will be for screening/training, the following three visits will be treatment 
visits. On each of these treatment visits you will attend the laboratory around midday, and 
remain in the lab for approximately 3.5hours (see below).   
 
Screening/Training Visit: At the screening visit you will be screened by the researcher to 
confirm your eligibility to take part in the study and undergo training on the computer tasks. 
The format of the session will be the same as for the testing sessions. The tasks will last for 
approximately 30 minutes and will assess attention and performance; they do not measure 
any aspect of intelligence or personality. You will complete the tasks 3 times in order to 
familiarise yourself with them. You will also be asked to complete some mood scales. 
Demographic data such as height and weight will also be taken.  Before leaving you will be 
provided with a food diary.  This visit will take approximately 1.5 hours.  
 
Study visit 1: This will take place after the initial screening/training visit. Upon arrival you will 
meet with the researcher and confirm your compliance to any study restrictions and hand in 
your completed food diary which will document what you have had for breakfast that morning. 
If you usually have a cup of tea or coffee in the morning you must consume this 1.5 hours 
before testing.  You should have your breakfast and coffee or tea (if you normally consume it) 
1 hour and 30 minutes prior to your study visit.  You will then have your blood pressure and 
heart rate taken and complete a set of mood scales and following this will be provided with a 
light snack (a choice of cheese or ham sandwich).  The NIRS headband will then be fitted 
across your forehead in order for brain activity to be monitored (please see section 1 for 
further information regarding how the NIRS is used to measure your brain activity).  You will 
then begin the cognitive tasks, which will provide your baseline performance for the day 
(identical to those completed on your training day and will take approximately 20 minutes).  
Once you have completed the tasks the NIRS will begin recording and you will have a 10 
minute rest period where you will be required to sit quietly.  Following this you will be given 
your treatment to take for the day.  You will then remain in the testing laboratory with the 
headband on for a further 90 minutes whilst readings are taken at rest (you will watch a DVD 
during this time).  Following this period you will complete six repetitions of the same battery of 
tasks.  You will then have your blood pressure and heart rate taken and complete a set of 
mood scales for the second time.  The procedures will be conducted by appropriately trained 
staff. All procedures have been risk-assessed. Should the tests reveal an abnormality (where 
recognised clinical guidelines regarding test results exist) the researcher will recommend to 
you that you seek further medical advice from your GP, bear in mind though that a single test 
may not always provide an accurate reflection of your health status.  The whole visit will last 
approximately 3.5 hours. 
Study visits 2 and 3 will be exactly the same as visit 1 apart from the treatment that is 
received. 
• You will need to turn up at the laboratory promptly on the agreed days and at the 
agreed times.  
• You will need to abstain from alcohol from 8pm the evening before your treatment 
visits until you have completed your visit to the lab.  
• If you occasionally smoke you will also need to abstain from smoking on the morning 
of your visits until the end of the testing day. 
• You will need to perform the computer tasks to the best of your abilities. 
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• You will need to consider your response to each item on the mood scales carefully. 
• You will not undertake any exercise on the day of the study visits until the visit is 
complete. 
• You will need to agree not to take any herbal or dietary supplements whilst you are 
participating in the study. If prior to, or during, your participation in this study you are 
prescribed medication you need to notify the research team as soon as possible as it 
may impact upon your ability to take part in the study.  
• You will also need to maintain a similar lifestyle and nutrition to what you did prior to 
the study. 
 
4. What are the exclusion criteria (i.e. are there any reasons why I should not take 
part)?  
You should not take part if you are allergic to Ginkgo biloba.  You are not eligible to take part 
in this study if you: are not proficient in English, are (or are seeking to become) pregnant, are 
currently taking illicit, or over the counter/prescription medication (excluding the contraceptive 
pill), and/or dietary/herbal supplements. You are also ineligible if you have any food allergies 
or sensitivities that are relevant to the study and if you have a history of/current head trauma, 
learning difficulties, ADHD and migraines, gastric problems, dyslexia or colour blindness. This 
will be discussed/confirmed at the initial screening session along with other relevant health 
issues that may impact upon your eligibility for the study. If you are unsure about your 
eligibility then please email me and we can discuss any issues or ambiguity 
 
5. Will my participation involve any physical discomfort? 
You will be required to wear a headband across the forehead that holds the NIRS 
optodes in place.  Because you have to keep the headband on for a period of 3.5 
hours it may cause minor discomfort.   The study will also involve long periods of 
sitting in front of a computer screen which you may find uncomfortable. These 
procedures have been assessed for potential risks and deemed to be minor.  
 
6. Will my participation involve any psychological discomfort or embarrassment? 
No 
 
7. Will I have to provide any bodily samples (i.e. blood, saliva)? 
No 
 
8. How will confidentiality be assured? 
The research team has put into place a number of procedures to protect the confidentiality of 
participants. These include: 
Allocation of  an individual participant code that will always be used to identify any data 
provided. Your name or other personal details will not be associated with your data, for 
example the consent form that you sign will be kept separate from your performance data. 
All paper records will be stored in a locked filing cabinet, accessible only to the research 
team,  and all electronic information will be stored on a password-protected computer. All of 
the information you provide will be treated in accordance with the Data Protection Act. 
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9. Who will have access to the information that I provide? 
The principal investigator and members of the research team will have access to the 
information that you provide. However, any data that leaves the site will only be identifiable by 
a study number and it will not be possible for anybody outside of the investigational site to 
connect your identifying information to your data.  
 
10. How will my information be stored / used in the future? 
It is intended that the results of the study will eventually be published in a peer-reviewed 
journal. In the meantime, if you wish to find out what effect the treatments had, we will email a 
summary of the results to you approximately two weeks after the study finishes. At no time 
will you personally be identified as having taken part. We will not be able to provide any 
information on your own individual performance. All information and data gathered during this 
research will be stored in line with the Data Protection Act and will be destroyed 5 years 
following the conclusion of the study. 
 
11. Has this investigation received appropriate ethical clearance? 
Yes, this study has received ethical approval from the School of Psychology and Sports 
Science Ethics committee.  If you require confirmation  of this please contact the Chair of this 
Committee, stating the title of the research project and the name of the principle investigator: 
Chair of School of Psychology & Sport Science Ethics Committee, Northumberland Building, 
Northumbria University, Newcastle upon Tyne, NE1 8ST 
 
12. Will I receive any financial rewards / travel expenses for taking part? 
You will receive £72 for taking part in the study to cover your out of pocket expenses and 
potential loss of earnings. If you decide to drop out of the study you will still be paid for the 
days that you have completed (at the discretion of the researcher). We will endeavour to 
have your payment available for you on the day you complete the study, however, this 
may not always be possible. If your payment is not available on your final study day then 
the researcher will let you know when you can expect to receive it. 
 
13. How can I withdraw from the project? 
You are free to withdraw from the study for any reason and do not have to disclose this 
reason to the investigators. If you wish to withdraw your data please contact the investigator 
within a month of your participation. After this date, it may not be possible to withdraw your 
individual data as the results may already have been published. However, as all data are 
anonymised, your individual data will not be identifiable in any way. 
 
14. If I require further information who should I contact and how? 
If you need more information, would like to discuss your participation, or experience any 
problems as a consequence of taking part in the study you should contact: Fiona Dodd 
(fiona.dodd@unn.ac.uk) in the Brain, Performance and Nutrition Research Centre. 
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Appendix B 
     
General Health Screen 
 
Please read the following list carefully. You are not eligible to participate in the research if:  
1. You have history of neurological, vascular or psychiatric illness (excluding 
depressive illness and anxiety). 
2. You have learning difficulties, dyslexia or colour blindness. 
3. You have visual impairment that cannot be corrected with glasses or contact 
lenses. 
4. You have a current diagnosis of depression and/or anxiety. 
5. You have a history or current diagnosis of drug/alcohol abuse. 
6. You have migraines. 
7. You have anaemia. 
8. You have a heart disorder. 
9. You have high blood pressure. 
10.  You have respiratory disorder. 
11.  You have type-I diabetes. 
12.  You have food intolerances/sensitivities. 
13.  You have phenylketonuria. 
14.  You are pregnant or seeking to become pregnant. 
15.  You smoke more than 3 cigarettes per day. 
16.  You are currently taking any prescribed (excluding contraceptives), illicit or  herbal 
drugs. 
If you are unsure or wish to discuss any of these points with the researcher then you are 
welcome to do so. 
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Appendix C 
 
Caffeine Consumption 
 
Subject No.______  Subject Initials______ 
 
Do you drink coffee?………………………Yes   No     
 
How often do you drink CAFFEINATED coffee?  (Normal coffee) 
 Tick one box 
Every day  
Most days  
Some days  
Hardly ever  
Never  
 
If you drink coffee regularly (Every Day or Most Days) 
 
Quantity per day…………………………………………  
Or if you only drink coffee occasionally (Some Days or Hardly Ever) 
 
Quantity per week………………………………………. 
 
How often do you drink DECAFFEINATED coffee?   
 
 Tick one box 
Every day  
Most days  
Some days  
Hardly ever  
Never  
 
If you drink decaf coffee regularly (Every Day or Most Days) 
 
Quantity per day…………………………………………. 
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Or if you only drink decaf coffee occasionally (Some Days or Hardly Ever) 
 
Quantity per week………………………………………. 
 
Do you drink tea?………………………Yes   No    
 
How often do you drink CAFFEINATED tea?  (Normal tea) 
 
 Tick one box 
Every day  
Most days  
Some days  
Hardly ever  
Never  
 
 
If you drink tea regularly (Every Day or Most Days) 
 
Quantity per day…………………………………………..  
Or if you only drink tea occasionally (Some Days or Hardly Ever) 
 
Quantity per week………………………………………… 
 
How often do you drink DECAFFEINATED tea? (don’t include Herbal Tea)   
 Tick one box 
Every day  
Most days  
Some days  
Hardly ever  
Never  
 
If you drink decaf tea regularly (Every Day or Most Days) 
 
Quantity per day…………………………………………… 
Or if you only drink decaf tea occasionally (Some Days or Hardly Ever) 
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Quantity per week…………………………………………. 
 
 
Do you drink soft drinks?………………Yes   No  
  
How often do you drink CAFFEINATED soft drinks?   (e.g. coke, pepsi, lucozade)  
 
 Tick one box 
Every day  
Most days  
Some days  
Hardly ever  
Never  
 
 
If you drink caff. soft drinks regularly (Every Day or Most Days) 
 
Quantity per day…………………………………………. 
Or if you only drink caff. soft drinks occasionally (Some Days or Hardly Ever) 
 
Quantity per week………………………………………… 
 
How often do you drink NON-CAFFEINATED soft drinks?   (e.g. fruit juice, squash, lemonade, 
orangeade etc)  
 
 Tick one box 
Every day  
Most days  
Some days  
Hardly ever  
Never  
 
If you drink non-caff. soft drinks regularly (Every Day or Most Days) 
Quantity per day………………………………………….. 
Or if you only drink non-caff. soft drinks occasionally (Some Days or Hardly Ever) 
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Quantity per week………………………. 
 
If you never drink caffeinated drinks is there any particular reason for 
this?…………………………………… Yes   No   
 
If yes, please give details 
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________ 
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